



Smart Micro/Nano Particles in Stimulus-Responsive Drug/Gene Delivery Systems

Journal:	<i>Chemical Society Reviews</i>
Manuscript ID	CS-REV-10-2015-000798.R1
Article Type:	Review Article
Date Submitted by the Author:	03-Dec-2015
Complete List of Authors:	<p>Karimi, Mahdi; Iran University of Medical Sciences, Ghasemi, Amir; Sharif University of Technology, Zangabad, Parham; Sharif University of Technology Rahighi, Reza; Sharif University of Technology, Basri, S. M.; Sharif University of Technology, Mirshekari, Hamed; University of Kerala, Amiri, Mohammed; Sharif University of Technology, Pishabad, Zahra; Kharazmi University, Aslani, Arya; Sharif University of Technology, Borzogomid, Mashnaz; Central Branch of Islamic Azad University of Tehran, Ghosh, Deepanjan; Tehran University of Medical Sciences, Beyzavi, Ali; Boston University, Vaseghi, Akbar; Faculty of Advanced Science and Technologies of Isfahan, Aref, Amir; Harvard Medical School Haghany, Leila; , International Campus of Tehran University of Medical Science, Bahrami, Mohsen; Tehran University of Medical Science Hamblin, Michael; Harvard Medical School, Department of Dermatology</p>

Cite this: DOI: 10.1039/c0xx00000x

Review

www.rsc.org/xxxxxx

Smart Micro/Nano Particles in Stimulus-Responsive Drug/Gene Delivery Systems

M. Karimi¹, A. Ghasemi², P. Sahandi Zangabad², R. Rahighi^{3,4}, S. M. Moosavi Basri^{5,6}, H. Mirshekari⁷, M. Amiri², Z. Shafaei Pishabad⁸, A. Aslani², M. Bozorgomid⁹, D. Ghosh¹⁰, A. Beyzavi¹¹, A. Vaseghi¹², A. R. Aref¹³, L. Haghani¹⁴, S. Bahrami¹, M. R. Hamblin^{15,16,17*}

1. Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
2. Department of Materials Science and Engineering, Sharif University of Technology, 11365-9466, Tehran, Iran
3. Department of Research and Development, Sharif Ultrahigh Nanotechnologists (SUN) Company, P.O. Box: 13488-96394, Tehran, Iran.
4. Nanotechnology Research Center, Research Institute of Petroleum Industry (RIPI), West Entrance Blvd., Olympic Village, P.O. Box: 14857-33111, Tehran, Iran
5. Bioenvironmental Research Center, Sharif University of Technology, Tehran, Iran
6. Civil & Environmental Engineering Department, Shahid Beheshti University, Tehran, Iran
7. Department of Biotechnology, University of Kerala, Trivandrum, India
8. Department of Cell & Molecular Biology, Faculty of Biological Sciences, Kharazmi University. Tehran, Iran
9. Department of Applied Chemistry, Central Branch of Islamic Azad University of Tehran, Tehran, Iran
10. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran
11. School of Mechanical Engineering, Boston University, Boston, MA, USA
12. Department of Biotechnology, Faculty of Advanced Science and Technologies of Isfahan, Isfahan, Iran
13. Department of Cancer Biology, Center for Cancer Systems Biology, Dana-Farber Cancer Institute, Department of Genetics, Harvard Medical School, Boston, MA, 02215, USA
14. School of Medicine, International Campus of Tehran University of Medical Science, Tehran, Iran
15. Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, 02114, USA
16. Department of Dermatology, Harvard Medical School, Boston, MA, 02115, USA
17. Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, 02139, USA

Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX

DOI: 10.1039/b000000x

Abstract

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

New achievements in the realm of nanoscience and innovative techniques of nanomedicine have moved micro/nanoparticles (MNPs) to the point of becoming actually useful for practical applications in the near future. The various differences between the extracellular and intracellular environments of cancerous and normal cells and the particular characteristics of tumors such as physicochemical properties, neovasculature, elasticity, surface electrical charge, and pH have motivated the design and fabrication of inventive “smart” MNPs for stimulus-responsive controlled drug release. These novel MNPs can be tailored to be responsive to pH variations, redox potential, enzymatic activation, thermal gradients, magnetic fields, light, and ultrasound (US), or can even be responsive to dual or multi-combinations of different stimuli. This unparalleled capability has increased their importance as site-specific controlled drug delivery systems (DDSs) and has encouraged their rapid development in recent years. A deeper understanding of the underlying mechanisms of these DDS approaches is expected to further contribute to this groundbreaking field of nanomedicine. Smart nanocarriers in the form of MNPs that can be triggered by internal or external stimulus are summarizedly discussed in the present review, including pH-sensitive peptides and polymers, redox-responsive micelles and nanogels, thermo- or magnetic-responsive nanoparticles (NPs), mechanical- or electrical-responsive MNPs, light or ultrasound-sensitive particles, and multi-responsive MNPs including dual stimuli-sensitive nanosheets of graphene. This review highlights the recent advances of smart MNPs categorized according to their activation stimulus (physical, chemical, or biological) and looks forward to future pharmaceutical applications.

20

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx**ARTICLE TYPE****Table of Contents**

1- Introduction	4
2- Different stimuli-responsive MNPs	8
2-1 Physical stimuli-responsive MNPs.....	8
5 2-1-1 Thermo-responsive MNPs	8
2-1-2 Magnetic-responsive MNPs.....	15
2-1-3 Electrical-responsive MNPs.....	21
2-1-4 Light-responsive MNPs	22
2-1-5 Mechanical-responsive MNPs	29
10 2-1-6 Ultrasound-responsive MNPs	30
2-2- Chemical stimuli-responsive MNPs	37
2- 2-1 pH-responsive MNPs.....	37
2-2-2 Redox-responsive MNPs	47
2-3 Biological stimuli-responsive MNPs	51
15 2-3-1 Different biomolecular-responsive MNPs	51
2-3-2 Enzyme-responsive MNPs.....	54
3- Dual and multi-responsive MNP in DDSs and the role of graphene	64
4- The protein corona effect and nanotoxicology of NPs in biological systems	73
4-1 Protein corona	73
20 4-2 Nanotoxicology of NPs in biological systems	78
5- From Concepts to the Drugstore Shelves.....	81
6- Conclusion and future perspective	83

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

1- Introduction

Breakthroughs in nanotechnology have had an important influence on many different industries, especially materials science, biotechnology, and pharmacotherapy. Different nanocarriers such as liposomes, polymers, micelles, and carbon-based nanomaterials are increasingly being used for medical purposes¹⁻⁶, such as the delivery of macromolecules (drugs and genes) as therapeutic agents. It is undoubtedly a challenging issue, since the required drug delivery system (DDS) is expected to be both site-specific and time-release controlled. Controlled release of drugs can be triggered by various external or internal stimuli of heat, solvent polarity, ionic strength, action of biomolecules, or the effects of electric/magnetic fields or light, as illustrated in Fig. 1. While temperature can be either an internal or external stimulus, pH, redox, and enzyme activity are known as internal stimuli, and on the other hand, light, magnetic fields, and US are recognized as external stimuli⁷⁻⁹. Robust and efficient nano-carriers that can respond to changes in their ambient environmental parameters are of particular importance for drug and gene delivery purposes. The term “smart” has been applied to micro/nanoparticles (MNPs) that can react in a predictable and specific way to external/internal stimuli. This property of such carriers to undergo controlled-release of the loaded drugs results in overall mitigation of their side-effects and increases their treatment efficacy. Well-designed smart-MNPs might even be responsive to multiple combinations of different stimuli to further improve their specificity for targeted and controlled drug delivery¹⁰. There exists a similarity between the main action algorithm of multi-responsive smart MNPs and the computer logic gates; an exciting issue to be discussed further.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig. 1 Different physical and chemical stimuli exploited for triggering smart MNPs in controlled release of drugs, namely, magnetic induction, light irradiation, USagitation, temperature difference, enzyme activation, redox potential, or pH difference.

5 The emergence of novel nanomaterials from the flourishing field of nanoscience has given a boost to research in many areas of technology^{11, 12}. Smart nanostructures have been intensively investigated during the last decade, and their unique and intriguing properties have given hope for the design of more efficient drug delivery vehicles. MNPs can play a crucial role as DDSs as their size (and hence their physical, chemical, and electrical properties) can be tuned and they can be easily functionalized
 10 and used in non-toxic concentrations for selective or passive drug delivery. Smart MNPs are considered to be promising agents for targeted delivery of drugs, particularly water-insoluble compounds, and can also

be helpful in the field of dual-function cancer diagnosis and treatment systems (theranostics)¹³. They

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

can escape the reticuloendothelial system and even have the potential to cross the blood-brain barrier (BBB)¹⁴ and the blood-testicle barrier (BTB). Their functionalization is a relatively easy process and appropriate functionalization can enable imaging and real-time monitoring of drug delivery to tumors. Although the protein corona-induced screening of MNPs has an important role in mitigation of their cytotoxicity, protein attachment can also reduce the efficiency of targeted MNPs due to covering-up or shielding of active targeting ligands¹⁵. Different organic and inorganic MNPs have been utilized in DDSs. As a particular example, nanosheets of graphene (the first class of two-dimensional crystals¹⁶) discovered only a few years ago, have made a tremendous impact on all areas of applied science ranging from nanoelectronics¹⁷, gas sensor¹⁸, and biosensors¹⁹ to composites²⁰⁻²³ and somewhat surprisingly, to nanomedicine²⁴⁻²⁸. In the field of stimuli-triggered DDSs, intense investigation is being focused on graphene²⁹, as it is relatively biocompatible³⁰ and can be functionalized easily³¹. Thanks to its theoretically-calculated outstanding specific surface area of 2630 m²/g,^{32, 33} a single sheet of graphene oxide (GO) can be loaded with drugs to more than two times its own weight. The superior electrical³⁴ and thermal³⁵ conductivity of the graphene nanosheets, the high absorbance of near-infrared (NIR) radiation³⁶, and most importantly, its nontoxicity at low concentrations^{37, 38} has motivated many investigators to prepare this nanomaterial (micrometer-sized sheets with a thickness of only one nanometer) in a stimuli-responsive form^{39, 40}.

The uptake of very small particles by cells is critically dependent on the particle size, which can range from only a few nanometers up to a few microns. For example, although there is no consensus on the optimum size of the particles used for vaccine delivery (according to a review elsewhere⁴¹), it is reasonably believed that NPs, particularly, those with diameters less than 100 nm, are better candidates for targeted-delivery purposes due to their good stability in the blood circulation, their ability to pass thorough capillaries, their efficiency in permeating biological barriers⁴², and even their ability to accumulate in cells without being recognized by efflux pumps such as P-glycoprotein⁴³. However, due to the fact that the volume of the particles diminishes by three orders of magnitude when the diameter is shortened by a factor of ten, care must be taken that the loading capacity or “cargo space” is large enough to carry the desired drug payload⁴⁴.

The increasing prevalence of various types of cancer is becoming a serious global health concern as it is the second most common cause of death after cardiovascular diseases. Treatment of cancer is

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

feasible in many cases and can even result in its complete eradication provided it is diagnosed early. However, even though there are innovative attempts in the realm of nanotechnology to achieve detection of cancer at the single-cell level⁴⁵, in most cases, due to the low detection limit of the available technologies^{46, 47}, cancer is often not detected until many different parts of the body have
5 been affected. The undesired side-effects of anti-cancer drugs may severely limit their use, since these cytotoxic compounds unfavorably affect the normal proliferating cells at the same time as they kills the cancerous cells, since both have active DNA replication and cell cycle progression. Likewise in radiotherapy, surrounding normal tissue can be damaged by the radiation beam, although improvements are being pursued through emerging approaches of hadron therapy and promising
10 techniques of modern nanomedicine.

Pathological lesions within normal tissue, such as tumors and abnormal cancerous cells, can be discriminated from their normal counterparts due to the unique pathophysiology of tumors, and the peculiarities of malignant and transformed cells⁴⁸. Cancerous cells have been reported to differ from normal cells in their morphology, elasticity, and permeability. They often express different glycans
15 compared with their normal counterparts⁴⁹. Intracellular glutathione (GSH) levels⁵⁰ and the concentration of some enzymes⁵¹ within tumors can be more than two orders of magnitude higher in comparison with the extracellular levels. Interestingly, it has been reported that the extracellular pH in solid tumors tends to be significantly more acidic (~6.5) than the pH of the blood (7.4)⁵².

Controlled drug delivery is not only advantageous in suppressing the side-effects of the toxic drugs by
20 passive or active targeting of the diseased tissue, but also by overcoming the drawbacks of insoluble anti-cancer drugs like the widely-studied doxorubicin (DOX).

The state-of-the-art developments of micro/nanostructures used in smart drug/gene delivery systems are summarized in the present review. A comprehensive perspective is presented for the first time classifying their responsiveness to different stimuli, either physical (temperature, magnetic force,
25 electricity, light irradiation, mechanical agitation, or ultrasound), chemical (pH or redox), or biological factors (specific biomolecules or enzymes). We also discuss the corresponding nanotoxicity of these nanocarriers, their fate and pathology in biological systems, and the cell vision effect resulting from the protein corona formation. Furthermore, a brief background discussion of each category and its corresponding mechanism of action are covered in this compendium and the latest progress and current

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

challenges are highlighted.

2- Different stimuli-responsive MNPs

2-1 Physical stimuli-responsive MNPs

2-1-1 Thermo-responsive MNPs

5 Temperature is among the most often investigated stimuli to control the release of drugs from stimuli-responsive DDSs with spatiotemporal control. The hyperthermic nature of most inflamed pathological sites and tumours can act as an internal stimulus. Applying external temperature changes can also activate thermo-responsive MNPs to provide an attractive option for stimulus-responsive DDSs as they can rapidly response to temperature changes. Another important advantages of these DDSs is that they
10 can be formulated as injectable fluids so that no surgical operation is needed for implantation in the diseased tissue⁵³. The ideal smart DDSs should retain their load at inappropriate times and place and release the drug inside with controlled kinetics in the target tissues such as tumors.

On of the most well-known materials which have been applied in DDSs, are temperature-sensitive polymers that can switch their structure from a shrunken form to a swollen form (or vice versa) in
15 response to a change in temperature. In fact, since there is a change in solubility with temperature, the significant properties of these polymers lead to release of the encapsulated drug. They are characterized by an upper critical solution temperature (UCST) or a lower critical solution temperature (LCST). By changing the temperature around the UCST or LCST, a phase transition leading to swelling or shrinking occurs. Fig. 2 illustrates this concept. Drugs can be easily loaded into LCST
20 polymers at room temperature, and then delivered to the target tissue where they are released⁵⁴⁻⁵⁷.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig. 2 Schematic representation of LCST and UCST concept and their properties.

PNIPAAm and its derivatives have attracted the most attention as thermo-negative hydrogel-based DDSs, since their corresponding LCST is about 32 °C, which is close to the physiological temperature of the human body⁵⁸⁻⁶⁰. Also, by coupling other polymers, peptides, liposomes and proteins to PNIPAAm, its properties can be optimized in order to get improved targeting and drug release^{8, 61}. For example, in a semi-interpenetrating polymer network with increased LCST and improved swelling ratio synthesized by Fu et al.⁶² through a free radical polymerization method, the LCST of the modified PNIPAAm increased from 32°C to 41°C when AAm content exceeded 5.5% and the hydrophilic nature of AAm could form bonds with PNIPAAm.

Nanovalves have been used by researchers in order to control drug release and the opening of gates that control the mesopores of mesoporous silical nanoparticles (MSNs) and can be made to be sensitive to light, pH or temperature⁶³. Thermo-responsive polymers can be used as an “on-off switch”. For example, Okahata et al.⁶⁴ first used a nylon capsule (membrane) and attached N-isopropylacrylamide

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

(NIPAAm) to the surface of the membrane. They showed that, at temperatures above 35°C when shrinkage and collapse of NIPAAm occurred, the nanovalve closed and drug release was reduced, whereas at a temperature below the LCST (35°C), the valve opened and increased the drug release due to swelling of the polymer (Fig. 3 a). Lue et al.^{65, 66} used a different technique involving the use of a NIPAAm and acrylic acid (AAc) copolymer as “brush hydrogels” that were grafted on the surface of a porous polycarbonate support, and showed that by increasing the temperature above the LCST, the NIPAAm-co-AAc brush underwent shrinkage resulting in increased release of the drug through the pores, while by decreasing the temperature below the LCST, the drug delivery route was blocked due to swelling of the brushes (Fig. 3 b).




Fig. 3 Schematic illustration of on-off switch/membrane. a) Drug release in temperature below LCST. b) Drug release in temperature above LCST.

The insolubility of hydrophobic drugs and anticancer agents in water (e.g., the anticancer drug Deguelin), limits their application in drug delivery⁶⁷. To overcome this problem, core-shell thermo-responsive DDSs can be used, which often consist of a hydrophobic core such as polystyrene (PS) acting as a reservoir for the loaded drug, together with a temperature-sensitive shell of a hydrogel such as PNIPAAm^{68, 69, 70}. Yan-Ling Luo et al.⁷¹ prepared a four-armed star multiblock copolymer with the hydrophobic HTPB acting as the central block with the thermo-sensitive PNIPAAm arranged as arms. The average hydrodynamic diameter of the micelles was under 150nm. The micelles showed a temperature-dependent size change, with a LCST of about 33–35°C. Water insoluble CPT was loaded into the micelles as an anti-cancer drug which showed strong antitumor properties^{71, 72}.

Azobenzene can be attached to temperature-sensitive polymers because of its transition from trans to

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

cis (or cis to trans) by ultraviolet (UV) or visible light irradiation. In this manner, the LCST of temperature-sensitive polymers such as PNIPAAm can be controlled by the amount of azobenzene. For example, reversible alteration of LCST could be achieved through E-to-Z photoisomerization in azobenzene-conjugated PNIPAAm⁷³. A linear increase in the LCST point (up to 10 °C) upon irradiation was also claimed and attributed to a decrease in the molecular weight of the employed PNIPAAm. In another study, chemotherapy and hyperthermia were concurrently applied by Kim et al.⁷⁴ activating a core-shell system to improve the effectiveness of gemcitabine for pancreatic cancer. They used super paramagnetic iron oxide NP with 7 nm diameter which formed a cluster with a core diameter of 60 nm encapsulated in a porous silica shell. The surface of the shell was modified by conjugation to polyvinylpyrrolidone in order to allow grafting of hydroxypropyl cellulose as a thermo-sensitive polymer. By this design gemcitabine release (chemotherapy), magnetic heating and magnetic resonance imaging (MRI) could be accomplished concurrently. They suggested that concurrent chemohyperthermia could improve tumor cell death compared to chemotherapy or hyperthermia alone. Although PNIPAAm is a well-known candidate for temperature-sensitive DDSs, it is not degradable in the body, so polymers such as polyethylene glycol (PEG) which have better biocompatibility can be an alternative to PNIPAAm⁷⁵. Na et al.⁷⁶ synthesized biodegradable temperature-responsive poly(L-lactic acid)/poly(ethylene glycol) NPs for DOX controlled release. They showed by increasing the temperature, the release of DOX increased and the temperature sensitivity depended on the poly(L-lactide)(PLLA) polymer chain length. Polysaccharides such as alginate, hyaluronic acid (HA), dextran, chitosan, and carrageenan which have no significant toxicity, good biodegradability, biocompatibility, and are natural materials with antibacterial and mucoadhesive properties which can be used in drug delivery, cell encapsulation and injectable matrices for tissue engineering⁷⁷⁻⁸⁰. For example, Ana et al.⁷⁸ synthesized K-carrageenan polysaccharide thermo-sensitive nanogels. Methylene blue was used as a model drug loaded at temperatures between 25-45 °C in phosphate buffered saline (PBS), and it was shown that both encapsulation efficiency and loading capacity doubled when the K-carrageenan increased from 1% to 4%. This behavior was attributed to the interaction between sulfate group from K-carrageenan and cationic methylene blue. They also reported an increase in methylene blue release when the temperature increased from 25°C to 37 and 45°C, as the nanogel swelled. Similarly, poly(methyl vinyl ether), poly(N-vinyl caprolactam), poly(N-ethylloxazoline), poly(N-

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

vinylalkylamides), PEG, poly(ethylene oxide)-poly(propylene oxide), PAAc and PAAm or their copolymers have been studied and tested in this regard⁸¹⁻⁸⁸.

Temperature-sensitive liposomes (TSL) can be nanocarriers for DDSs and exhibit a phase transition after a change in temperature. Liposomes formed from lipid bilayers, in addition to reducing drug side effects and limiting toxicity, can decrease the drug uptake in non-diseased tissues. "ThermoDox" is a liposome-based drug produced by Celsion American Corporation, which received FDA approval to conduct a phase III clinical trial for hepatocellular carcinoma and a phase II clinical trial for breast cancer. ThermoDox gives an increase between 25 and 5 times in drug release in comparison with IV DOX and standard liposomal DOX respectively in tumors. In order to provide the external temperature stimulus, heat is often induced by radiofrequency thermal ablation (RFA), microwave hyperthermia and high intensity focused ultrasound (HIFU) for activating TSL. Chen et al.⁸⁹ encapsulated DOX and incorporated ammonium bicarbonate in the TSL membrane. When the temperature increased to 40 °C, the ammonium bicarbonate decomposed releasing carbon dioxide that disrupted the liposome bilayers. Then DOX was then delivered to the diseased tissue through the pores generated in the liposomes. TSL nanocarriers have the potential to be tuned and modified by attaching polymers or molecular ligands for specific targeting to receptors. In an study, Ta et al.⁹⁰ fabricated a TSL using PNIPAAm-co-PAAc in order to release DOX in solid tumors. Here, PNIPAAm acted as a temperature-sensitive component inducing enhanced drug release above 40 °C. Temperature-sensitive nanovalves can be used in liposomes. For example, Al-Ahmady and coworkers⁹¹ inserted a leucine peptide zipper into the liposome membrane and when the temperature increased to 43°C, the zipper opened and DOX was released. However, DOX can cause toxic effects toward healthy tissue in case of its sudden release at 42°C. To overcome this drawback and in order to render the liposome thermo-sensitive and decrease toxicity, Elk et al.⁹² conjugated N-(2-hydroxypropyl)methacrylamide mono/dilactate to the liposome surface with different molecular weights and used HIFU as a thermo-generator. They could control DOX release over 10 min at 42°C using this hyperthermia technique. They also concluded that the temperature required for efficient DOX release had a reverse relation with the polymer molecular weight.

"Smart nanobombs" are another class of temperature-sensitive DDSs showing a reversible phase transition, and which swell from the nanoscale to the microscale when the temperature decreases. This

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

reduction in temperature is similar to "cold shock" or "cryotherapy". For example, Lee et al.⁹³ fabricated a super-expandable Pluronic/PEI nanogel with 150 nm diameter at 37 °C, which was taken up by diseased cells by an endocytic mechanism. After cell uptake, the temperature was decreased to 20 °C and the nanogel underwent a phase transition with dramatic swelling and its size increased by 800-fold to 1.4 μm. This size increase generated a large internal hydrostatic pressure within the cells and the physical force induced the breakdown of the intracellular endosomal compartments and "blew up" the tumor cells generating necrotic cell death. (Fig. 4). Furthermore drugs such as DOX could be loaded in the nanogel and released inside tumor cells.




Fig. 4 Schematic illustration of intracellular explosion of volume-transition nanogels (Nanobomb) (Reproduced from ref.⁹³. Copyright 2009 with permission from Elsevier).

Smart stimuli-responsive nanocarriers with the highest sensitivity to minimal changes of body temperature (such as tumors) are required in the near future. In recent studies thermo-sensitive DDSs have been used for: co-delivery of drugs and genes⁹⁴, induced therapeutic angiogenesis in peripheral vascular disease⁹⁵, allowed ophthalmic drug delivery with enhanced corneal permeation and retention capacity⁹⁶, produced a new intelligent dermatological formulation⁹⁷, allowed mucoadhesive-thermogel-based vaginal delivery⁹⁸, protein delivery in tissue engineering⁹⁹ and for bone regeneration¹⁰⁰. Other applications have been reported in cutaneous protein delivery¹⁰¹, delivery to the uterus for efficacious therapy of uterine diseases (e.g. bovine reproductive disorders)¹⁰², therapy of inflammatory bowel disease with enhanced colonic retention of drugs¹⁰³, real-time image-guided theranostic drug delivery in cancer chemotherapy¹⁰⁴, efficient mild hyperthermia with increased tumor retention and high specificity toward cancer and angiogenic cells¹⁰⁵, and treatment of hypoxic hepatocellular carcinoma¹⁰⁶. Fig. 5 illustrates studies focused on bone regeneration and image-guided theranostic drug delivery by Seo et al.¹⁰⁰ and Rosca et al.¹⁰⁴, respectively.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig. 5 a) Schematic of image-guided thermo-sensitive liposome (ITSL) injection and their accumulation in the tumor followed by agent release by hyperthermia and consequent tumor regression, b) Topotecan release from ITSL at different incubation temperatures, c) schematic of dual-acting hydrophobic and anionic charged nanocomplex hydrogel carriers for localized release of BMP-2 leading to bone generation (a and b reprinted with permission from ref.¹⁰⁰. Copyright 2015 “American Chemical Society”, and c reproduced from ref.¹⁰⁴. Copyright 2015 “Elsevier”).

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Thermo-responsive polymers have also been used for delivery of genes and nucleic acids¹⁰⁷⁻¹⁰⁹. Similar to the case of drug delivery, PNIPAAm has often been used as the temperature-sensitive component in temperature-responsive polymers for nucleic acid delivery^{55, 110}. At a temperature above the LCST, the complexes between the polymer and the DNA become more densely bound, because the PNIPAAm shrinks due to rapid dehydration. As a result, the complexes can better protect the DNA from enzymatic degradation in environments such as the endosomes. By decreasing the temperature below the LCST, hydration occurs and increases the water solubility of PNIPAAm, that in turn makes the complexes less compact and finally results in facilitation of DNA release from polymer/DNA complexes^{111, 112}.

2-1-2 Magnetic-responsive MNPs

The force of magnetism is considered as one of the best options for an external stimulus as it scarcely has any physical interaction with the body, in comparison to other stimuli such as light irradiation, US or electrical fields. Also, magnetic-responsive materials can provide a real-time response to a brief triggering impulse¹¹³. Engineered magnetic NPs (MNPs) can be functionalized and magnetically driven and controlled, and hence magnetic field-responsive particles are being studied as useful vehicles in drug delivery¹¹⁴ and biomedical targeting¹¹⁵. These engineered MNPs can also be triggered by external stimuli such as alternating magnetic field (AMF) for targeted and controlled drug-release. In 1960, Freeman et al.¹¹⁶ first conceived the idea of using magnetic fields as an external trigger to release drugs. Single domain MNPs with intrinsic superparamagnetic features above their blocking temperature, T_B , are promising candidates for biomedical purposes, as compared to ferromagnetic particles, because they display no dipolar attraction in the presence of magnetic fields, have good colloidal stability, and homogenous dispersion within a polymeric matrix¹¹⁷.

The unique ability of MNPs to generate heat under the influence of external high-frequency AMFs is called magnetic hyperthermia. MNPs (with superparamagnetic behavior) exposed to a strong magnetic field can withstand internal stresses caused by the fluctuating distortions induced by magnetic forces (via alternating current (AC) or direct current (DC)). It is considered that the

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

heat generated by MNPs in an AMF is due to two mechanisms of intrinsic rotational motion (Brownian) and extrinsic motion (Neel); i.e. thermal rotation of the particle's magnetic moment and relaxation via diffusion. This inductive hyperthermia depends on several factors including the saturation magnetization and the hysteresis coercivity, both of which are related to the size of the MNPs. Magnetic fields can be used for applications including controlled/local drug release, guidance, targeting, imaging (MRI and fluorescence) as well as hyperthermal therapy¹¹³. For example, polymeric NP can undergo thermodynamic phase/conformational transitions depending on their LCST/UCST followed by swelling/shrinkage as described above. This phenomenon can be induced by magnetic heating with potential for drug-release e.g. via structural disruption of the NP or by a "pumping effect" (i.e. squeezing the drugs out from the NPs)^{113, 118, 119}. It is worth noting that magnetic NPs can be trapped inside polymer particles e.g. hydrogels with a second polymer chain either as a random copolymer or semi/fully-interpenetrated network, by adsorption of the chains to the surface of MNPs¹¹⁷. An external magnetic field can also enhance cellular uptake of NPs¹¹⁹. Louguet et al.¹¹⁸ developed silica-coated magnetic NPs functionalized with thermo-sensitive block copolymer brushes with an LCST transition. Application of an AC-magnetic field induced heat generation by the magnetic core and enhancement of the triggered release of the drug (DOX) due to conformational changes occurring in the brushes (Fig. 6-a and 6-b). Nanoporous membranes prepared as electrically conductive flexible electrodes can act as a magnetically-triggered smart-nanocarrier with tunable drug-release profiles. These can include reversible, burst, stepwise, sustained and slow-release profiles depending on the mode of magnetic triggering. They show zero drug release in the absence of a magnetic field (see fig. 6-c)¹²⁰. A hybrid nanocarrier composed of iron oxide nanocubes (cubic-IONPs) (with semi-superparamagnetic/semi-ferromagnetic behavior) encapsulated by a thermo-sensitive polymeric shell with a LCST phase transition at 37°C showed minimal drug release below 37°C but a consistent on-demand release due to heat generation under an AMF¹²¹.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig. 6 a) Design of a hybrid silica-coated copolymer functionalized magnetic NP followed by release of DOX via application of an AMF inducing the LCST transition, b) cumulative release profile of DOX from the nanocarrier, c) weak and strong drug release (an ON/OFF reversible switch) from a nanoporous membrane comprised of thermo-sensitive nanogels and superparamagnetic MNPs, before and after AMF trigger; (a and b reproduced from ref.¹¹⁸ with permission from the Royal Society of Chemistry; c reprinted with permission from ref.¹²⁰. Copyright 2011 American Chemical Society).

Magnetic hyperthermia can also be controlled by adjusting the field strength. Incorporation of micro- and nano-scale metal NP into the hydrogel matrix has led to the introduction of magnetic hybrid hydrogels as a group of novel materials with unique properties that are of great importance in controlled drug delivery¹²². Super paramagnetic iron oxide (SPIO)NPs, functionalized with FA and β -cyclodextrin (β -CD), were reported to generate heat in presence of an AMF¹²³. These MNPs showed a specific absorption rate of 132 Wg^{-1} at 230 KHz and 100 Oe where drug release from the CD has been triggered by the induced heating. Giani et al.¹²⁴ cross-linked CoFe_2O_4 NPs into a carboxymethylcellulose polymer to fabricate hybrid hydrogels. The

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

magnetic NPs were functionalized with (3-aminopropyl)-trimethoxysilane (APTMS) in order to introduce NH_2 groups onto their surface. The preliminary results showed controlled drug-release from the matrix under influence of AMF. Hyperthermia has been considered to be a promising way to treat cancer for some years, based on the assumption that cancer cells are more affected by heat than the surrounding normal cells¹²⁵. Many studies have utilized hyperthermia for clinical use, the results of which have shown tumor regression after application of magnetic field to solid tumors that had been directly-injected with MNPs¹²⁶. In a study by Severine et al.¹²⁷ MNPs and DOX were incorporated inside alginate microbeads for dual hyperthermia and drug release. Human breast cancer MCF-7 cells were exposed to 37°C for 2 hours with or without an AMF (frequency 700 kHz, amplitude 10 mTesla, 45°C). DOX release was higher at 43 and 50°C in comparison to temperatures of 20 and 37°C. No DOX was detected at 4°C, indicating that drug release was controlled by increased temperature.

Polymersomes have been used for magnetic field-triggered drug delivery.¹²⁸ In a recent study, it was shown that polymersomes could entrap up to 6% (w/w) of DOX along with 30% (w/w) of ultra-SPION; $\gamma\text{-Fe}_2\text{O}_3$. When internalized by HeLa cells and subsequently triggered by a high frequency AC magnetic field (14mT at 750 kHz), an 18% greater cytotoxicity was observed along with increased DOX release. Another important advantage of polymersomes over other delivery systems is the capacity to carry a larger drug load, for instance polymersomes could accommodate up to 12% DOX LC coupled with 50% LC USPIONPs, compared with only 2.4% DOX LC by other systems.^{129, 130} The efficacy of a lipid-polymer hybrid NP system with improved drug release kinetics containing Fe_3O_4 magnetic beads providing site-specific release of CPT to treat breast cancer of MT2 mouse was evaluated by an external radio frequency (RF) magnetic fields¹³¹.

The guidance and triggering abilities of magnetic-responsive materials are superior to those of temperature and pH triggers¹¹³ and they are effective over a distance as large as a few centimetres¹¹⁷. Extracorporeal magnetic guidance can serve to overcome several limitations of DDSs such as natural physiological barriers and lack of specificity to the targeted cells/tissue

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

because spatial/magnetic fields can be spatially focused. For example to overcome high blood flow in arteries or capillaries after an intravenous injection of nanocarriers, powerful magnets can be placed at the desired sites¹¹⁷. Image-guided drug delivery is an important component of the magnetic responsive DDS approach. Singh et al.¹³² fabricated magnetic carbon nanotubes (CNT) ensheathed with surface-layered MSN (the MNPs were located inside the multiwalled CNTs) for drug delivery accompanied by MR imaging. MSN were chosen for their enhanced loading of bioactive molecules such as the protein cytochrome C, the drug gentamicin, and the nucleic acid siRNA within the mesopores. Along with high loading-capacity, the cellular uptake was also increased via application of magnetic fields, and negligible cytotoxicity was observed. Magnetofection or magnetically-aided transfection is another way for controlled gene delivery. By linking MNPs with viral vectors, Mah et al.¹³³ first reported magnetofection in 2009. A novel magnetite-silica nanocomposite (Fe₃O₄-SBA-15) nanocomposite was surface-coated with short chain PEI-DNA complexes for the strategic purpose of gene delivery and transfection. Surprisingly, this composite led to 15% higher transfection after applying an external magnetic field¹³⁴. Furthermore, MSNs can be utilized to entrap nucleotides in their pores while also being functionalized to form a magnetic field-responsive delivery system as was reported by¹³⁵. Ruiz-Hernandez et al.¹³⁶ devised stimulus-responsive MNPs in which ‘caps’ were formed from iron oxide NPs (IONPs) entrapping drug molecules/genes within the porous matrix. The caps were conjugated with one strand of DNA and the complementary strand was conjugated to the mesoporous silica membrane. Hence, the structures could maintain their closed conformation due to the double-helix DNA binding, so under normal condition no drugs/genes were released. When exposed to an AMF, their temperature was locally raised, the DNA was dehybridized and the entrapped molecules were released from the matrix. This stimuli-responsive delivery mechanism works like an ‘on-off’ switch and aids in controlled drug release (Fig. 7).

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig. 7 a) Alginate-microbead system loaded with MNPs (nanoheaters) and DOX for drug delivery using thermotherapy, b) magnetically triggered release using reversible magnetic nanogates based on DNA hybridization/dehybridization.

Polymer nanoassemblies made up of biocompatible block copolymers can also be made to be responsive to magnetic fields¹³⁷⁻¹³⁹. In an innovative approach, where drug molecules (DOX) and IONPs were loaded into block polymer self-assembled nanoassemblies (SNAs) or cross-linked analogs (CNAs) with 100 nm diameter; DOX release was detected at 40-42°C after the temperature was raised by inductive heating using AMF. It was also observed that CNAs released DOX at a faster rate than SNAs¹⁴⁰. While many research groups have used direct intratumoral injection claiming it has low systemic toxicity and permits a higher tumor load of MNPs, the inability of this route to allow MNPs to reach small metastatic cancers, the poor distribution within inhomogeneous tumors, and its relatively invasive approach, make the intravenous approach much more preferable¹⁴¹. In a study by Huang et al.¹⁴² using an intravenous injection, the tumor to non-tumor ratio was >16 where they employed a concentration of 1.9 mg

Cite this: DOI: 10.1039/c0xx00000x


www.rsc.org/xxxxxx

ARTICLE TYPE

Fe/g in a mouse model of subcutaneous squamous cell carcinoma. Their approach was validated as the surrounding normal tissues were completely left intact after a two-minute exposure to AMF (38 kA/m) at 980 kHz during which the target tumor tissue was heated to 60°C. In a study by Silva et al.¹⁴³, antibiotics were loaded into a nanostructure composed of Fe₃O₄ NPs with a TiO₂-co-pectin shell then were released slowly by application of a remote magnetic field.

2-1-3 Electrical-responsive MNPs

Electrically-triggered DDSs can be utilized for sustained, pulsed, or on-demand drug release via the application of external electric fields. Electro-responsive drug release can be performed with various platforms including electro-responsive nanostructures, electro-responsive compound-loaded nanostructures, and the combination of electroresponsive materials with other stimuli-responsive vehicles such as temperature or magnetic. The introduction of polyelectrolytes containing large numbers of ionizable groups confers responsiveness to an electrical stimulus through shrinking or swelling of the polymers^{144, 145}. Xiaoying Ying et. al. for instance, developed electro-responsive hydrogel NPs (ERHNPs) for targeted delivery of the antiepileptic drug-phenytoin sodium (PHT) (Fig. 8)¹⁴⁶. An increased degree of ionization in the structure was achieved under influence of an electric field due to the presence of the polyelectrolyte poly(sodium 4-vinylbenzene sulfonate) (PSS). The swelling ratio and the particle size could be tuned via the external electric field. In this study in-vitro triggering and increased drug release with potential application in epilepsy treatment was shown.



Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Fig. 8 Schematic representation of electro-responsive hydrogel NPs containing PSS, with in-vitro favorable sustained release (inset); Reproduced from ref.¹⁴⁶. Copyright 2014 with permission from John Wiley & Sons, Inc.

In another example a GO-conducting polymer [poly(pyrrole)(PPy)] nanocomposite film with favorable electrical properties, linear drug release profile, and a good level of temporal control of dexamethasone release in response to electrical magnitudes was developed¹⁴⁷. Electroresponsive scaffolds have also been developed for on-demand and pulsatile drug delivery^{148, 149}. These were composed of a hybrid between graphene and poly(methylacrylic acid) (PMAA)-(MWNT) hydrogels with electro-responsive properties. The drawbacks of traditional electro-responsive DDSs such as an increase in temperature due to resistive heating after exposure to an electric field, and poor reproducibility of the drug release between the ON/OFF stimuli, were overcome by using the heat-dissipating and good electrical properties of graphene. Other applications of electrically-triggered smart nanostructures include the externally controlled on-demand release of an anti-HIV drug by CoFe₂O₄@BaTiO₃ magneto-electric NPs¹⁵⁰, polymer-MWCNT network in a electro-sensitive transdermal DDS¹⁵¹, and PPy-loaded PLGA-PEG-PLGA NPs¹⁵² with on-demand drug delivery. These all possess excellent spatio-temporal control of dosage, and have potential clinical applications in multiple diseases. Apart from the above-mentioned advantages of electro-responsive DDSs, there are some limitations such as cell damage and poor tissue penetration, which should be considered in future investigations.

2-1-4 Light-responsive MNPs

Light irradiation can be used to stimulate or trigger drug release. Absorbance of photon energy by materials depends on the corresponding energy band-gap of the electron in the highest occupied molecular orbital. Light absorbing materials have a broad range of practical applications like shielding against UV irradiation in sunlight, generation of electrical power from solar radiation, and acting as optical contrast agents and fluorescent reporter molecules. Among the several stimuli exploited in smart DDSs, light irradiation has attracted a significant amount of attention due to the ease of precisely tuning its intensity, the ability to control the exposure

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

duration and tissue location (via the selection of appropriate beam parameters), and the fact that photoregulated activation is perceived as non-invasive. Ultraviolet (10-400nm), visible, or near infrared (IR) regions (650-900 nm) of the light spectrum can be used to trigger drug or gene release from appropriately designed nanocarriers. Although the higher energy per photon of UV light enables it to ionize and cleave covalent bonds with energies of the order of 100 kcal/mol), the potential hazards of far-UV (wavelengths shorter than 200 nm) to tissues and the possible photodestruction of active molecules makes these wavelengths unsuitable for therapeutic purposes. However the application of continuous wave (CW) long-UV lasers (wavelengths of 200-400 nm) can leave both drugs and tissues intact¹⁵³. UV irradiation is much more cytotoxic than the other regions of the light spectrum and its inability to penetrate deeply into the tissue due to its absorption by endogenous chromophores (such as oxy- and deoxy-hemoglobin, lipids, and water) is considered as another disadvantage. Thus, wavelengths below 650 nm are considered to be only suitable to trigger drug release for topical treatment of pathological states affecting the skin and mucosa¹⁵³. Supramolecular assemblies designed to use visible light are relatively rare¹⁵⁴.

NIR has better transmission through tissue due to its lower absorption and scattering in tissue (penetrating into the body about 10 cm) because hemoglobin, water, and lipids barely absorb it, and causes less damage to cells than visible light, due to its lower energy per photon¹⁵⁵. To solve the problem of low energy of NIR photons, some organic chromophores capable of simultaneously absorbing two photons of low-energy have been studied¹⁵⁶.

Diverse MNPs have been exploited for fabrication of light-sensitive DDSs including carbon dots with strong fluorescent emission¹⁵⁷, polymeric hydrogels exhibiting a hydration/dehydration transition mechanism¹⁵⁸, gold NPs for photo-generated localized heating¹⁵⁹, core-shell particles¹⁶⁰, and MSNs possessing high surface area, good targeting ability and controlled drug-release especially toward tumor cells^{135, 161}.

In general, light-responsive NPs have found a wide range of applications. The most commonly studied types are micelles and liposomes¹⁶². Although light-responsive MNPs can be made of different materials, all of them have a chromophore in their architecture to harvest the light.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Chromophores are therefore the key component of light-sensitive NPs¹⁶³ which may rely on photo-isomerization (a conformational change of a double bond that is restricted in rotation usually accompanied by a change in the hydrophilic/hydrophobic balance of the photo-excitable molecules), photo-induced cleavage of bonds, photo-oxidation (generation of singlet oxygen or other reactive oxygen species (ROS)), and reversible photo-cross-linking¹⁶⁴.

Photo-cleavage reactions occur in *o*-nitrobenzyl^{165, 166} and coumarin^{167, 168} containing molecules. In this regard, Dong et al.¹⁶⁹ designed a *s*-(*o*-nitrobenzyl)-L-cysteine N-carboxyanhydride monomer and synthesized a novel block copolymer derivative for controlled release of DOX via photo-cleavage in the core of the NPs. In another work, Zhao et al.¹⁵⁶ synthesized a novel block copolymer containing a coumarin chromophore [7-(diethylamino)coumarin-4-yl]methyl methacrylate that was disrupted by both UVA (365 nm) and by 2-photon NIR (794 nm) absorption. A Ti:sapphire laser, generating 80 fs pulses at 794 nm with a repetition rate of 1 kHz and energy per pulse about 300 mJ was able to photocleave coumarin and release encapsulated Nile red from the hydrophobic core of the micelle into an water-based solution.

Photo-induced rearrangements of components of micelles are rare. The most common chromophore exploited in these type of light-sensitive micelles is 2-diazo-1,2-naphthoquinone (DNQ)¹⁷⁰. This hydrophobic molecule changes into hydrophilic 3-indenecarboxylic acid through a Wolf rearrangement reaction¹⁷¹. DNQ has been widely used in many nanocarriers in order to deliver different cargos. For example Wang and coworkers synthesized a triple-stimulus responsive copolymer consisting of DNQ as a chromophore which was modulated by pH, light, and temperature¹⁷².

Another common type of chromophore employed in light-responsive NPs is azobenzene and its derivatives. These molecules such as azobenzenes, spirooxazines, and spiropyrans are organic photochromic compounds that are used to disrupt NPs due to their ability to undergo reversible isomerization in response to UV¹⁷³. Suhyun et al.¹⁷⁴ used a synthetic photoresponsive molecule to induce destabilization of polymeric micelles of hyperbranched polyglycerols into individual chains by UV irradiation. In other words, they employed the solubility-switching (from hydrophobic to hydrophilic) characteristic of the molecule to release cargo inside the micelles.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

MSNs can contain drugs that are retained in the pores by different capping agents¹⁷⁵. Cargo molecules are released only in the presence of an external stimulus like UV light or visible-light that induces destruction of capping agents. To this end, a supramolecular assembly was used to deliver cargo molecules from a MSN-based structure upon irradiation of visible-light¹⁷⁶. Sulforhodamine 101 was loaded inside the mesopores of mercaptopropyl (MP)-MSN and entrapped by mercaptopropyl-coordinated Ru(bpy)(2)(PPh(3))-moieties.

Photo-isomerization induced by upconversion luminescence (UCL) is another mechanism used for drug release activated via low intensity (e.g. 0.35 W/cm²) light irradiation and with features such as minimal damage to biological sites (considering that the maximum permissible light intensity for skin exposure is 0.726 W/cm²). For example, upconverting NPs (UCNPs) doped with lanthanide ions have been used to convert NIR irradiation to UV/visible light. After the upconversion emission another photo-sensitive material absorbs the upconverted light producing photo-reactions which induce drug-release mechanisms e.g. through degradation of polymeric NPs¹⁷⁷⁻¹⁷⁹.

Recently, the assembly/disassembly of NPs through light-triggered reversion of surface charge has been used as an efficient drug release mechanism. For example, colloidosome microcapsules fabricated via electrostatic assembly of organosilica NPs with oppositely charged surfaces were exposed to light irradiation (365 nm). This induced electrostatic interactions leading to surface charge reversion or “flipping” by which the positive charges turned to negative thus the repulsive forces between negative charges disassembled the colloidosomes and resulted in drug release¹⁸⁰.

An important photo-activated mechanism is two-photon NIR-triggered drug release, in which simultaneous two-photon absorption induces chemical reactions. However the low efficiency of energy absorption by chromophores using this mechanism can reduce its efficiency¹⁸¹. Furthermore, this mechanism has several advantages such as high three dimensional spatial resolution due to the required tight focus of the laser, low scattering losses, deep penetration in tissues¹⁸², insignificant premature drug release³³, and significant cytotoxic effects by generation of toxic ROS^{183, 184}. In this approach, two-photon fluorophores and photosensitizers are doped or covalently bound to a nanostructure such as MSN based nanovalves. Thereafter, by two-photon

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

NIR irradiation, the fluorophores with high two-photon cross-section and having maximum emission capability through mechanisms e.g. Forster resonance energy transfer (FRET) isomerize the photosensitizers (e.g. azobenzene) located on the fluorophores in the nanostructure. Thus, the drug release process is activated^{77, 185}.

The photo-reduction of metal-based prodrugs (e.g. Pt) is another novel technique to induce drug release in reductive milieus such as cancerous sites. Herein, via a photo-irradiation, a non-toxic inactive prodrug (e.g. a metal complex containing Pt(IV)) changes to the active cytotoxic form (e.g. a complex with toxic Pt(II))^{186, 187}. Photo-triggers such as UV light¹⁸⁸, visible light¹⁸⁹ and NIR irradiation⁶⁷ have been reported to induce photo-reductive activated prodrug release with advantages such as enhanced specific cytotoxicity against cancer cells, induction of apoptosis, *in vivo* bioavailability, maximal light penetration, significant inhibition of tumor growth as well as simultaneous imaging capability.

Several efforts have been conducted to develop photolabile protecting groups as a component of nanocarriers which can encapsulate drug molecules and sequester them. Thereafter, these protecting groups can be eliminated by light irradiation, hence the protected drug molecules are uncaged and delivered to a targeted biological site where they can bind to cell receptors¹⁹⁰. Photolabile protecting groups (i.e. photo-uncaging groups) can be employed in different nanostructures such as liposomes, peptides, and lipidic NPs for delivery of biomolecules including antimicrobial peptides, nucleic acids, and anti-tumor agents, etc.¹⁹⁰⁻¹⁹².

In photothermal therapy by DDSs, the light absorbed by a nanomaterial is converted to localized heat via plasmonic mechanisms (i.e. collective oscillation of free electrons in the conduction band leading to light scattering due to localized surface plasmon resonance(LSPR))¹⁹³ which can induce enhanced detrimental effects on bacterial cells¹⁹⁴, tumor cells and tissues^{195, 196}. LSPR enhanced heating can be effective although conventional hyperthermia (41-44°C) has adverse effects such as protein unfolding, and DNA denaturation¹⁹⁷. In photo-triggered thermal activated drug release, low power densities e.g. 0.20 W/cm² (Ag-Au shell-core)¹⁶⁰, 0.6 W/cm² (reduced GO)¹⁹⁸, and 1-2 W/cm² (gold nanocage-CNT hybrid)¹⁹⁹ have been reported that do not damage tissue. Photo-triggered thermal systems have also led to a type of photochemotherapy with

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

advantages including on-demand drug release, destruction of tumor cells either in light treated or light-shielded areas (the latter one due to heat-generated diffusing in the tissue), with a light-dosage dependent response²⁰⁰. Novel hollow plasmonic nanocrystals made from caged gold nanorods (CGNRs) were fabricated by Xiong et al.²⁰¹. They showed broad-band dipolar surface plasmon resonances to NIR, obtained via tuning their length and thickness. The strong plasmon coupling between the surrounding gold nanocages and the internal gold nanorods could potentially intensify the efficiency of the photothermal effect thus providing a multifunctional theranostic CGNR-based nanoconstruct for cancer treatment (Fig 9).




Fig. 9 TEM images of CGNR and the schematic mechanism of 1-tetradecanol and dye/drug loading and release, Reproduced from ref²⁰¹. Copyright 2014 with permission from “Royal society of Chemistry”.

Furthermore, photothermal therapy that is combined with photodynamic therapy (i.e. generation of ROS such as singlet oxygen and free radicals) has shown high cytotoxic efficacies and enhanced damage to tumors⁴⁵ but can have disadvantageous features such as low ROS production, a tendency toward self destruction, inadequate selectivity, and meager water-solubility²⁰². A NIR-activated aptamer-silver-gold shell-core nanocarrier showed insignificant destructive effects against normal cells along with highly sensitive detection of various cancer cells at low concentration¹⁶⁰. Another system based on chitosan nanospheres showed a synergistic photothermal effect (due to hyperthermia from gold nanorods) and photodynamic effect (due to ROS production by indocyanine green (ICG)) against cancer tissues as well as localized accumulation in these sites. Fig. 10-a shows the significantly reduced cell viability after NIR-irradiation²⁰³. Fig. 10-b illustrates a DOX loaded GO-poly(allylamine

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

hydrochloride) (PAH) composite capsule was fabricated. Here, NIR irradiation ruptured the capsules and drugs were released²⁰⁴. Chang et al. studied drugs encapsulated inside Au-nanorods capped by oligonucleotides. NIR was utilized in their attempt to produce photothermal conversion of Au nanorods and subsequently dehybridization of their light-sensitive gate of duplex DNA²⁰⁵.




Fig. 10 Cell viability evaluation of cancer cells before and after NIR irradiation using a ICG-Au –chitosan based nanocarrier, Reproduced from ref.²⁰³. Copyright 2013, with permission from Elsevier, b) cumulative release curves before NIR-irradiation (curve 1) and after NIR irradiation (curve 2 and 3) and the schematic of drug release process (inset image), Reproduced from ref.²⁰⁴ with permission from “the Royal Society of Chemistry”.

Another light-sensitive drug release mechanism, known as photochemical internalization (PCI), has recently been used to treat cancer in both animals and patients²⁰⁶. In PCI which was first reported in 1999²⁰⁷, photosensitizing compounds are localized in intracellular endocytic membranes and are then excited by light, producing ROS, whereupon cargo inside the endosomal vesicles is released after disruption of the membranes. This route is often utilized in releasing macromolecules (such as ribosome inactivating proteins or nucleic acid therapeutics) that have been taken up into cells by endocytosis, but need to get out of endosomes to reach the nucleus or the ribosomes to have their best effect^{207, 208}. Sabira et al.²⁰⁹ utilized this method to

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

silence epidermal growth factor receptors by siRNA. They concluded that endosomal escape was a limiting step for the efficiency of siRNA silencing. In addition they found that lipid-based carriers of nucleic acids had an increased efficacy in PCI. The location of some photosensitizing compounds inside cytoplasmic membrane is one of the main problems in PCI as photoactivation would be detrimental to the cells³¹. It could be suggested that a pH-sensitive linker between the photosensitizing compound and the drug-bearing MNP may be engineered so that release of drug/gene happens only within either/both lysosomes or/and endosomes. Consequently, only the membrane of these two organelles would be destroyed after light irradiation and release of the loaded material occurring in the cytoplasm.

2-1-5 Mechanical-responsive MNPs

Mechano-responsive nanostructures are another approach to smart DDSs for which only a few studies have so far been reported. Generally this concept is based on assembly and disassembly of mechano-responsive molecules/structures with applied pressure or other physical stimuli with the aim of changing the overall volume¹⁴⁵. This approach proposes a biomimetic and simple mechanism for controlled DDS compared to other external stimuli-based systems²¹⁰. For example cyclodextrin (CyD) inclusion complexes can be affected by pressure, and the destabilization of the inclusion complex in CyD-alginate (AL) hydrogels by mechanical compression was reported for the purpose of patient-controlled release of ondansetron (ODN) (Fig. 11-a)²¹¹. Accelerated drug release occurred when the inclusion ability of the β -CyD was reduced by applying pressure to an implantable gel thus forming an on-demand strategy for the treatment of severe nausea caused by chemotherapy.

Shear stress is a less often discussed mechanical stimulus that can be used in the design of smart DDSs. Shear stress is higher in narrowed segments of arteries compared to healthy arterial segments. This difference could be a better physical/mechanical signal to trigger drug release in arteries in comparison with other biological or chemical stimuli²¹². Cardiovascular diseases such as stenosis and atherosclerosis could be promising applications of these endogenous mechano-stimuli-responsive systems. For example a study prepared lenticular liposomes that were stable

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

under static conditions but unstable in the elevated shear stress of atherosclerosis²¹³. The lenticular morphology led to preferential rupture along the equator of the nanostructures followed by increased release of drugs in the areas of high shear stress (Fig. 11-b).




Fig. 11 a) Concept of controlled release of ODN from a pressure-sensitive hydrogel. The inset shows accelerated releasing in response to mechanical compression, b) Endogenous shear stress as a drug releasing stimulus, mechanoresponsive lenticular vesicles 100 nm (inset); a) Reproduced from ref.²¹¹. Copyright 2013 with permission from the Royal Society of Chemistry, b) Reproduced from ref.²¹³. Copyright 2012 with permission from Nature publishing group.

Another study developed microscale aggregates of NPs that were broken up into their individual nanoscale components under high local shear stress, for treatment of thrombosis²¹⁴. Rapid clot dissolution, lower required doses, restoration of normal flow dynamics, minimized side-effects with maximized drug efficacy were all obtained after *in vivo* administration.

2-1-6 Ultrasound-responsive MNPs

Ultrasound (US) is one of the external stimuli that can induce mechanical or thermal stimulation. US is of great importance in modern medicine and has a role in many medical applications such

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx**ARTICLE TYPE**

as diagnosis (at low frequencies for imaging) and treatment (at high frequencies for removal of masses such as tumors). In the design of US responsive nano-carriers, three main properties are required; reliable and stable drug encapsulation before delivering the applied US waves to the tissue, efficient drug release owing in response to particular US waves, and the capability of monitoring drug release for imaging and therapeutic purposes. The biomedical range of US waves varies from 0.1 to 50 MHz, although the minimal required frequency is 1 MHz in deep therapy and imaging⁴⁵⁸²¹⁵.

US not only can trigger the release of drugs from carriers, but can also increase the permeability of biological barriers (cell membranes, blood brain barrier, etc.) by formation of cavitation bubbles and increased temperature resulting in enhanced drug diffusion²¹⁶. Insonated medium can cause unidirectional flow in an aquatic medium, which can affect the tissue structures. Furthermore these waves produce an oscillating pressure between the two layers of biological membranes and create pores in them, thus enhancing the permeability of cell membranes. The effects of US for transdermal drug delivery were widely discussed in a review by Azagury et al.²¹⁷. The absorption coefficients of US vary among the different body parts and tissues. Some tissues such as bones have much higher coefficients compared to soft tissues, but studies have revealed that the threshold of US pressure and frequency as well as the burst length can influence this tissue disruption and control brain damage when US is applied to the head²¹⁸.


The most suitable structure for US responsive drug-carriers is microbubbles (not nanobubbles) consisting of a gas core such as perfluorocarbons, nitrogen or air, surrounded by a shell of lipids, polymers and proteins such as albumin. The radius of the microbubbles needs to be in a particular range and the number of sites at which microbubbles interact with the vasculature, must be maximized by considering the saturation level. The bubbles are typically on the micron scale (1-10 micrometers) and do not leave the circulation after injection unless they are phagocytosed. Their activation by US also causes physiological changes that enhance drug penetration into the cells²¹⁹, ²¹⁸. Optimizing the gas-core is a good strategy to enhance US responsivity of the core-shell nano-carriers, even in more complicated structures in which several

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

liquid and elastic layers surround a gas-core. Each layer of this type of carrier could possess different hydrophobic and hydrophilic properties and could incorporate different types of active cargo molecules. Microfluidic technology provides a good method to produce a gas-core triple emulsion with a gas-in-oil-in-water-in-oil (G/O1/W/O2) structure as shown in Figure 12. In this study, Chen et al. demonstrated the importance of the gas-core in US responsivity by comparing the effect of US triggering on double oil-water-oil (O/W/O) emulsion structures without the gas-core and the triple G/O/W/O emulsion. The O/W/O emulsions only slightly vibrated without a major response to US waves, whereas the G/O/W/O emulsions disintegrated and their cargo was released²²⁰(Fig. 12 B, C). Moreover the materials comprising the core and shell govern the interaction of immune system with the microbubbles. Soft-shell microbubbles have a thin layer of phospholipid or protein which provides higher sensitivity to the US waves. On the other hand hard-shell microbubbles contain entangled or cross-linked polymers that have higher stability and lower US response^{478,480, 481}.



Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Fig. 12 Production of US responsive gas-core triple emulsion nanocarrier. (A) Schematic of microfluidic apparatus for fabrication of the triple emulsion. Dashed lines show the encapsulation of gas in oil and aqueous phases by microcapillary needle. Active cargo might be present in either the oil or the water, then the outer layer of oil surrounds the whole drop. (B) The double emulsion O/W/O drops do not respond to US waves (C) The gas-core triple emulsion disintegrates by US trigger. Arrows show the direction of U.S waves. Reproduced from Ref.²²⁰ with permission from the Royal Society of Chemistry.

The two principal advantages of US, namely energy focusing and good effective depth, make US an attractive route for gene delivery. Many commercial US contrast agents are available such as SonoVue, Optison and Levovist which can be used to monitor the delivery of therapeutic genes by low intensity US. The low intensity of the US prevents the harmful effects on tissues and organs. After the carrier has reached the targeted tissue, high intensity US is applied that causes cavitation in the microbubble gas core and release of the attached DNA to the targeted cells²²¹⁻²²⁵.

Yuneet al.²²⁶ used US-mediated collapse of microbubbles to deliver siRNA to enhance therapy against yolk sac carcinoma in vitro. They suggested that owing to the negative charge of DNA, cationic lipid microbubbles would be suitable candidates for gene delivery. Unger et al.²¹⁶ showed the capability of US to increase gene expression and transfection efficiency using cationic liposomes into cells²²⁷. Lawrie et al.²²⁸ reported that US could enhance vascular gene delivery used for a cardiovascular application such as prevention of restenosis. Kuo et al.²²⁹ showed that poly-L-lysine (PLL) and polyethylenimine (PEI) both protected nucleic acids from 20 KHz US waves, better than PEG. Hou et al.²³⁰ transfected the gene for inducible Smad 7 by US-triggered microbubbles in order to block TGF β and decrease renal fibrosis in chronic kidney disease. Moreover, nanoscale bubbles also can be designed for targeted drug delivery. For example Zhang et al.²³¹ combined poly lactic-co-glycolic acid (PLGA) nanobubbles with monoclonal anti-HLA antibody to generate a carrier for targeted delivery to cancer, and enhanced high-intensity focused US ablation of tumors, and Chen. et al.²³² used US-triggered

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

nano/microbubbles to transfect a model gene (luciferase) into periodontal tissue and observed high gene expression localized in the muscle cells of gingival tissues.

Different structures have been used to deliver drugs and release them by US stimulation. Naked DNA and free drugs can enter into the cell through endocytosis after application of US without using nano/microbubbles and the percentage of Ca^{2+} has a central role in this phenomenon. Ca^{2+} increases inside the cell by cell membrane disruption, although the amount of unspecific delivery will also significantly increase which is more important in the case of gene delivery²³³. Micelles with 10-100 nm diameter have been used for delivery of hydrophobic drugs. They self-assemble from amphiphilic polymers in aqueous solution and under the influence of US they release their cargo. The highest drug release occurred at 20 KHz although low frequency 20-90 KHz was also effective for drug release from micelles. Rapaport et al.²³⁴ generated US-responsive micelles by composing PEG-PLLA poly(ethylene oxide)-co-poly (L- lactide) or PEC- microbubbles PCL poly (ethylene oxide-co-polycaprolactone) (PEO-co-PCL). They introduced a core containing 1% PFP (perfluoropentane) that was coated by PEG-PLLA. The resulting microbubbles had a maximum diameter of 500-700 μm and possessed the ability to deliver paclitaxel (PTX) to A2780 ovarian carcinoma or MDA MB 231 breast cancer cells exposed to unfocused 1 MHz US for 1 min. Figure 13 depicts this mechanism.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig. 13 US-induced phase change particles to facilitate drug release from bubbles.

Hosseini et al.²³⁵ studied the factors that triggered drug release, and highlighted the role of cavitation as the single most important factor in drug delivery. The size and material properties of bubbles along with the US amplitude directly influenced the type of cavitation (formation of gas filled cavities such as bubbles when exposed to an oscillating pressure). The mechanical index (MI) of cavitation, in tissue without micro-bubbles, should be less than 1.9, whereas in the presence of micro-bubbles it is reduced to less than 0.8. Increased cell uptake of drugs was proposed as the second reason since the cell membrane can be temporarily permeabilized by the cavitation-induced shock wave. Geer et al.²³⁶ designed a liposomal microbubble for increasing cytotoxicity of cancer drugs even at very low doses. Nonlinear reflection of US with low acoustic pressure led to particle destruction in addition to the increased membrane permeability.

The energy of the acoustic waves, when they pass through cells and tissues, is transformed into heat, and therefore applying a focused US beam can generate local tissue heating which can be monitored by different thermometric devices. US also led to the cavitation of the NPs and the destruction of nearby cancer cell membranes, therefore increasing drug uptake. In 2013 Rapoport

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

et. al.²³⁷ loaded PTX into NPs (nanoemulsions) with 200-300 nm diameters for the treatment of pancreatic cancer activated by FUS (focused US). Here, US delivery (pressure \geq 1MPa), 6h after injection of the NPs, enhanced tumor regression. In addition US can improve the contractile strength of the myocardium. In a study Spivak et al.²³⁸ utilized US-mediated sonoporation to increase the uptake of 30 nm AuNPs conjugated with Simdax (a calcium sensitizer) in a rat model of heart failure. The strong antioxidant property of AuNPs was observed, and the Simdax was released under US beams.

Rather than the usual advantages of liposomes such as being a stable carrier for lipophilic and hydrophobic compounds, the US beams applied for liposomal drug release should be strong enough to disrupt the liposomal structure and low frequency beams have better efficiency. Furthermore, the combination of US with hyperthermia can also enhance drug release. Smet et al.²³⁹ used HIFU mediated drug delivery under MR image guidance. They used temperature responsive liposomes (TSLs) co-encapsulating DOX and an MR contrast agent (250 mM [Gd(HPDO3A)(H₂O)]) and showed release of DOX while no leakage of the MRI contrast agent was reported over 1 h at 37°C. Owing to many simultaneous processes occurring *in vivo*, identifying the dominant mechanism of action is difficult, US-responsive lipid nano-carriers still have good potential for treatment of cancers²⁴⁰⁻²⁴². Xie et al.²⁴³ utilized a lipid-encapsulated formulation (MRX 802) with 1µm diameter that included platelet targeted ligands such as the peptide (cyclo-CRGDWPC)-OH) and targeted glycoprotein 2b/3a receptor. In pigs afflicted with acute left anterior descending thrombotic occlusions, a low-MI (mechanical index) US pulse sequence was utilized to guide the delivery of high-MI (1.9 MI) US and image the myocardium. They observed epicardial recanalization, myocardial blood flow and infarct size were significantly improved by US induced cavitation of MBs.

Di et al.²⁴⁴ described a three-dimensional cohesive gel-like nano-network formed from PGLA through electrostatic interaction between positively-charged (chitosan) and negatively-charged (alginate) NPs. This nano-network could be loaded with insulin, subcutaneously injected into diabetic mice, whereupon the insulin was released in a controlled fashion by US-induced shock

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

waves causing cavitation (frequency: 950 kHz, pulse duration: 20 μ s, output power: 4.31 W, administration time: 30 s).

Although sometimes the size of microbubbles is too large to reach the targeted tissues outside the vasculature, they can be combined with other NPs such as liposomes and micelles. This strategy can enhance drug loading capacity, increase the systemic targeting capability and increase the vascular permeability of microbubbles. For example, Burke et al.²⁴⁵ showed that the delivery of PLGA NPs containing 5FU was improved by covalently linking them to US-activated microbubbles. After intravenous injection into Rag-1 knockout mice with C6 gliomas, mice were exposed to pulsed 1MHz US giving a 67% reduction in tumor volume at 7 days. Improved drug delivery to PC3 prostate cancer xenografts and the subsequent controlled release were shown using air-containing microbubbles consisting of poly(butylcyanoacrylate) (PBCA) loaded with the model drug Nile red after exposure to 300 kHz or 5 MHz US²⁴⁶.

2-2- Chemical stimuli-responsive MNPs

2- 2-1 pH-responsive MNPs

It is well-known that significant pH gradients exist within body (especially the gastrointestinal tract (GI) tract) and also considerable pH differences exist among healthy and pH values vary among the lysosomes (4.5-5), endosomes (5.5-6), Golgi apparatus (6.4), cytosol (7.4). pH alterations can be induced by the growth of microorganisms (directly or through induction of the release of host enzymes)²⁴⁷, there is an acidic milieu in healing wounds and an alkaline milieu in non-healing wounds²⁴⁸. Most importantly there is a lower pH profile in tumors than in corresponding normal tissues (i.e. 7.4). This occurs due to the rapid proliferation of cancerous cells outrunning the blood supply, and causing inadequate supplies of oxygen and nutrients, and the thus formation of lactic acid produced by glycolysis rather than oxidative phosphorylation in normal cells. This phenomenon is known as the Warburg effect. These widely varying pH conditions in diverse biological systems have motivated the design of pH-responsive DDSs^{52, 249}. pH-responsive nanomaterials have demonstrated a variety of applications including pH-sensors²⁵⁰, theranostic applications^{251, 252}, controllable switches, controlled-release surfaces,

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

controllable wettability, cell-recognition devices²⁵³, etc. Novel pH-responsive nanocarriers of biphasic colloidal particles and “Janus particles”²⁵⁴ have been recently developed with advanced features enabling them to undergo morphological alterations upon pH changes, a new concept of great importance in the design of pH-sensitive DDSs.

There have been abundant advances in smart DDS based on pH-responsiveness of nanosystems in the past few years, that have resulted in remarkable breakthroughs in diagnosis and therapy of a range of diseases and disorders such as malignancies and infections. They have shown enhanced antitumor efficacy and reduction of the toxicity of chemotherapy²⁵⁵, delivery of nucleic acids, proteins, peptides, etc.²⁵⁶. pH-responsive DDSs can significantly enhance oral bioavailability of anticancer drugs, producing efficient inhibition of tumor growth, reduction of systemic toxicity²⁵⁷ as well as improving selectivity to tumor cells while only giving extremely low cytotoxicity toward normal cells²⁵⁸.

The pH-sensitive nanomaterials that have been used in DDSs can be classified into organic, inorganic and hybrids²⁵⁹ and their methods of synthesis, properties and applications have been recently reviewed²⁶⁰. The design of pH-responsive nanocarriers requires a good comprehension of their features and mechanisms. For example, the degradation of the spacers conjugating the drug to the polymeric NP at the low environmental pH of tumors or in endosomes/lysosomes²⁶¹, the protonation of moieties (e.g. carboxylic groups or titratable amines) attached to the surface of the polymeric micellar particles and subsequent structural changes²⁶², the cleavage of dendrimer particles induced by sensitivity of its hydrophobic groups to acidic condition²⁶³, and utilizing acid-labile zwitterionic peptide-lipid derivatives in lipidic nanocarriers²⁵⁵ are several examples of pH-dependent mechanisms that can be used for smart drug-delivery. However, the concept of the instability of different pH-responsive nanocarriers in biological media is mostly based on ionizable pH-sensitive groups present in polymeric and peptide NPs, and on acid-labile chemical bonds; both topics are discussed below.

Ionizable chemical groups (e.g. amines, carboxylic acid) including weakly acidic groups (proton donor) or weakly basic groups (proton acceptor) are used in anionic and cationic pH-sensitive polymers, respectively^{264, 265}. These pH-triggered delivery systems show advantageous features

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

such as enhanced cellular uptake, high efficiency of drug or gene (e.g. plasmid DNA (pDNA), and small interfering RNA (siRNA)) delivery, facilitated endosomal membrane rupture induced by the proton sponge effect (i.e. endosomal destabilization by osmotic swelling), surface charge reversion of nanocarriers and deshielding in the low extracellular pH of the tumor environment²⁶⁶⁻²⁷¹. The pH-sensitivity of chitosan derivatives and chitosan-based NPs make them good candidates for pH-responsive oral drug delivery²⁷²⁻²⁷⁴ with properties such as drug release in the intestinal environment (pH 6.8)²⁷⁵, delivery of macromolecules, drugs, and gene (non-viral) delivery²⁷⁶⁻²⁷⁸, apoptotic effects produced in tumor cells²⁷⁹, low cytotoxicity, and increased gene transfection and expression in cancer cells²⁷⁸. Various chitosan-based nanoassemblies are illustrated in Fig. 14.




Fig. 14 Chitosan-based nanoassemblies applied in biomedicine.

A) nanospheres, (B) vesicles, (C) micelles, (D) nanogels.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Peptides have been considered as efficient and safe nanocarriers for non-viral delivery of genes to cells²⁸⁰, as compared to viral gene delivery systems, although the structure has been inspired by these viral vectors. Peptide vectors have advantageous features such as the ability to penetrate the cell membrane, endosomal fusion (in low pH of endosome), and nuclear delivery^{281, 282}. Moreover they avoid the side-effects seen with viral vectors such as inflammation, sustained immune response, and development of cancer and even death²⁸³⁻²⁸⁵. In addition, multiple repeats of peptide motifs such as glutamic acid-alanine-leucine-alanine (a 30 amino acid)(GALA), shorter version of GALA (shGALA), lysine-alanine-leucine-alanine (KALA) and a 16-amino-acid peptide (RALA) peptides have also been utilized as efficient gene delivery platforms with advantages such as increased interactions with cellular lipid bilayers (especially at lower pH), a long blood circulation time, efficient tumor growth inhibition, improved gene expression, reduced cytotoxicity, increased binding ability to DNA, improved cell-internalization, ability to carry both hydrophilic and hydrophobic molecules with a broad size range (e.g. small molecules, viruses, antibodies, plasmids, proteins), pH-sensitivity to regions of the gastrointestinal tract and good oral delivery^{280, 286-289}. Such gene delivery platforms can be also envisioned for clinical applications²⁸⁰.

Among pH-sensitive moieties, the acid-labile linkers responding to only slight pH changes can provide new classes of highly sensitive pH-responsive MNPs. Acid-labile covalent linkages can be rapidly hydrolyzed in acidic environments such as tumor tissues and several cellular compartments including lysosomes (pH ~4.5-5.0), early endosomes (pH ~6.0-6.5) and late endosomes (pH 5.0-6.0)²⁹⁰. Polymers containing these cleavable linkers (e.g. acetal/ketal, hydrazine, imine groups etc.) are stable at physiological pH, while drug release occurs due to hydrolysis of the linker bonds in response to the decrease in pH. Cleavable linkages can either be placed in the backbone of the polymer or in the side chains^{290, 291}.

Acid-labile linkages in nanostructures (e.g. polymers) have shown noticeable advantages in gene delivery including biocompatibility, biodegradability, highly efficient delivery, efficient serum-resistant gene transport, low cytotoxicity²⁹²⁻²⁹⁴. pH-responsive micelles with an acid-labile ketal

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

linkage in the hydrophobic backbone were dissociated at an acidic pH thus their anticancer cargo was released. Fig. 15 illustrates assembly and release of drug from micelles²⁹⁵.




Fig. 15 Schematic illustration of assembly and drug release from a micelle encapsulating hydrophobic drugs.

pH-sensitive micellar structures have other favourable features including multi-functionality, good stability at physiological pH (7.4), partial hydrolysis at the extracellular pH of solid tumors and complete hydrolysis at the lower endosomal pH, a positively charged surface at tumor pH, improved cellular uptake through surface ionization and electrostatic interaction with cell membranes, good endosomal dissociation of micelles, and endosomal membrane disruption leading to enhanced intracellular delivery via the endocytic pathway²⁹⁶.

Acid-labile hydrazone bonds can be utilized in pH-responsive DDSs for cancer treatment²⁹⁷⁻³⁰². pH-responsive nanosystems containing hydrazone bonds such as polyurethane (PU) have shown diverse advantages including multi-functionality, biocompatibility, biodegradability of the carriers, anticancer drug release in response to the acidic intracellular environment, ability to be loaded with lipophilic agents in physiological conditions³⁰³, controlled stepwise drug release, and non-toxicity³⁰⁴. Micelles containing hydrazone bonds have also been developed, especially for cancer therapy³⁰⁵ with advantages such as more rapid drug release at acidic pH³⁰⁶, and delivery of hydrophobic drugs with no need for conjugation sites³⁰⁷. Furthermore, the use of nanosystems containing pH-sensitive hydrazone bonds enables co-delivery of drugs such as DOX together with siRNA to tumor cells^{298, 302}. Fig 16-d illustrates a self-assembled dendronized NP containing heparin conjugated to DOX using an acid-labile hydrazone linkage and a negatively

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

charged surface. This NP showed more rapid drug release at pH 5.0 than at pH 7.4 followed by significant killing of 4T1 cancer cells by apoptosis, an antiangiogenesis effect in a breast cancer model with insignificant side-effects³⁰⁸.

The deep penetration of anticancer drugs (especially those loaded into nanocarriers) into the tumor tissue is a challenging issue. The size and the surface charge of the nanocarriers are the key parameters determining penetration, but the drug release in response to slight pH-changes will lead to better tissue penetration and cellular uptake in cancer cells³⁰⁹. Smart pH-triggered nanocarriers including micelles with hydrazone bonds³¹⁰, liposomes³¹¹ have shown good cytotoxic effects and high tumor targeting capability.

Lale et al. reported an acid-sensitive hydrazone-linked nanosystem for breast cancer targeting. It combined the proton sponge-mediated endo-lysosomal escape ability and dual targeting (flatastuzumab) had minimal cardiotoxicity, hepatotoxicity, and nephrotoxicity along with its high therapeutic efficacy³¹². Sun et al.³¹³ reported two DOX functionalized prodrugs, one that was acid-sensitive (cis-aconitic anhydride conjugated to PEG (CAD-PEG-CAD)) and the other was insensitive to pH changes (succinic anhydride conjugated to PEG (SAD-PEG-SAD)) which both self-assembled into micelles. Both micelles were stable at physiological pH (i.e. pH 7.4), however the CAD-PEG-CAD micelles underwent swelling and drug release at intratumoral and endosomal pH values (pH 6.8 and 5.5, respectively) (Fig. 16-a). There was good cellular uptake, remarkable tumor suppression (Fig. 16-b) and high cytotoxicity (Fig. 16-c) along with reduced side-effects.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig. 16. a) DOX release from SAD-PEG-SA and CAD-PEG-CAD at pH 5.5, 6.8 and 7.4 at 37°C, b) cytotoxic effects and c) tumor volume evaluation, for free DOX, SAD-PEG-SA and CAD-PEG-CAD, d) dendronized heparin-DOX based NPs with hydrazone bonds. (a, b and c reproduced from ref.³¹³. Copyright 2013 with permission from “John Wiley & Sons, Inc.”, and d reproduced from ref.³⁰⁸.

Copyright 2013 with permission from “Elsevier”).

Multi/dual pH-responsive DDSs are new concepts with the promise of future refinements in smart drug delivery. Dual pH-responsive delivery nanosystems can be designed to be sensitive to both tumor pH and to endosomal pH. A pH-triggered polymer-DOX drug conjugate smart nanosystem was developed capable of responding to both extracellular and to intracellular pH values. This nanosystem reversed its negative surface charge to positive at extracellular tumor pH (~6.8) leading to facilitated cellular uptake. Afterwards, enhanced intracellular drug release from endocytosed nanocarriers was obtained at the more acidic pH (~5.0) of intracellular

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

endosomal compartments. Increased cytotoxicity and reduction of anticancer drug resistance in cancer cells was achieved³¹⁴. Graphene and GO nanocarriers have been designed to be pH-responsive in DDSs^{315,316}. In anticancer therapy, pH-responsive GO nanocarriers have shown less resistance in cancer cells, accelerated drug release with slow efflux, and synergistic therapeutic effects against tumors³¹⁷.

Photodynamic therapy (PDT) has been combined with DDSs. Recently fullerenes have shown great potential as photosensitizers. For example, a DOX loaded poly(ethyleneimine)-derivatized fullerene (DOX-PEI-C60) showed a synergistic combination of chemotherapy and PDT, with high cytotoxicity, good tumor targeting, efficacious tumor growth inhibition, and a strong pH dependence with no evident systemic toxic effects against normal cells³¹⁸.

MSNs containing a pH-sensitive compartment have favorable properties including large surface area, high pore volume and large capacity for cargo delivery^{319, 320}, good pH-sensitivity³²¹, improved oral bioavailability and long-term preservation of the active drug inside the nanomatrix³²², sensitivity to the acidic endosomal pH³²³, and the ability for pH-sensitive gating of controlled drug release^{86,324}. Very recently Chen et al. fabricated MSNs that were acid-sensitive. These MSN showed pH-triggered drug release and better cytotoxicity against cancerous cells³²⁵.

pH-responsive DDSs can be potentially used for delivery of protein and peptide drugs such as insulin and can shield them against denaturation by the "crowding effect"³²⁶. A dendritic polyglycerol (dPG) nanogel containing acid-labile benzacetal bonds was prepared. Protein release without loss of activity was achieved at the low pH milieu of acidic cell compartments^{326, 327}. Several pH-sensitive DDSs have been developed for targeted delivery of live bacteria (e.g. *Lactobacillus casei*) to the small intestine by protecting from the acidic environment of the stomach (i.e. pH 1-3)³²⁸. Imbalances in the concentration of metal ions in biological sites can cause several disorders such as Alzheimer's disease (induced by dysregulation of copper ions that causes formation of aggregation of amyloid-beta (A β) peptides in the brain)³²⁹. pH-responsive delivery systems could be a possibility for treatment^{330, 331} since metal ions could be transported and released at the biological site using pH-triggered delivery systems³³².

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

A carbon dot-coated calcium alginate bead (CA-CD)-based DDS was used to deliver drugs in the gastrointestinal tract at low pH³³³. In another study, a nanocarrier comprising a synthetic chitosan-modified gold NP attached to the anionic surface of a liposome (AuChi-liposome) was reported for delivery of antimicrobial drugs (e.g. doxycycline) to the stomach as a therapy for *Helicobacter pylori* infection. The nanocarrier was stable at gastric pH=1.2 but at neutral pH=7.4 regions (where the bacteria are situated) became destabilized through detachment of the gold NPs followed by the active fusion of the liposome to the bacterial membrane which induced subsequent drug release (Fig. 17)³³⁴.




Fig.17 a) Schematic of phospholipid liposomes stabilized by chitosan-modified gold NPs: these are stable at gastric pH 1.2 but become destabilized at pH 7.4 in sites of *H. pylori* infection by deprotonation and detachment of gold NPs from the liposomes, b) accumulative doxycycline release profile from AuChi-liposome at pH=1.2 and 7.4; Reprinted with permission from ref.³³⁴. Copyright 2013 “American Chemical Society”.

pH-sensitive nanocarriers can be used to avoid the premature degradation of drugs in cellular compartments such as lysosomes. These carriers respond to reduced pH by rupturing and destabilizing the endosomal membrane causing drug release into the cytoplasm⁷. The drug loading capacity, release rate and dosage are vital factors in this regard. pH-responsive DDSs can

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

have a high loading capacity for drugs^{253, 257}. In some cases, in order to achieve long-term drug administration, a slower drug release rate can be obtained using pH-responsive DDS based on the β -cyclodextrin inclusion complex³³³. Furthermore, achieving a sufficient therapeutic dosage of drug after a single oral administration is sometimes important in the case of drugs with limited bioavailability e.g. high isoelectric point therapeutic proteins that need to reach the small intestine and penetrate through the intestinal epithelium. The desired release rate of the therapeutic drug can be tailored to the required dosage³³⁵.

Dual cargo release systems with selectively controlled release of two different drugs can be considered an important topic. Wanyuan designed a nanocarrier from which one cargo was released at a lower pH value, while the other one was released at higher pH³³⁶. To overcome cancer multi-drug resistance (MDR), which causes clinical treatment failures, various attempts have been conducted; for example through pH-responsive co-delivery systems³⁰². In one study nucleic acid (e.g. siRNA) transfection was utilized to induce efficient gene silencing (e.g. luciferase expression) within various carcinoma cell lines accompanied by simultaneous administration of anticancer chemotherapeutics such as PTX³³⁷. Chiang et al.³³⁸ designed trastuzumab-conjugated pH-triggered double emulsion nanocapsules (DENCs) for co-delivery of hydrophilic DOX and hydrophobic PTX. Here, PMA_{SH} was conjugated to the shell of the DENCs for dual drug release in intracellular acidic compartments (Fig. 18-a and -b). Enhanced cellular uptake, cytotoxicity and suppressed cancer growth were obtained. Zhang et al.³³⁹ showed efficacious accumulation of liposomal nanocarriers in tumors followed by their lysosomal escape (Fig. 18-c).

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig. 18 a) Deformation of DENCs due to the shrinkage of acid-labile PMA_{SH} at acidic pH leading to drug release, b) Cumulative drug release of PTX-DOX-DENCs containing 1wt% PMA_{SH} at pH 4 and 7, d) *ex vivo* images of ft1-bearing BALB/C mice after injecting Cy5-labeled antagomir-10b-loaded liposomes (tumors are indicated by the black arrows); (a, and b reproduced from ref.³³⁸. Copyright 2014 with permission from Elsevier, and c reproduced from ref.³³⁹. Copyright 2015 with permission from “Elsevier”.

2-2-2 Redox-responsive MNPs

Redox-responsive DDS are one of the most efficient systems for stimulus-responsive cancer and gene therapy^{334, 340}. Redox-sensitive degradable nanosystems (RSDNs) provide some benefits over other stimuli such as pH. A good response to the high intracellular levels of GSH, release of the drug directly into the nucleus and the cytosol, and stability in extracellular environment where GSH levels are low are examples of these benefits³⁴¹. The redox environment is governed by a linked set of redox couples such as NADP⁺/NADPH³⁴².

Different redox conditions between the intracellular and extracellular compartments, and also between healthy cells and diseased cells provide the stimulus for drug release. These RSDNs can

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx**ARTICLE TYPE**

be designed for different therapeutic goals. The central thiol/disulfide redox couples, GSH/GSSG, cysteine/cystine (CySH/CySSCy), Trx-1 and thioredoxin-2(Trx-2) govern the redox potential inside cells, and can have a major role in drug delivery. The intracellular concentration of GSH is about 2-10mM, while the GSH concentration in extracellular fluid in tissue is only about 2-20 μ M³⁴³. Furthermore, the endosomal compartment is redox-active due to the gamma-interferon-inducible lysosomal thiol reductase which is a reducing enzyme in the presence of some reducing agents (e.g. cysteine but not GSH). The concentration of GSH in tumor tissues and the cytosol of tumor cells is at least four times higher than that in normal tissues, so tumors can be considered a reducing environment.

The cytoplasm has metabolic oxidases that make an environment for redox signaling which is dependent on NO synthases and NADPH oxidases. Mitochondria contain the most reducing environment and are highly sensitive to oxidation. The rate of electron transfer in mitochondria is higher than other cellular compartments. Nuclei are quite resistant to oxidation but have lower redox potentials. The secretory pathway introduces disulfide bonds into proteins that are exported, by the action of oxidizing systems and enzymes. The redox potentials of cells can be affected by the functional state of the cell such as induction of apoptosis, differentiation, adhesion and proliferation. A general picture showing biologically relevant redox couples and the compartmental organization of cells and their function is given in Fig 19^{344, 345}.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig.19 Standard reduction potentials of biologically relevant redox couples with subcellular compartmentalization of disulphide/thiol redox potentials in cultured cells. The most validated data (based on limited cell culture studies) is for the cytoplasmic GSH redox potential, ranging from -260 mV (in rapidly proliferating cells) to -220 mV (in non-dividing cells).

The design of reduction-sensitive nanosystems has usually been achieved by degradable micelles using disulphide links in the hydrophobic backbone³⁴⁶. Amphiphilic copolymers with a single disulphide bond connecting the two polymer blocks³⁴⁶ can self-assemble into micelles^{347, 348}. Other approaches employ GSH-responsive crosslinking agents that are incorporated either in the core³⁴⁹ or in the shell³⁵⁰ of the micelles. Redox-sensitive systems can also use coated mesoporous

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

silica nanomaterials³⁵¹, disulphide crosslinked nanogels³⁵², liposomes³⁵³ or dendrimer-drug conjugates containing thiol-cleavable bonds³⁵⁴.

In polymeric micelles, micellar de-crosslinking and full destabilization/disassembly may be caused by reduction of disulfide bonds in polymeric assemblies by the action of intracellular GSH^{355, 356}. On the other hand oxidation of redox-active micelles could shift the hydrophobic/hydrophilic balance, leading to micelles fragmentation into water-soluble monomers and release of hydrophobic drugs³⁵⁷. In redox environments, selective drug release at pathogenic sites can be enhanced by taking advantage of the presence of activated macrophages in inflamed tissues and certain tumors. Different kinds of approaches have been made use to improve the stability of micelles in such biological systems, such as chemical cross-linking of the core^{358, 359} or shell³⁶⁰ of self-assembled micelles. Wang et al.³⁶¹ showed GSH triggered release of DOX from reduction-sensitive shell-detachable micelles with improved cytotoxicity, and overcoming the MDR in A549 cancer cells pre-treated with GSH monoester (GSH-OEt). This is a laboratory method utilized for artificial elevation of the intracellular GSH level³⁴⁷.

An intracellular GSH responsive RGD containing peptide-capped MSNs including the antitumor drug DOX (DOX@MSN-S-S-RGD) was developed. The RGD containing peptide acted as gatekeeper and was immobilized onto MSNs using disulfide bonds. Hence, after uptake by tumor cells, DOX was rapidly released by cleaving the disulphide bonds triggered by GSH. This study suggested this nanosystem could have great potential for cancer therapy (Fig.20)³⁶².

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig.20 DOX release from DOX@MSN-S-S-RGD in PBS with different concentrations of GSH for 90 min. Reproduced from Ref.³⁶² with permission from the Royal Society of Chemistry.

Core-cross-linking can increase the stability of micelles with minimal impact on the micelle surface property and can lengthen their half life in the blood circulation³⁶³. In a study, Wang et al.³⁶⁴ developed a promising DDS based on a new class of redox-responsive degradable core-cross-linked (CCL) micelles with conjugated hydrophobic camptothecin (CPT), that were subject to redox-responsive cleavage of the integral disulfide bonds. These CCL micelles showed better stability in physiological conditions compared to non-cross-linked micelles, while they underwent fast dissociation in a reducing environment, leading to burst release of CPT and higher cytotoxicity against human breast cancer cells in vitro.

2-3 Biological stimuli-responsive MNPs

2-3-1 Different biomolecular-responsive MNPs

The existence of specific biomolecules such as glucose, ATP, DNA, and ROS in specific physiological sites or in pathological conditions of living systems has encouraged the development of biomolecule-sensitive smart systems. Glucose-responsive controlled release systems have been the most investigated smart DDS to control insulin therapy for diabetics in

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

response to blood glucose levels. Different mechanisms have been used to fabricate these smart systems, that are usually based on the conversion of glucose to gluconic acid by glucose oxidase (GOx)³⁶⁵. For example human insulin, chitosan and GOx enzyme were incorporated into nanocapsules in the form of monodisperse microgels that swelled in hyperglycemic conditions through enzymatic conversion of glucose, protonation of the pH responsive chitosan matrix and release of insulin as a self-regulating nanovalve system for treatment of type 1 diabetes³⁶⁶ (Fig. 21).




Fig. 21 a) Schematic illustration of glucose-responsive insulin encapsulated microgels, b) Insulin in vitro release kinetics in solution with different glucose concentrations at 37°C. (Reprinted with permission from ref.³⁶⁶. Copyright 2013 American Chemical Society).

Insulin delivery by glucose-binding proteins such as lectins is another possible strategy. The high affinity interaction between concanavalin A (ConA) lectin and mannose was used to encapsulate insulin cargo within the MSN pores for construction of a glucose-responsive delivery system³⁶⁷. Other glucose-responsive micro/nanostructures such as fast responsive implantable microdevice³⁶⁸ and highly selective glucose responsive silica nanocontainers³⁶⁹ have also been reported.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

ROS-responsive systems can be designed to operate based on ROS-induced degradation or a ROS-mediated solubility switch³⁷⁰. ROS species such as hydroxyl radicals (HO \cdot) and hydrogen peroxide (H₂O₂) are produced in different parts of the cell as a by-product of electron transfer reactions³⁷⁰. In one study well-defined ROS-sensitive β -CD-based smart DDSs³⁷¹ were prepared by incorporation of oxidation-responsive boronic ester units in the structure. Cytocompatible micelles containing polypropylene sulfide (PPS) were developed to form a ROS-triggered drug release system taking advantage of the increased hydrophilicity of the PPS core that was disassembled after oxidation by the ROS rich environment³⁷². Another study took advantage of the EPR effect to deliver DOX nanosystems with controlled drug release after degradation of an arylboronic ester linker in the presence of ROS³⁷³.

ATP is the cellular energy source and is an important cellular metabolite with higher intracellular concentrations compared to the extracellular environment and can be used for the development of smart systems based on natural materials³⁷⁴ or on synthetic polymers³⁷⁵. In one study high ATP concentrations induced conformational changes of the protein-based nanocarrier formed from multiple units of the barrel-shaped chaperonin protein, followed by disassembly of the tubular structure powered by ATP hydrolysis, preferential accumulation in tumor tissue and cargo release³⁷⁴. Another study reported that an ATP/ATP aptamer binding complex could induce dissociation of a two dimensional (2D) DNA-graphene hybrid nanoaggregate for site-specific DOX controlled release in an ATP rich environment³⁷⁶ (Fig. 22).

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx




Fig. 22 a) Schematic of an ATP-sensitive DNA-graphene nanosystem for controlled drug delivery; The DNA aptamer bound to ATP was used as a linker. b) Cumulative DOX in vitro release at different ATP concentrations. (Reproduced from ref.³⁷⁶. Copyright 2015 with permission from Elsevier).

Other biomolecule-responsive nanostructures have been used in smart DDSs. For example controlled drug release triggered by microRNA-responsive traceable DNA-anchored MSNs operating via competitive hybridization between microRNA and the DNA caps was reported³⁷⁷. Another study also described protein responsive-amphiphilic polypeptide nanoassemblies that disassembled when a particular protein bound to the nanostructure with potential applications in protein-specific delivery and diagnostics³⁷⁸.

2-3-2 Enzyme-responsive MNPs

As an important component of the bio-nanotechnology toolbox, enzymes play a significant role owing to their exceptional bio-recognition capabilities and outstanding catalytic properties. Their high selectivity and favourable efficiency in enzyme-catalyzed reactions are very beneficial in nanomedicine³⁷⁹. Since some enzymes are over-expressed in specific tissues, and moreover their concentration may become higher in a diseased state, enzyme-responsive NPs can be an excellent candidate for designing a smart DDS. Moreover, for diagnosis purposes, measuring or detecting an enzyme activity can be very useful as its dysregulation is a particular feature of many

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

diseases³⁸⁰. A DDS design in this regard can utilize either a physical or a chemical mode of action. In the chemical mode, when the nanomaterials are exposed to the enzyme, it is possible to design the nanomaterials to release their drug load by degrading the different structures ranging from those formed from polymers to those with mesoporous silica cores³⁸¹. According to this strategy, transformation or degradation of the nanocarrier by the enzyme can also release the therapeutics and hence multimodal nanomedicines with synergistic effects can be further designed to this end. In the physical mode of action, the enzyme-responsive NPs can be designed so that their macro-scale structure is altered by the enzyme and results in controlled-release. In this approach, the surface of the nanomaterials can be modified by attaching molecules that are affected by enzymatic reactions which causes a change in their physical characteristics. Dysregulation of enzymatic activity has been observed in a number of different pathological situations and this has led to not only new ideas for drug delivery *in vivo*, but also to fabrication of new ultrasensitive sensors for diagnosing disease³⁸²⁻³⁸⁴. Nanomaterials which are used in enzyme-responsive DDS are often responsive to hydrolases or to oxidoreductases³⁸⁵⁻³⁸⁷.

The enzyme-responsive approach to smart drug delivery is based on smart polymers that act as carriers that are able to release the payload only upon the catalytic action of the enzyme. An enzyme-responsive material can be defined as a system that undergoes macroscopic changes in its physical/chemical properties upon the catalytic action of an enzyme. The response mechanism of enzyme responsive materials requires one component to be an enzyme sensitive moiety, that usually is a substrate or a substrate mimic of the enzyme, and a second component that is responsible for changes in the interactions inside the nanomaterial that can lead to macroscopic transitions and drug release. This strategy does not always require modifications of existing drugs, as they need not be chemically attached, but can be physically entrapped.

Hydrolases are often used as effector biomolecules in enzyme-activated DDS. In a smart DDS, the carrier nanomaterial can be digested by the enzyme, whenever the concentration of both species is high enough³⁸¹. This strategy can be particularly useful in some treatment methods such as chemotherapy since it can reduce side effects of some hazardous drugs. Some of the developments of enzyme degradable nanocarriers are reviewed here.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx**ARTICLE TYPE**

Protease enzymes play powerful roles in many cellular processes such as DNA replication and transcription, cell proliferation, differentiation, angiogenesis, conception, wound repair, stem cell mobilization, hemostasis, inflammation, blood coagulation, immune response, necrosis and apoptosis³⁸⁸. Proteases are also an ideal enzyme for designing smart DDSs as they are often over-expressed in diseases, such as cancer and inflammation, and protease activation can be used to release drug from carriers at specific locations within cells³⁸⁹. In these conditions, the therapeutic effect of cargo release occurs after incorporation of the NPs inside the specific cell by endocytosis. By doing so, the therapeutic effects of the drug will be increased and the toxic effects will be decreased due to lower required doses. For instance, Vicent et al.³⁹⁰ used a specific peptide sequence as a linker to attach DOX and aminoglutethimide (AGM) to N-(2-hydroxypropyl) methacrylamide HPMA NPs for controlled release.

Proteases are produced either by tumor cells themselves or by other different cells present in the tumor site. However, another approach can use an exogenously administered protease in which a polymeric nanocarrier containing the drug connected by a peptide sequence is administered to the patient. After that, when the NPs have accumulated in the tumor region with leaky blood vessels, another NP that includes the effector protease can be administered so that activation of the first prodrug NP causes localized drug release with a minimum of nonspecific toxicity.

Studies show that many proteases are only found in the intracellular compartment. With this in mind, using protease-triggered drug release can enhance the therapeutic effect of the drug and even decrease the toxic side effects of drug release³⁸¹. For instance, Imperiale et al.³⁹¹ innovatively designed a delivery system consisting of pure drug nanocrystals of the potent protease inhibitor indinavir free base (served as a model poorly water-soluble protease inhibitor) fabricated via nanoprecipitation that were encapsulated within mucoadhesive polymeric microparticles. The results supported the outstanding ability of this platform to decrease the dose and the administration frequency of protease inhibitors, a pivotal step to overcome the current problem of patient non-compliance in highly active antiretroviral therapy for HIV infection.

Trypsin is one of the most important digestive proteinases and this enzyme represents the second group of hydrolase-responsive nanomaterials. In the digestive process, trypsin together with the

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

other proteinases lead to breakdown of dietary protein molecules to their constituent peptides and amino acids. It also carries out the digestion process (begun in the stomach) in the small intestine, within which a slightly alkaline milieu elevates its rate of enzymatic activity³⁹². As the task of trypsin is to degrade dietary protein, it is frequently referred to as a proteolytic enzyme, or proteinase. Also involved in the activation of other digestive enzymes, trypsin plays a key role in controlling functioning of exocrine pancreatic secretion³⁹³.

The use of two or more enzymes simultaneously, for enzyme-triggered drug release could increase the accuracy and sensitivity of the method. Radhakrishnan et al.³⁹⁴ investigated the effect of using either hyaluronidase or trypsin enzymes, which are both over-expressed under specific pathological conditions, to degrade capsules produced using protamine and chondroitin sulphate. Recently there was a report of nanocapsules that were degraded in the milieu containing either trypsin or hyaluronidase, which lead to the freeing of encapsulated drugs. When these nanocapsules were at pH 7.4, the cross-linking was maintained, while the drug molecules were rapidly released in the presence of either of the triggering enzymes³⁹⁵.

Hou et al.³⁹⁶ constructed a novel supramolecular NP for controlled drug release at specific sites in presence of target enzyme. They successfully used two biocompatible materials, namely protamine and sulfato- β -cyclodextrin (SCD), that were non-covalent associated together. Results showed that the disassembly of the nanoparticles was specific to trypsin compared to other enzymes, and efficiently released the encapsulated model drug.

Phospholipases are considered to be therapeutic targets as their expression can be up-regulated in both infectious and inflammatory diseases. Furthermore, they have a high concentration at the invading edge zone of tumors as a part of the host defense mechanism^{397, 398}.

Helicobacter pylori infection in the stomach is the cause of several diseases such as peptic ulcers, chronic gastritis, and gastric malignancy^{399, 400}. These bacteria secrete phospholipase A2 (PLA2) that can be used to degrade liposomes membrane integrity for triggered cargo release⁴⁰¹. Thamphiwatana et al.⁴⁰² used a liposomal formulation with a lipid composition responsive to

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

secreted PLA2 and demonstrated that the more bacteria or enzyme that was present at the targeted site, the more drugs was released to treat the infection.

Glycosidase enzymes catalyze the hydrolysis of carbohydrates and can be used for triggering drug release at sites when their concentrations are elevated compared to normal tissue. These conditions include HIV, cancer and its metastases, inflammation and infections. For example researchers have shown that hydrolysis of carbohydrates is increased significantly (85%) in some carcinomas such as breast, lung, pancreas, stomach, uterine, ovarian, osteosarcoma and multiple myeloma. therefore sugar based NPs could be an appropriate anti-cancer drug carrier³⁸¹. Bernardo et al. synthesized a hybrid silica mesoporous (Si-MPs) NP that showed glycosidase-responsive intracellular controlled release. They found that the delivery of DOX to HeLa and LLC-PK1 cells increased drastically in the presence of β -D-galactosidase⁴⁰³.

Elastase enzyme are another type of proteases (peptidases) that degrades a number of proteins including elastin (present in different organs such as lungs and extracellular matrix) and collagen. For instance, among elastase enzymes, human neutrophil elastase is over expressed in inflammation^{404, 405}. Elastase based DDS can be used for triggered release of drugs especially for lung diseases. These therapeutic cargoes include α 1-antitrypsin, Eglin C, and peptidyl carbamates which prevent the remodelling of lung tissue and the formation of fibrosis by decreasing the free elastase.

Azoreductase is an enzyme secreted by the microbial flora existing in the human colon, and has received attention as a target for triggered drug release, especially for colonic diseases. In a study by Rao et al. an azoreductase-responsive vehicle was assembled by covalent coupling between azobenzene and an amphiphilic diblock copolymer. In the presence of the enzyme azoreductase and nicotinamide adenine dinucleotide phosphate (NADPH) the vehicle disintegrated releasing its cargo^{406, 407}. Patel et al.⁴⁰⁸ used enzyme-responsive snap-top covered silica nanocontainers in order to release a payload of small molecules. Porcine liver esterase could trigger the release of rhodamine B, monitored by fluorescence spectroscopy⁴⁰⁸.

Oxidoreductases have been considered as therapeutic targets owing to their central role in oxidative stress and their involvement in diseases such as Alzheimer's and cancer^{409, 410}.

Cite this: DOI: 10.1039/c0xx00000x


www.rsc.org/xxxxxx

ARTICLE TYPE

Recently, many studies have concentrated on oxidoreductase enzymes both for therapeutic drug delivery and diagnostic including bio-imaging probes. The major groups of oxidoreductase enzymes which have used in DDSs are discussed below.

Hydrogels which have been rendered sensitive to biomolecules could be the next generation of smart biomaterials. Oral administration of proteins and peptides such as insulin is unsuitable due to their sensitivity to chemical and enzymatic hydrolysis in the stomach and poor cellular uptake in the intestine. The release of drugs from hydrogels can be induced by enzyme action that affects the local pH and alters the hydrogel structure. Since glucose-responsive pulsatile insulin release systems are an important goal, glucose oxidase enzymes have been widely studied. For the treatment of diabetes, hydrogels that respond to glucose by swelling have the potential to be a self-regulating insulin release system⁴¹¹⁻⁴¹⁵.

In one study, glucose oxidase was encapsulated in polymeric vesicle nanocarriers⁴¹⁶. In the presence of a moderate amount of glucose, the polymeric shell was degraded and the interaction with glucose oxidase increased. This system that transforms glucose to gluconolactone, also produces hydrogen peroxide that can oxidize sulfur containing bonds to sulfones and sulfoxides (Fig. 23). As a result, the nanocarriers can be destabilized and dissolve.



Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Fig. 23 Oxidoreductase-responsive vesicles for DDSs; a) An SEM image of the vesicles that encapsulate glucose oxidase to form a responsive material; b) Enzymatic formation of gluconolactone followed by disruption of the vesicles in order to release the cargo. Reprinted with permission from ref.⁴¹⁷. Copyright 2004 “American Chemical Society”.

Bacterial enzymes have a significant role in combating infectious diseases because they can be potentially used to release antibiotics inside cells as a triggered smart nanosystem. Xiong et al.⁴¹⁸ recently treated murine salmonellosis using gentamicin in silica xerogel-based DDSs. They used bacterial enzymes to degrade a polyphosphoester core of the antibiotic-loaded DDSs.

There are many different components that have high potential in smart DDSs. For example, future studies could focus on proteases for targeting the mitochondria in hematological cells of patients, and oxidoreductase for targeting chloroplasts in plants. Owing to recent progress in protein engineering and molecular modeling, different classes of enzymes have been discovered that also play a significant role in disease diagnosis and controlled drug release. Table 1 summarizes the different classes of enzymes utilized in different applications.

Journal Name

[Dynamic Article Links▶](#)

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx**ARTICLE TYPE****Table 1** Examples of enzyme-responsive nanomaterials and their applications.

Enzyme Category	Subgroup	Micro/Nano Particle	Application	Benefits	Drawbacks/Limitations
------------------------	-----------------	----------------------------	--------------------	-----------------	------------------------------

Journal Name

[Dynamic Article Links▶](#)

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx**ARTICLE TYPE**

Hydrolases	Trypsin/Gelatinase	<ul style="list-style-type: none"> • Ag NPs • Au NPs 	<p>The diagnosis and treatment of pancreatitis³⁹³</p> <p>Enhancing the hydrolysis of bovine serum albumin⁴¹⁹</p> <p>Quartz crystal microbalance⁴²⁰</p>	<ul style="list-style-type: none"> • Enzymes are natural products with specific reactions • The responsiveness of a material to different enzymes • Polymeric materials respond to different enzymes with any changes in chemical structures • The enzyme-responsive biomolecules are very flexible so that they can be easily adjust to match each enzyme specificity • A comprehensive data bank is available on enzyme/substrate pairs 	<ul style="list-style-type: none"> • Low resistance of carriers to enzymatic attacks • Such requirements as separate surface treatments for polymeric materials • The optimum activities of enzymes generally happen in physiological conditions • Low stability of polymers in complex biological environment
	Proteases	Au NPs	Establishing an optical biosensing platform to monitor proteinase activity ⁴²¹		

Journal Name

[Dynamic Article Links ►](#)

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx**ARTICLE TYPE**

	Channel-Activating Proteases (CAPs)	Liposomes	Drug delivery devices ³⁸⁹		
	Lipases(PLA ₂)	Au NPs	High-throughput screening Care diagnostics		
Oxidoreductase	Glucose oxidase	<ul style="list-style-type: none"> • Chitosan - Based Capsules • Au NPs 	Insulin delivery systems ³⁶⁶ Biosensor technology for monitoring of blood glucose		
	Peroxidase	Au NPs	ELISA ⁴²²		

Cite this: DOI: 10.1039/c0xx00000x

Review




www.rsc.org/xxxxxx

3- Dual and multi-responsive MNP in DDSs and the role of graphene

The basic principle of the dual and multi-responsive drug carriers is based on the action of logic gates. In the logic gate algorithm, two or more factors can stimulate a system and according to type of the gates, different results will be obtained. The main type of logic gate include AND, OR, and their derivatives such as XOR, NOR, XNOR, and NAND. Table 2 represents these gates' symbols and their main action. In the OR gates the presence of any one stimuli out of them all, is enough to launch the response, whereas in the case of AND gates, all the stimuli must exist at the same time to trigger the action. NAND gates will not respond to the stimuli when all of them are present and NOR gates will respond only if no single factor can stimulate the gate.

10




Table 2 Different types of logic gates: their symbols, response mechanisms, and main action.

Type of the logic gate	Symbol	Algorithm			Main function
AND		x	y	$A = x \cdot y$	Activated only in the presence of both stimuli.
		0	0	0	
		0	1	0	
		1	0	0	
NAND		x	y	$A = x \cdot y$	In the simultaneous presence of all stimuli is inactive, whereas in the presence of none of them or in the presence of some of them is active.
		0	0	1	
		0	1	1	
		1	0	1	
OR		x	y	$A = x + y$	Any single stimulus can trigger the response.
		0	0	0	
		0	1	1	

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

		1	0	1	
		1	1	1	
NOR		x	y	$A = x + y$	Only in the presence of none of the stimuli the gate is active.
		0	0	1	
		0	1	0	
		1	0	0	
		1	1	0	
XOR		x	y	$A = x + y$	In the presence of all stimuli at once and in presence of none of them the gate is inactive.
		0	0	0	
		0	1	1	
		1	0	1	
		1	1	0	
XNOR		x	y	$A = x \cdot y$	In the presence of all stimuli at once and in presence of none of them the gate is active.
		0	0	1	
		0	1	0	
		1	0	0	
		1	1	1	

The human body is a complex collection of different environments. Each cell is surrounded with special receptors and enzymes as well as other molecules to increase its redox potential above that of extracellular body fluid. The combinations of two or more different stimuli described in the preceding sections can be rationally chosen to further increase the versatility and specificity of triggered drug/gene delivery^{423, 424}. Not only may these multi-functional NPs be smarter but they may possess higher loading efficiency and longer sustained release times. Moreover a multi-responsive nano-carrier has better ability to sense very slight changes in the environment such as small variations of pH and temperature^{425, 426}.

Combinations of temperature with other factors as a stimulus have some special advantages. The temperature sensitivity can be applied in different ways. Firstly, the sensitivity of the carrier to temperatures around 37°C, can lead to release of drug at the normal temperature of the body in the

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

presence of the second stimulus. This strategy would protect the drug out of the body and its life time will be increased. Moreover it is possible to design a gelation system to be active only at body temperature, and as a result the carrier is in the liquid form in laboratory conditions and after injection into the body, it is converted to the gel form. Furthermore if this sensitivity is designed for higher temperature (e.g. 40-42°C) it would be possible to apply external heating to the local area like a cancer site, leading to release of the drug in the specific location along with another stimulus such as reduction or pH. These advantages make temperature the most common stimulus in dual-stimuli-responsive carriers.

Among the various dual stimulus-responsive nano-carriers, temperature and pH is the most common combination that has been studied, but the disadvantages of this type of carriers can be premature gelation of the carrier in the body and rapid degradation, while anionic and cationic conditions may influence the pH responsive elements. Nearly all the dual and multi-responsive reported so far carriers have OR or AND logic gates. Shim et al.^{427, 428} generated a dual temperature/pH-responsive hydrogel consisting of three thermo-sensitive polymers. The degradation rate of the pH- and thermo-responsive block copolymers considerably diminished in comparison to the control block copolymer due to the buffering effects of the acidic monomer slowing the rapid degradation. This approach resolved two main disadvantages related to thermo-sensitive block copolymers: rapid degradation and premature gelation. This polymer could provide sustained release of PTX for 2 weeks after a single injection.

In another study, PTX was encapsulated in two types of polymers which self-assembled into supramolecular dendrosomes via a host-guest interaction, and had high sensitivity to pH <7.4 and temperature >37°C. Under these conditions, the dendrosome was destroyed and the polyglycerol released the encapsulated PTX⁴²⁹. A co-polymer based hydrogel that released human growth hormone (hGH) under both acidic and basic conditions and at body temperature was tested in animal models, and the results displayed both burst and sustained release of hGH⁴³⁰. In some cases a rise in temperature can stimulate a reaction in the outer part of the nanocarrier, leading to increased protons concentration that stimulate the pH-responsive part of carrier. In one study, DOX was inserted into the core of a thermo-sensitive micelle having pH-labile histamine residues (due to the presence of imidazole rings) by the heat-shock process. The formation of lactic acid after a temperature increase, led to protonation of the histidine imidazole ring and to release of the drug⁴³¹.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Among logic gates, OR and AND have also been reported. A self-assembled thermo-pH-dual responsive micelle was prepared. These micelles encapsulated methotrexate, and released it at both pH7 and temperature 37°C⁴³². In an interesting study, Du et al. generated an onion-shaped carrier with a pH-responsive inner layer and a thermo-responsive outer layer surrounding a magnetic core of Fe₃O₄ embedded in SiO₂. The thermo-pH responsive action of this polymeric microsphere was triggered by magnetic stimulation⁴³³.

The external application of magnetic fields, can be combined with another stimulus to make a dual stimuli-responsive carrier many of which are based on Fe₃O₄¹¹⁵. Moreover the presence of a magnetic core allows MRI imaging of drug delivery. The drug release strategy in this system is based on AND gates. Zhu et al.⁴³⁴ reported a multifunctional pH-sensitive SPIO nanosystem for simultaneous tumor MRI and therapy. pH-sensitive acyl-hydrazone linkages, DOX and PEG were attached to SPIO NPs. The pH-sensitive acyl-hydrazone linkages were cleaved in acidic condition and DOX was released from the SPIO. High cellular uptake and better antitumor effects were also shown due to the action of externally applied magnetic fields.

Sometimes the presence of a magnetic responsive element in the nanocarrier (such as Fe₃O₄) can act like a gateway to induce chemical reactions which can be used to follow the carrier distribution. Jing et al.⁴³⁵ loaded DOX onto a polylactic acid polymeric NP and combined it with Mn-porphyrin to create a nano-carrier for imaging as well as therapeutic applications in HeLa cells. A DOX loaded magnetic coated polymeric NP could be useful for imaging and also showed high anticancer activity against prostate tumor cells at 40°C and pH of 6⁴³⁶. Moreover external magnetic induced heating can control drug release when it is combined with thermal responsive compounds. For a nanobubble-based dual contrast agent consisting of SPIO encapsulated with perfluoropentane. Both the US and MR imaging contrast agent could be optimized by varying the shell thickness and SPIO-concentration. *In vivo* investigations of SPIO-embedded nano-bubbles in excised tumors under external magnetic fields revealed that both the US and MR signals increased. These dual function nano-bubbles could increase drug delivery by increasing the permeability due to HIFU, and external magnetic fields^{437, 438}. In the case of ischemia, due to acidic conditions caused by low aerobic metabolism, the combination of pH responsive and magnetic responsive elements, could simultaneously increase the efficacy of drug release as well as monitoring the location and extent of ischemia.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Reduction-sensitivity can be combined with pH-responsive carriers for intracellular drug release due to the low pH of intracellular compartment, combined with redox sensitivity. Dual sensitivity to pH and redox is an attractive modification of NPs because the pathogenic tissues almost always contain reducing condition as well as low pH. Oxygen concentration is also very low in the tumor tissue that can serve as a target for hypoxic-responsive carriers⁴³⁹. Figure 24 illustrates the process of drug release based on acid/redox responsiveness with an OR logic gate. This carrier consisted of a micelle that has minimum drug release at normal pH and normal redox concentration, but the highest drug release in the presence of 10 mM GSH concentration and an acidic environment (pH 5), although both of them can cause some drug release individually⁴⁴⁰.




Fig.24 Dual-responsive DOX release. The lowest amounts of DOX were released in the normal environment (pH: 7 and 0 mM GSH) (Black line). Both GSH concentration and acidic conditions can stimulate drug release based on OR gates (Red and Dark Blue lines). The maximum delivery takes place at the present of both low pH and 10 mM GSH concentration. Reproduced from Ref.⁴⁴⁰ with permission from the Royal Society of Chemistry.

Each enzyme possesses its own specific pH, co-enzymes, temperature, and site of action. Therefore an enzyme responsive nano-carrier itself intrinsically possesses multi-responsive modes of action. The presence of particular enzymes at the surface of individual cells can allow the uptake of the drug into that cell whereas presence of an enzyme inside a cell allows drug release inside that cell. Enzymes can also provide reversibility and compatibility to the carrier according to the acting conditions. Besides,

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

the high levels of ROS in cancer cells, suggests the oxidative environment could be a good target for delivery of anticancer drugs. Self-assembled micelles were prepared by the polymerization of the pro-drug benzoyl oxycinnamaldehyde (BCA), to produce PBCAE, that was loaded with zinc protoporphyrin (ZnPP). ZnPP can inhibit heme oxygenase-1 (HO-1) a pro-tumor enzyme that is over-expressed in tumor cells. ZnPP occurs naturally in the body, but when administered as a targeted drug, ZnPP- PBCAE was able to inhibit human tumor growth in a xenograft mouse model⁴⁴¹. Several dual and multi responsive nano-carriers, their method of preparation, drug type, loading efficiency and size are summarized in table 3.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

Review

Table 3 Some selected dual and multi responsive nano-carriers, their method of preparation, drug, loading efficiency and size.

Type	Name	PH-sensitive part	Method of preparation	Drug conjugates	Loading efficiency	Size (nm)	Ref
Dual thermo/pH responsive	mPEG-NIPAm-MAAm	MAAm	Crosslinked conjugation	cisplatin (CDDP)	95	130-250	⁴⁴²
Dual redox/pH responsive	amphiphilic thiolated carboxymethyl chitosan	Chitosan	self-assembly and ultrasonication in DI water	MTX	43.4	160	⁴⁴³
Dual glucose/pH responsive	Concanavalin A (Con A)-glucosyloxyethyl methacrylate- (dimethylamino) ethyl)-methacrylamide (Con A-E/GEMA/DMAEMA)	DMAEMA	transesterification	Insulin	3.5	38 um	⁴⁴⁴
Dual magnetic/pH responsive	DOX-Fe ₃ O ₄ @mSiO ₂ - β-thiopropionate-PEG	B-thiopropionate	Gatekeeper method	DOX	2.74	65	⁴⁴⁵
Dual Enzyme/pH responsive	Hyaluronic acid-diethylaminopropyl (HA-g-DEAP)	Protonation of DEAP	simple chemical reaction	DOX	82	95	⁴⁴⁶
Dual oxidation/pH responsive	poly(3-benzoyloxyphenyl)prop-2-	PBCAE copolymer	Conjugated polymerization	Zinc protoporphyrin (ZPP)	5	200	⁴⁴¹

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

	ene-1,1-diyl)bio(oxy))bis(ethane-2,1-diyl)diacrylate-co-4,4'(trimethylene dipiperidine). Co poly(ethylene glycol)(PBCAE)-ZnPP						
Dual Photo/pH responsive	Azobenzene-containing acrylate units	Acrylic acid	post-polymerization	Nile Red	-----	155-200	⁴⁴⁷
Dual thermo-magnetic responsive	poly-N-isopropylacrylamide-Chitosan (PAC)	Chitosan	Hydrothermal and solvent evaporation methods	Curcumin	86	20-35	⁴⁴⁸
Multi pH/Redox/Photo-responsive	Phenylboronic pluronic Chitosan spiropyran poly dimethylaminoethylmethacrylic acid (PC-SPMAc)	Pluronic-Chitosan	Cross-linked polymerization	Taxol	-----	226-277	⁴⁴⁹
Multi Glucose/enzyme/pH responsive	Glucose oxidase-catalase-Chitosan nanogel	Chitosan	Two step enzymatic procedure	Insulin	45	12	³⁶⁶
Multi thermo/magnetic/pH	P(NIPAAm-co-MAc) coated magnetic MSNs	Methacrylic acid	precipitation polymerization	DOX	91.3	210	⁴⁵⁰

Cite this: DOI: 10.1039/c0xx00000x

Review

www.rsc.org/xxxxxx

GO has been under intense investigations as a targeted DDS since it possesses a high surface area and can be functionalized with targeting ligands. GO nanosheets has been utilized as dual and even multi-stimuli-responsive drug delivery vehicles^{147, 451-454}. A hybrid hydrogel of GO nano-sheets and PNIPAAm was fabricated by Sun and Wu that showed reversible responsiveness to both temperature and pH⁴⁵⁵. Shrinkage occurred through heating from 20 to 50 °C and the sample returned to its initial volume upon rapid (10s) cooling. The pH-responsiveness of the sample was attributed to the existence of residual carboxyl groups in the hydrogel forming hydrogen bonds that were ionized at high pH leading to swelling of the structure.

There have been a few reports of multi-responsive NPs that respond to three or more different stimuli. In the case of these triple-responsive nanocarriers drug release usually acts based on AND gates, although the recognition processes and assembly of the carrier might be considered similar to the OR gate systems. For example, Qiao et al. bound OEGA to the thermo-sensitive DMDEA and added bis-(2-acryloyloxyethyl) disulfide to cross-link the polymers to produce a thermo/redox/pH tri-responsive nanocarrier. Subsequently DOX or PTX were encapsulated with high loading efficiency giving drug-release in MCF-7 cancer cells⁴⁵⁶. Liu et al.⁴⁵⁷ used polyvinyl alcohol conjugated with PAA and then loaded with Fe₂O₃ to form a tri-responsive (magnetic/thermo/pH) carrier with average size of 7.5 nm and a good ability to deliver methylene blue into MEL-5 cells. Using a magnetic hyperthermia/pH approach, daunorubicin hydrochloride (DNR) encapsulated microspheres were fabricated with 98% loading capacity, and good drug release under acidic conditions⁴⁵⁸.

A self-assembled hydrogel formed from GO nanosheets cross-linked in a Pluronic solution, was reported by Sahu et al. to be responsive to the triple stimuli of pH, NIR light, and temperature. Its thermo-sensitive gelation occurred at near body temperature and these nanosheets could also trigger photothermal-assisted gel formation by NIR laser irradiation in less than 30 s⁴⁵⁹.

Combining the optical properties of graphene, Kurapati et al.²⁰⁴ prepared polymeric microcapsule of GO composite with NIR-laser-controlled release of DOX with a power of only 30 mW that raised the temperature of the capsule suspension from 25 °C to 40 °C. Kim et al. achieved photothermally-controlled delivery of DOX, using a functionalized reduced GO. The loaded drug could be released by

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

GSH from the extensive surface of the nanocarrier that could escape the endosome due to the combination of the proton sponge effect and photothermal-assisted endosomal disruption⁴⁶⁰.

Dual and multi-responsive smart nano-carriers possess the ability to overcome the general difficulties of specific delivery such as prolonged stability, cellular internalization, cellular uptake and intracellular release of the drug. In this regard different type of stimulation including external stimulation for reproducibility of delivery and internal stimulation for self-regulation can be considered. Their use can provide a real and efficient anti-cancer action with good site-specific targeting, specificity, and controlled-release, while lowering cancer multi-drug resistance. Stimulation and response can in principle happen at different times and places separately, but almost always they take place simultaneously. For example, in co-delivery of genes and drugs, the issue of the time-gap between onset of the function of genes (24-72 h for transcription and translation of genetic materials or for suppression of protein expression) and the onset of drug action must be fully addressed before the co-delivery of combination drug/gene therapy become an effective treatment⁴⁶¹. As a suggestion for future work in this regard, the issue may be resolved by the new class of smart MNPs which are capable of the sequential release of genes and drugs at optimized time intervals. For this purpose, the use of internal stimuli (such as pH or enzyme activity) and external stimuli (such as temperature or light⁴⁶²) could act as a release-triggering agent for genes and drugs separately. In these conditions, by internalization of MNPs inside the cells and endosomal compartment, the genes are released by an internal stimulus and within 24-72 h the function can be completed, then by exerting external stimuli the release of drugs in a sequential manner will occur.

Here, that is good to mention that the delivery and releasing systems based on OR logic gates have the lowest specificity although possess good efficiency. That means each stimuli can trigger the response in carrier whereas if carriers be designed based on AND and NOR logic gates, will provide restricted system for specific delivery and releasing of the drugs.

4- The protein corona effect and nanotoxicology of NPs in biological systems

4-1 Protein corona

A comprehensive understanding of the interactions between NPs and various biological systems has been the goal of numerous studies and previous literature⁴⁶³. More importantly, the array of nano-bio

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

interactions have to be considered in the design and improvement of MNP based DDSs especially the stimuli-responsive smart systems covered in the present review. Upon exposure of NPs to a biological environment in the form of a fluid rich in proteins and cells such as plasma and blood, the NP tend to bind to the surrounding biolomecules (mainly proteins and lipids), and interact with them through various adsorption mechanisms to form a new complex surface layer on the NPs. Therefore, the NP surface is covered by these serum proteins including albumin, apolipoproteins, immunoglobulin G (IgG), complement factors, and fibrinogen. This “natural functionalization”⁴⁶⁴ is known as biomolecular corona or a protein corona^{15, 465-467}. Lundqvist et al. studied the various proteins detected in different coronas. They compared the corona phenomenon as a “fingerprint” encompassing the history, transport pathways, the biological fate, and behavior of the NPs⁴⁶⁸. This fingerprint can be utilized to predict the biological responses to different NPs, NP-cell interactions, specific cell associations, etc.⁴⁶⁹. Also, a large variety of nanomaterials have been shown to be accompanied by this protein corona in biological environments, whether *in vitro* or *in vivo*, including polymers^{470, 471}, metallics and ceramics^{469, 472}.

The structure of the protein corona surrounding a NP is divided into two compartments: the hard corona (the inner layer with strong binding, long lifetimes of several hours, and a low exchange rate with the environment) and the soft corona (the outer layer with loose protein binding and higher exchange rates)⁴⁷³⁻⁴⁷⁵. The protein corona and its diverse effects on NP-cell interactions strongly depends on the various physicochemical characteristics of different NPs, and on the cellular components and biological fluids (e.g. types and concentrations of protein)^{15, 476}. The particular characteristics of the NPs such as shape, size and surface chemistry are the most important parameters in determining the protein corona⁴⁷⁷. Moreover, the chemical modification of the NP surface can significantly change its physicochemical interactions with biological systems^{463, 468}. Fig.25 shows the protein corona compartments (Fig. 25-a), Different factors influencing nano-bio interactions (Fig. 25-b), and TEM images of protein corona formation around NPs (Fig. 25-c).

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig. 25 a) Protein corona compartments including the hard corona (inner side) and soft corona (outer side), b) Various factors influencing the nano-bio interactions related to the features of NPs, microenvironment and biomolecules, c) TEM images of protein corona surrounding Au NPs (10% FBS) BSA corona-coated Au nano-rods (NRs), protein-coated AgNCs (with an \square 3.5 nm thick hard corona after 24 h incubation in RPMI-1640 with 1% FBS); (c-(left image) Reprinted with permission from ref.⁴⁷⁸. Copyright 2013, c-(middle image) Reprinted with permission from ref.⁴⁷⁹. Copyright 2013, and c-(right image) Reprinted with permission from ref.⁴⁸⁰. Copyright 2014 "American Chemical Society".

Biological milieus have an intrinsic ability to sense externally induced changes even at the nanoscale in such components of DDS and nanocarriers⁴⁸¹. So, in such biological milieus, the formation of a protein corona has been suggested to cause significant effects on other phenomena and systems and to have been responsible for ambiguous and vague results¹⁵. It is increasingly understood that the

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

interactions of NPs with cells, as well as their mobility and toxicity is controlled by the protein corona and biological characteristics of the NPs^{466, 482}. The role of the protein corona in the process by which cells recognize nanomaterials has given rise to a new concept called “cell vision”⁴⁸¹. The initial contact point between NPs and the cell surface determines the consequent cell response which is very different between the protein coated NP to the pristine NP. In this respect, the type of the NP and the cell type can significantly affect the cell vision⁴⁸¹. Importantly, the definition of cell vision can be applied in the evaluation of the toxicity of the nanomaterials against cells, and the various detoxification strategies that different cells employ when facing various nanomaterials, either *in vitro* or *in vivo*^{467, 481}. Notably, the protein corona can lead to changes in the pharmacokinetics and pharmacodynamics of the nanomaterials in biological milieus, and therefore can affect their toxicity⁴⁸³. Therefore, the protein corona formation can potentially be utilized in decreasing the toxicity of NPs in biological milieus.

The protein corona has been reported to have crucial influences on cellular uptake mechanisms, biodistribution, drug release, localization in subcellular organelles and cellular protein substructures (e.g. cytoskeleton)^{15, 467}. At the molecular scale, it has been suggested that at the NP-cell membrane interface, the hard corona around the NP interacts with cell receptors⁴⁷⁴. For example, in one study, reduced drug release was reported by Behzadi et al.⁴⁸⁴ for various NPs depending on the protein corona. It has been hypothesized that the protein corona could potentially suppress the mutual interactions between the targeting sites on the cell surface and the functionalized ligands on the surface of NPs¹⁵. Recently, it was shown that the protein corona reduced the specificity of the surface modified NPs used for targeting cells within a biological environment through several different mechanisms including: screening active sites of the functionalized targeting ligands by establishing a protein barrier¹⁵, and shielding the therapeutic agent from binding to the targeting sites (e.g. cell receptors) by interaction by binding to the therapeutic agent in the biological medium⁴⁸⁵. So, it is likely that the destructive effect of the protein corona on the targeting efficiency of nanocarriers is considerable¹⁵. In recent studies, the cellular adhesion and uptake of diverse NPs such as quantum dots⁴⁸⁶ or carboxylated polystyrene (PS-COOH) NPs⁴⁸⁷ exposed to a protein corona were shown to be reduced in comparison to bare pristine nanomaterials. In rare circumstances, the uptake of NPs by cells in presence of a protein

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

corona could be enhanced⁴⁸⁸. Protein corona formation can also influence the cell internalization mechanisms of NPs⁴⁸⁹ and lead to altered transduction of cell signals⁴⁹⁰.

On the other hand, the protein corona phenomenon can be considered as an opportunity in the design of new DDSs. For example, in one study, Au@protein NPDDS were designed to have pH-sensitive properties and showed reversible agglomeration (due to enzymatic degradation in lysosomes at low pH (4-5)) and disagglomeration and increased stability in biological milieus with higher pH (7.4) e.g. cytosol, extracellular matrix, and the blood where proteins are present to form a corona⁴⁶⁵. Several copolymers with brush compartments showing conformational changes in response to pH changes can reversibly bind to or repel the charged biomolecules (e.g. proteins, anticancer drugs) at different pH values⁸.

With regard to drug delivery applications it has been shown that protein corona formation could decrease the release of an anticancer drug from MSN nanocarriers. Furthermore, the hydrophobic drugs could be replaced by the molecules present in the dispersion medium through hydrophobic functionalization of MSN pores⁴⁹¹. Hence, to obtain a controlled and enhanced drug release rate, with smart targeting, inhibition of the protein corona formation can be considered a promising strategy. For instance pH-labile polymer linkers could be explored to control the adsorption and attachment of proteins to the NPs in biological media. It may be possible to engineer the detachment and depletion of adsorbed proteins from the NP surface. For example, the cationic charges occurring near cancer cells induced by the acidic condition around them is a great opportunity to build such a pH-triggered delivery system. It can be suggested that another possibility could be to fabricate nanocarriers with the capability to denature and induce aggregation of protein molecules around the NPs to reduce corona formation. Furthermore, different administration routes for delivery of smart drug/gene carrier systems can be tested. The different proteins the NP encounter on their journey to their target is expected to depend on their route of administration.

In one study, high resistance to the adsorption of nonspecific serum proteins to the surface of gold NPs as well as a strong pH-sensitive adsorption to the cell membrane in the biological environment was found⁴⁹². Through a computational chemistry simulation, it was shown that protein corona formation on positively charged hydrophobic NPs enhanced their cellular interaction with macrophage cells and

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

reduced the targeting to cancer cells at pH 7.4. However at pH 6.5, the protein corona tended to detach and improved cancer cell internalization was shown for a strongly charged NP⁴⁹³.

4-2 Nanotoxicology of NPs in biological systems

Double-checking the safety of new nanomaterials, and evaluating a range of toxicology issues is a prime priority before utilization of nanotechnology in nanomedicine and clinical trials. Recently, the effect of different features of the nanostructures including material, size and shape, as well as the way the biological systems and the cells interact with well-defined nanostructures, and how this affects the clinical and biomedical applications has been discussed in the literature⁴⁹⁴. Besides the biological fate of NPs in various biosystems, the nanotoxicology and related toxicity issues such as cytotoxicity⁴⁹⁵⁻⁴⁹⁷, ecotoxicity^{498, 499} and genotoxicity^{500, 501} are still of crucial importance in nanotechnology⁵⁰². Toxicity issues affecting a wide variety of NPs including oxide NPs, magnetic NPs, metal NPs, quantum dots (QDs), carbon-based nanomaterials, polymeric NPs, and liposomes have all been extensively reviewed⁵⁰³⁻⁵¹⁰. Many efforts have been conducted to understand the toxicity mechanisms that apply to nanomaterials⁵¹¹ and to reduce or mitigate them^{512, 513}. Moreover, the way the toxicity of nanomaterials depends on their physicochemical properties (e.g. composition, surface area, surface coating, surface charge, shape, size, etc.) has been studied⁵¹⁴⁻⁵¹⁶. However, in de novo biomedical applications, the cytotoxicity of nanomaterials can also be considered as a therapeutic potential and can be utilized in the killing of cancer cells, and the eradication of bacterial cells, etc.⁵¹⁷.

Different adverse and toxic effects may be caused by nanomaterials including damage to the cell membrane (e.g. oxidative, surfactant or metal ion-mediated damage), induction of apoptosis, disruption of ATP production and DNA replication, lysosomal degradation/disruption, production of ROS, release of radicals, mitochondrial damage, induction of structural alterations of intracellular proteins (e.g. protein misfolding or oxidation), alternation of gene expression, and blood platelet aggregation^{510, 515, 518-520}.

New strategies for mitigation of various nanomaterials nanotoxicity have been introduced recently. For example, the protein corona formation on the nanomaterial surface in biological environments (e.g. blood plasma) can cause immunotoxicity by affecting various cells of the immune system^{481, 521}. On the other hand the protein corona has been reported to attenuate cytotoxicity of NPs against other cell types^{464, 522, 523}. Fig.26 illustrates the protein corona on surface of GO nanosheets and its effect on

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

cellular viability and cytotoxicity after exposure to A549 cancer cells. Here, the cell viability was enhanced through an FBSprotein corona coating on GOs, but was reduced by increasing the GO concentration and the incubation time⁵²². Some other approaches have been suggested to mitigate the toxicity of NP toward healthy tissue and cell. These include utilizing NPs with sizes that can undergo hepatobiliary clearance or can be cleared by the renal system (e.g. after intravenous administration), imparting biodegradability to NPs (e.g. polymeric hydrogels, micelles, etc.) or functionalizing the NP surface with biodegradable groups (e.g. PEG), and using auxiliary devices (e.g. medical catheters, microneedles, etc.) to administer the NPsto the targeted organ. Importantly, biodegradable nanosystems can be employedto design stimuli-responsive DDSstaking advantage of pH changes in different organs, or various routes of administration (e.g. intravaginal administration)⁵²⁴. Slight adjustmentof the temperature of the cells, tissues or organs can change the toxicity of nanomaterials⁵²⁵. This should be considered in the design of temperature-responsive DDSs. Different routes of administration of the NP also seem to influence the immune response⁵²⁶. Charge-dependent biological interactions of NPs have shown to induce diverse responses for different charged NPs. For example, negatively charged NPshave a lower cytotoxicity than positively charged NPs⁵²⁷. Cationic NPs induce more damage to plasma membrane integrity, mitochondrial and lysosomal compartments, and a higher extent of autophagosomes compared to anionic NPs⁵¹⁸. Size-dependent investigations have mostly shown that smaller NPs can cause more toxicity than larger ones⁵²⁸, however contrary results also have been reported⁵²⁹. For example, 10 nm sized silver (Ag) NPs induced higher cytotoxicity compared to those of larger which was attributed to more release of 10 nm Ag NPs⁵³⁰. The shape dependency of toxicity of nanomaterials has been shown in several studies. High aspect ratio nanomaterials such as fiber-like nanoparticulates and nanorods/nanowires can induce cytotoxicity, lysosomal damage and pro-inflammatory effects⁵³¹. Zhao et al.⁵³² studied the toxicity of hydroxyapatiteNPs according to their different shapes including needle, sphere, plate, and rod-shaped NPs and showed that the needle and plate-shaped NPs induced high cytotoxicity and cell-death as well as the least particle-cell association, cellular uptake, and internalization.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE




Fig. 26 Cytotoxicity and cell viability evaluation of A549 cells treated with GO nanosheets and FBS-coated GO nanosheets via MTT test: a) AFM images showing GO (left) and FBS-coated GO nanosheets (right), b) TEM images showing A549 cells treated with GO nanosheets at a concentration of 100 $\mu\text{g/mL}$ (left) and FBS-coated GO nanosheets (right) at 37 $^{\circ}\text{C}$ for 2 h, c) Cell viability of A549 cells treated with GO nanosheets obtained at various incubation times and concentrations, d) cell viability of the A549 cancer cells incubated with 20 $\mu\text{g/mL}$ GO nanosheets or FBS-coated GO nanosheets for 2 h at 4 $^{\circ}\text{C}$ and 37 $^{\circ}\text{C}$. Reprinted with permission from ref.⁵²².

Copyright 2011 "American Chemical Society".

The crucial dispute of nanotoxicology concerning DDSs must be therefore considered⁵³³. In most cases, the toxicity of nanocarriers must be eliminated or drastically reduced before the DDS could be considered for clinical application. In one study, a hybrid chitosan/carrageenan/tripolyphosphate nanocarrier that was tested for transmucosal delivery showed very low toxicity and negligible inflammatory effects on respiratory cell lines⁵³⁴. However, the possible toxicity of the nanocarrier should be weighed against other considerations (especially for anticancer therapeutics) such as the lower cytotoxicity of the encapsulated drug compared to the free drug, slower cellular uptake of the encapsulated drug, and limited degradability of the nanocarrier after drug release³²⁷. Through the

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx


ARTICLE TYPE

application of novel stimuli-responsive smart nanocarriers such as pH-responsive DDSs, highly toxic anticancer drugs can be released only where they are required while sparing normal tissues and cells^{253, 258, 535}. Regarding the necessity of reducing the toxicity of nanocarriers, highly biocompatible materials such as chitosan are becoming widely accepted in pH-responsive DDSs. Biocompatibility and lower toxicity of chitosan capped MSNs in the pH-responsive anticancer DDSs has been recently confirmed⁵³⁶.

5- From Concept to the Drugstore Shelves

Having comprehensively reviewed the basic concepts and the most important mechanisms of the recently developed stimulus-responsive DDSs, it is in fact worth mentioning that in most of the reported studies, the evaluation tests that have been used have only included simple laboratory testing (*in vitro*, *in vivo*, or *ex vivo*). In reality, only a tiny fraction of these DDS have any realistic possibility (green light) to advance towards clinical trials. We will examine the current status and the newest achievements in this field, and point out those smart MNPs that have been assessed in preclinical animal testing and even in human clinical trials.

The process from drug discovery towards clinical trials is divided into five phases (Fig. 27) corresponding to five levels of testing, each of which has a specific purpose. The final approval for their clinical utilization as a new drug is only issued after these lengthy stages including clinical trials that progress from Phase 1 to Phase 3⁵³⁷.



Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Fig. 27 The five stages of drug development culminating in clinical trials Reproduced from ref. ⁵³⁷. Copyright 2013 with permission from Elsevier.)

As far as clinical medicine is concerned, the complexity of real human systems sometimes produces unexpected outcomes. The reports on the clinical applications of smart MNPs as controlled-release DDSs indicate that most of the late-stage clinical failures can be caused by less than optimal ADME (Absorption, Distribution, Metabolism, and Elimination), lack of efficacy, and toxicity issues. Optimization of these factors not only would reduce their potential adverse effects, but could even reduce drug exposure to off-target sites⁵³⁸. In addition, the complexity of drug production parameters such as quality control, manufacturing process, and reproducibility, further hamper the translation of stimulus-responsive DDS from preclinical models to clinical applications⁵³⁹. Hence, many of these achievements in the initial laboratory studies should be further tested in real biological systems, living animals, and in human beings.

In these consecutive stages of testing culminating in clinical drugs, controlling and understanding the behavior of internal stimulus-responsive MNPs, is much more difficult than the same approach to external stimulus-responsive DDS. In anti-cancer stimuli-responsive DDSs for instance, the temperature and pH of the target tumor tissue vary from one model (and one patient) to another. In this regard, control of the delivery depth and focused site-specificity by optimizing the parameters of an externally applied stimulus would be more appropriate to trigger drug release from a nanocarrier. While the investigation by Garcia et al.⁵⁴⁰ of Doxil® in clinical trials in 1998, showed an acceptable toxicity profile for the fabricated drug; while, the release of the bioavailable drug in this system was very slow compared to the free doxorubicin system. Two years later, Isrel et al.⁵⁴¹ showed favorable clinical results including prolonged clinical responses in gynecologic patients. Moreover, in similar studies, the Phase I clinical trials of Doxil® failed in combination with docetaxel⁵⁴² and topotecan⁵⁴³. In two separate phase III clinical trials, the treatment effects of pegylated liposomal doxorubicin (PLD) were tested on more than 300 patients with breast cancer^{544, 545}. Although in the both studies, the rate of progression-free survival between the arms was comparable and also with the overall survival rate, the results showed that the risk of cardiotoxicity was decreased in case of PLD compared to standard DOX therapy. They also demonstrated that PLD reduced the nausea/vomiting, myelosuppression, and alopecia, which are frequent and troublesome side-effects of DOX therapy.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Recent research on gene delivery systems show that viral and non-viral vectors play a significant role in the final success of gene therapy, so that, the expanded knowledge of *in vitro* and *in vivo* behavior of vectors is highly important to reduce the failure rate in clinical trials. As a matter of fact, understanding the mechanisms behind the efficiency of transfection can boost the chance of success in gene therapy applications in an exponential manner.

For instance, Stopeck et al. assayed liposome-based vectors in their clinical trials for cancer treatment. Their product (Allovectin-7®, a plasmid/lipid complex) contained a specific DNA molecule that carries the HLA-B7/β2-microglobulin complex. In their successive studies, they could demonstrate a logical transformation process from the formation of complexes and their intracellular delivery and the eventual achievement of acceptable results in patients with metastatic melanoma in both Phase 1 and Phase 2 clinical trials. Nevertheless, in the phase 3 trial where more than 375 patients from 100 clinical sites were enrolled to test Allovectin-7®, the outcome resulted in its failure to meet its efficacy endpoints. Consequently, the clinical trial failed and the program was terminated^{546, 547}.

6- Conclusion and future perspective

The design, construction and testing of smart drug and gene delivery vehicles has undergone a veritable explosion of interest in recent years. In some instances it can be reliably asserted that the era of true molecular engineering has arrived. When polymer chemists can construct analogs of everyday objects at the molecular level, such as “snap-top containers” for instance. There are a number of possible motivations for these efforts, in addition to the obvious one of gratifying the scientific ingenuity of the investigators. The first motivation is to overcome the unfortunate side-effects suffered by patients given otherwise highly effective anti-cancer drugs such as DOX. If the drug can be protected inside a vehicle during its journey to its target and only released at its final destination, then these side-effects could be substantially reduced. But how is the vehicle to know that it has arrived at its destination, without a driver to spot the signposts and pull a handle? One answer is to take advantage of physiological cues that are typical of cancer cells and tumors such as reducing conditions, lower pH and over-expression of various enzymes to trigger release of the drug. The same reasoning can be applied to non-viral gene delivery vehicles, where the need is to protect the cargo from degradation by nucleases that are present in normal tissue, to encourage uptake into target cells, and

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

also to allow escape from endosomes so the nucleic acids can reach the nucleus. Another motivation is to produce sustained release of active molecules, particularly in an auto-regulated manner, so that drug is released from its carrier when some biological signal is detected to show that release is needed. An example of this latter concept is the concept of insulin delivery vehicles that release their cargo in response to high tissue glucose concentrations. A third motivation is to take advantage of some externally applied source of physical energy to trigger the release of cargo, such as heat, magnetic fields, light, or US.

Since the individual stimulus-responsive components of the smart-release toolbox have to some extent been reasonably well validated, it is not surprising that investigators have begun to combine them with each other to form dual-responsive vehicles, tri-responsive vehicles and even to consider more than three response elements. Whether these ever-more complex systems provide sufficiently improved delivery parameters to justify the extra effort involved remains to be seen.

An analogy can be drawn between these smart drug delivery vehicles and the advent of driverless automobiles. A few years ago driverless cars were only dreamt of in science fiction, but now the entire automobile industry is anticipating their imminent arrival with the consequent upheaval it will bring. Will we have the same situation in drug delivery say one decade from now? Only time will tell, but we can be sure that there will be no slow-down in scientific efforts to continuously improve smart nanocarrier technology and new advances in triggered drug and gene release.

Acknowledgements.

Michael R. Hamblin was supported by US NIH grant R01AI050875.

Notes and References:

1. W.-Y. Qian, D.-M. Sun, R.-R. Zhu, X.-L. Du, H. Liu and S.-L. Wang, *International journal of nanomedicine*, 2012, **7**, 5781.
2. M. Ferrari, *Nature Reviews Cancer*, 2005, **5**, 161-171.
3. O. C. Farokhzad and R. Langer, *ACS nano*, 2009, **3**, 16-20.
4. M. Karimi, P. Avci, R. Mobasser, M. R. Hamblin and H. Naderi-Manesh, *Journal of nanoparticle research*, 2013, **15**, 1-14.
5. M. A. M. Jahromi, M. Karimi, K. Azadmanesh, H. N. Manesh, Z. M. Hassan and S. M. Moazzeni, *Comparative Clinical Pathology*, 2013, 1-7.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

6. M. Karimi, P. Avci, M. Ahi, T. Gazori, M. R. Hamblin and H. Naderi-Manesh, *Journal of Nanopharmaceutics and Drug Delivery*, 2013, **1**, 266-278.
7. V. P. Torchilin, *Nature Reviews Drug Discovery*, 2014, **13**, 813-827.
8. E. G. Kelley, J. N. Albert, M. O. Sullivan and T. H. Epps III, *Chemical Society Reviews*, 2013, **42**, 7057-7071.
9. Y. Shen, X. Fu, W. Fu and Z. Li, *Chemical Society Reviews*, 2015, **44**, 612-622.
10. R. Cheng, F. Meng, C. Deng, H.-A. Klok and Z. Zhong, *Biomaterials*, 2013, **34**, 3647-3657.
11. M. Karimi, N. Solati, M. Amiri, H. Mirshekari, E. Mohamed, M. Taheri, M. Hashemkhani, A. Saeidi, M. A. Estiar and P. Kiani, *Expert opinion on drug delivery*, 2015, 1-17.
12. M. Karimi, N. Solati, A. Ghasemi, M. A. Estiar, M. Hashemkhani, P. Kiani, E. Mohamed, A. Saeidi, M. Taheri and P. Avci, *Expert opinion on drug delivery*, 2015, 1-17.
13. Y. Wang and L. Chen, *Nanomedicine: Nanotechnology, Biology and Medicine*, 2011, **7**, 385-402.
14. G. Xu, S. Mahajan, I. Roy and K.-T. Yong, *Frontiers in pharmacology*, 2013, **4**.
15. V. Mirshafiee, M. Mahmoudi, K. Lou, J. Cheng and M. L. Kraft, *Chemical Communications*, 2013, **49**, 2557-2559.
16. M. Dávila, L. Xian, S. Cahangirov, A. Rubio and G. Le Lay, *New Journal of Physics*, 2014, **16**, 095002.
17. Y.-M. Lin, C. Dimitrakopoulos, K. A. Jenkins, D. B. Farmer, H.-Y. Chiu, A. Grill and P. Avouris, *Science*, 2010, **327**, 662-662.
18. F. Schedin, A. Geim, S. Morozov, E. Hill, P. Blake, M. Katsnelson and K. Novoselov, *Nature materials*, 2007, **6**, 652-655.
19. O. Akhavan, E. Ghaderi and R. Rahighi, *ACS nano*, 2012, **6**, 2904-2916.
20. R. Justin and B. Chen, *Journal of Materials Chemistry B*, 2014, **2**, 3759-3770.
21. A. Nourmohammadi, R. Rahighi, O. Akhavan and A. Moshfegh, *Journal of Alloys and Compounds*, 2014.
22. Y. Qiu, K. Yan, S. Yang, L. Jin, H. Deng and W. Li, *ACS nano*, 2010, **4**, 6515-6526.
23. W. Fan, Q. Lai, Q. Zhang and Y. Wang, *The Journal of Physical Chemistry C*, 2011, **115**, 10694-10701.
24. F. Liu, Y. Zhang, J. Yu, S. Wang, S. Ge and X. Song, *Biosensors and Bioelectronics*, 2014, **51**, 413-420.
25. H. Y. Mao, S. Laurent, W. Chen, O. Akhavan, M. Imani, A. A. Ashkarran and M. Mahmoudi, *Chemical reviews*, 2013, **113**, 3407-3424.
26. S. Some, A.-R. Gwon, E. Hwang, G.-h. Bahn, Y. Yoon, Y. Kim, S.-H. Kim, S. Bak, J. Yang and D.-G. Jo, *Scientific reports*, 2014, **4**.
27. O. Akhavan, E. Ghaderi, S. A. Shirazian and R. Rahighi, *Carbon*, 2016, **97**, 71-77.
28. S. Moradi, O. Akhavan, A. Tayyebi, R. Rahighi, M. Mohammadzadeh and H. S. Rad, *RSC Advances*, 2015, **5**, 47529-47537.
29. Y. Fazaeli, O. Akhavan, R. Rahighi, M. R. Aboudzadeh, E. Karimi and H. Afarideh, *Materials Science and Engineering: C*, 2014, **45**, 196-204.
30. O. Akhavan, E. Ghaderi and S. A. Shirazian, *Colloids and Surfaces B: Biointerfaces*, 2014.
31. E. Hashemi, O. Akhavan, M. Shamsara, S. Valimehr and R. Rahighi, *RSC Advances*, 2014, **4**, 60720-60728.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

32. D. Li, M. B. Müller, S. Gilje, R. B. Kaner and G. G. Wallace, *Nature nanotechnology*, 2008, **3**, 101-105.
33. I.-Y. Jeon, H.-J. Choi, M. Choi, J.-M. Seo, S.-M. Jung, M.-J. Kim, S. Zhang, L. Zhang, Z. Xia and L. Dai, *Scientific reports*, 2013, **3**.
34. A. K. Geim and K. S. Novoselov, *Nature materials*, 2007, **6**, 183-191.
35. Y. K. Koh, M.-H. Bae, D. G. Cahill and E. Pop, *Nano letters*, 2010, **10**, 4363-4368.
36. O. Akhavan and E. Ghaderi, *Small*, 2013, **9**, 3593-3601.
37. O. Akhavan, E. Ghaderi and A. Akhavan, *Biomaterials*, 2012, **33**, 8017-8025.
38. O. Akhavan, E. Hashemi, M. Shamsara, R. Rahighi, A. Esfandiari and A. R. Tayefeh, *RSC Advances*, 2014.
39. A. Servant, V. Leon, D. Jasim, L. Methven, P. Limousin, E. V. Fernandez-Pacheco, M. Prato and K. Kostarelos, *Advanced healthcare materials*, 2014.
40. J. Zhang, L. Song, Z. Zhang, N. Chen and L. Qu, *Small*, 2013.
41. M. O. Oyewumi, A. Kumar and Z. Cui, *Expert review of vaccines*, 2010, **9**, 1095-1107.
42. C. Monfardini and F. M. Veronese, *Bioconjugate chemistry*, 1998, **9**, 418-450.
43. K. Cho, X. Wang, S. Nie and D. M. Shin, *Clinical cancer research*, 2008, **14**, 1310-1316.
44. D. A. Lavan, T. McGuire and R. Langer, *Nature biotechnology*, 2003, **21**, 1184-1191.
45. O. Akhavan, E. Ghaderi, R. Rahighi and M. Abdolahad, *Carbon*, 2014.
46. O. Akhavan, E. Ghaderi, E. Hashemi and R. Rahighi, *Nanoscale*, 2014.
47. J. Liu Yin, *Best Practice & Research Clinical Haematology*, 2002, **15**, 119-135.
48. R. J. DeBerardinis, J. J. Lum, G. Hatzivassiliou and C. B. Thompson, *Cell metabolism*, 2008, **7**, 11-20.
49. C. Bies, C.-M. Lehr and J. F. Woodley, *Advanced drug delivery reviews*, 2004, **56**, 425-435.
50. G. Saito, J. A. Swanson and K.-D. Lee, *Advanced drug delivery reviews*, 2003, **55**, 199-215.
51. H. Inaji, H. Koyama, M. Higashiyama, S. Noguchi, H. Yamamoto, O. Ishikawa, K. Omichi, T. Iwanaga and A. Wada, *Virchows Archiv A*, 1991, **419**, 29-33.
52. P. Vaupel, F. Kallinowski and P. Okunieff, *Cancer research*, 1989, **49**, 6449-6465.
53. E. Ruel-Gariépy and J.-C. Leroux, *European Journal of Pharmaceutics and Biopharmaceutics*, 2004, **58**, 409-426.
54. G. Caneba, *Free-Radical Retrograde-Precipitation Polymerization (FRRPP): Novel Concepts, Processes, Materials, and Energy Aspects*, ISBN 978-3-642-03024-6. Springer-Verlag Berlin Heidelberg, 2010, 2010, **1**.
55. Y. Qiu and K. Park, *Advanced drug delivery reviews*, 2001, **53**, 321-339.
56. D. Schmaljohann, *Advanced drug delivery reviews*, 2006, **58**, 1655-1670.
57. S. D. Fitzpatrick, L. E. Fitzpatrick, A. Thakur, M. A. J. Mazumder and H. Sheardown, 2012.
58. D. Coughlan and O. Corrigan, *J. Pharm. Sci.*, 2008, **97**, 318-330.
59. H. Yan and H. Okuzaki, *Composite Interfaces*, 2008, **15**, 661-670.
60. M. Beija, J.-D. Marty and M. Destarac, *Chemical Communications*, 2011, **47**, 2826-2828.
61. K. Kono, A. Henmi, H. Yamashita, H. Hayashi and T. Takagishi, *Journal of controlled release*, 1999, **59**, 63-75.
62. G. Fu and W. Soboyejo, *Materials Science and Engineering: C*, 2010, **30**, 8-13.
63. J. Croissant and J. I. Zink, *Journal of the American Chemical Society*, 2012, **134**, 7628-7631.
64. Y. Okahata, H. Noguchi and T. Seki, *Macromolecules*, 1986, **19**, 493-494.
65. S. J. Lue, J.-J. Hsu and T.-C. Wei, *Journal of Membrane Science*, 2008, **321**, 146-154.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

66. S. J. Lue, C.-H. Chen, C.-M. Shih, M.-C. Tsai, C.-Y. Kuo and J.-Y. Lai, *J. Membr. Sci.*, 2011, **379**, 330-340.
67. K. Men, W. Liu, L. Li, X. Duan, P. Wang, M. Gou, X. Wei, X. Gao, B. Wang and Y. Du, *Nanoscale*, 2012, **4**, 6425-6433.
68. M. Ballauff and Y. Lu, *Polymer*, 2007, **48**, 1815-1823.
69. J. J. Crassous, M. Siebenbürger, M. Ballauff, M. Drechsler, O. Henrich and M. Fuchs, *The Journal of chemical physics*, 2006, **125**, 204906.
70. L. A. Picos-Corrales, A. Licea-Claverie and K.-F. Arndt, *Reactive and Functional Polymers*, 2014, **75**, 31-40.
71. Y.-L. Luo, X.-L. Yang, F. Xu, Y.-S. Chen and B. Zhang, *Colloids and Surfaces B: Biointerfaces*, 2014, **114**, 150-157.
72. K. E. Reinicke, M. J. Kuffel, M. P. Goetz and M. M. Ames, *Cancer Chemother. Pharmacol.*, 2010, **66**, 575-583.
73. H. Akiyama and N. Tamaoki, *Macromolecules*, 2007, **40**, 5129-5132.
74. D. H. Kim, Y. Guo, Z. Zhang, D. Procissi, J. Nicolai, R. A. Omary and A. C. Larson, *Advanced healthcare materials*, 2014, **3**, 714-724.
75. E. Wischerhoff, K. Uhlig, A. Lankenau, H. G. Börner, A. Laschewsky, C. Duschl and J. F. Lutz, *Angewandte Chemie International Edition*, 2008, **47**, 5666-5668.
76. K. Na, K. H. Lee, D. H. Lee and Y. H. Bae, *European journal of pharmaceutical sciences*, 2006, **27**, 115-122.
77. J. Croissant, M. Maynadier, A. Gallud, H. Peindy N'Dongo, J. L. Nyalosaso, G. Derrien, C. Charnay, J. O. Durand, L. Raehm and F. Serein-Spirau, *Angewandte Chemie*, 2013, **125**, 14058-14062.
78. A. L. Daniel-da-Silva, L. Ferreira, A. M. Gil and T. Trindade, *Journal of colloid and interface science*, 2011, **355**, 512-517.
79. R. A. Muzzarelli, F. Greco, A. Busilacchi, V. Sollazzo and A. Gigante, *Carbohydrate Polymers*, 2012, **89**, 723-739.
80. R. A. Muzzarelli, P. Morganti, G. Morganti, P. Palombo, M. Palombo, G. Biagini, M. Mattioli Belmonte, F. Giantomassi, F. Orlandi and C. Muzzarelli, *Carbohydrate Polymers*, 2007, **70**, 274-284.
81. R. Moerkerke, F. Meeussen, R. Koningsveld, H. Berghmans, W. Mondelaers, E. Schacht, K. Dušek and K. Šolc, *Macromolecules*, 1998, **31**, 2223-2229.
82. I. Negru, M. Teodorescu, P. O. Stanescu, C. Draghici, A. Lungu and A. Sarbu, *Materiale Plastice*, 2010, **47**, 35.
83. J. Rueda, S. Zschoche, H. Komber, D. Schmaljohann and B. Voit, *Macromolecules*, 2005, **38**, 7330-7336.
84. K. Suwa, K. Morishita, A. Kishida and M. Akashi, *Journal of Polymer Science Part A: Polymer Chemistry*, 1997, **35**, 3087-3094.
85. J. Wu, W. Wei, L.-Y. Wang, Z.-G. Su and G.-H. Ma, *Biomaterials*, 2007, **28**, 2220-2232.
86. M. Elluru, H. Ma, M. Hadjiargyrou, B. S. Hsiao and B. Chu, *Polymer*, 2013, **54**, 2088-2095.
87. W. Xiong, W. Wang, Y. Wang, Y. Zhao, H. Chen, H. Xu and X. Yang, *Colloids and Surfaces B: Biointerfaces*, 2011, **84**, 447-453.
88. T. Aoki, M. Kawashima, H. Katono, K. Sanui, N. Ogata, T. Okano and Y. Sakurai, *Macromolecules*, 1994, **27**, 947-952.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

89. K.-J. Chen, H.-F. Liang, H.-L. Chen, Y. Wang, P.-Y. Cheng, H.-L. Liu, Y. Xia and H.-W. Sung, *ACS nano*, 2012, **7**, 438-446.
90. T. Ta, E. Bartolak-Suki, E.-J. Park, K. Karrobi, N. J. McDannold and T. M. Porter, *Journal of Controlled Release*, 2014, **194**, 71-81.
91. Z. S. Al-Ahmady, W. T. Al-Jamal, J. V. Bossche, T. T. Bui, A. F. Drake, A. J. Mason and K. Kostarelos, *ACS nano*, 2012, **6**, 9335-9346.
92. M. Van Elk, R. Deckers, C. Oerlemans, Y. Shi, G. Storm, T. Vermonden and W. E. Hennink, *Biomacromolecules*, 2014, **15**, 1002-1009.
93. Y. Lee, S. Y. Park, C. Kim and T. G. Park, *Journal of Controlled Release*, 2009, **135**, 89-95.
94. Z. Peng, E. Fang, C. Wang, X. Lu, G. Wang and Q. Tong, *Journal of Nanoscience and Nanotechnology*, 2015, **15**, 3823-3833.
95. C. Herron, H. O'Neill, A. Lopez-Noreiga, C. Hastings, G. Duffy and C. McDonnell, *International Journal of Surgery*, 2015, **18**, 240-241.
96. R. Liu, L. Sun, S. Fang, S. Wang, J. Chen, X. Xiao and C. Liu, *Pharmaceutical Development and Technology*, 2015, 1-7.
97. D. Salmon, L. Roussel, E. Gilbert, P. Kirilov and F. Pirot, in *Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement*, Springer, 2015, pp. 315-328.
98. C. M. Caramella, S. Rossi, F. Ferrari, M. C. Bonferoni and G. Sandri, *Advanced drug delivery reviews*, 2015.
99. B. Sung, C. Kim and M.-H. Kim, *Journal of colloid and interface science*, 2015, **450**, 26-33.
100. B.-B. Seo, H. Choi, J.-T. Koh and S.-C. Song, *Journal of Controlled Release*, 2015, **209**, 67-76.
101. M. Witting, M. Molina, K. Obst, R. Plank, K. M. Eckl, H. C. Hennies, M. Calderón, W. Frieß and S. Hedtrich, *Nanomedicine: Nanotechnology, Biology and Medicine*, 2015.
102. C. Lu, M. Liu, H. Fu, W. Zhang, G. Peng, Y. Zhang, H. Cao and L. Luo, *European Journal of Pharmaceutical Sciences*, 2015, **77**, 24-28.
103. S. R. Sinha, L. P. Nguyen, M. Inayathullah, A. Malkovskiy, F. Habte, J. Rajadas and A. Habtezion, *Gastroenterology*, 2015.
104. E. V. Rosca, M. Wright, R. Gonitel, W. Gedroyc, A. D. Miller and M. Thanou, *Molecular pharmaceuticals*, 2015, **12**, 1335-1346.
105. B. M. Dicheva, T. L. ten Hagen, A. L. Seynhaeve, M. Amin, A. M. Eggermont and G. A. Koning, *Pharmaceutical research*, 2015, 1-15.
106. S. Quan, Y. Wang, A. Zhou, P. Kumar and R. Narain, *Biomacromolecules*, 2015.
107. K. Kamimura, T. Suda, G. Zhang and D. Liu, *Pharmaceutical medicine*, 2011, **25**, 293-306.
108. E. Pişkin, S. Dincer and M. Türk, *Journal of Biomaterials Science, Polymer Edition*, 2004, **15**, 1181-1202.
109. S. Dincer, M. Türk and E. Pişkin, *Gene therapy*, 2005, **12**, S139-S145.
110. P. S. Stayton, T. Shimboji, C. Long, A. Chilkoti, G. Ghen, J. M. Harris and A. S. Hoffman, 1995.
111. M. Kurisawa, M. Yokoyama and T. Okano, *Journal of Controlled Release*, 2000, **69**, 127-137.
112. M. Kurisawa, M. Yokoyama and T. Okano, *Journal of controlled release*, 2000, **68**, 1-8.
113. S.-Y. CHEN, S.-H. HUa and T.-Y. LIUb, *Smart Materials for Drug Delivery*, 2013, **2**, 32.
114. G. M. Whitesides, *Nature biotechnology*, 2003, **21**, 1161-1165.
115. V. I. Shubayev, T. R. Pisanic II and S. Jin, *Advanced drug delivery reviews*, 2009, **61**, 467-477.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

116. M. Freeman, A. Arrott and J. Watson, *Journal of Applied Physics*, 1960, **31**, S404-S405.
117. J. Thévenot, H. Oliveira, O. Sandre and S. Lecommandoux, *Chemical Society Reviews*, 2013, **42**, 7099-7116.
118. S. Louguet, B. Rousseau, R. Epherre, N. Guidolin, G. Goglio, S. Mornet, E. Duguet, S. Lecommandoux and C. Schatz, *Polymer Chemistry*, 2012, **3**, 1408-1417.
119. B. Koppolu, Z. Bhavsar, A. S. Wadajkar, S. Nattama, M. Rahimi, F. Nwariaku and K. T. Nguyen, *Journal of biomedical nanotechnology*, 2012, **8**, 983-990.
120. T. Hoare, B. P. Timko, J. Santamaria, G. F. Goya, S. Irusta, S. Lau, C. F. Stefanescu, D. Lin, R. Langer and D. S. Kohane, *Nano letters*, 2011, **11**, 1395-1400.
121. H. Kakwere, M. P. Leal, M. E. Matera, A. Curcio, P. Guardia, D. Niculaes, R. Marotta, A. Falqui and T. Pellegrino, *ACS applied materials & interfaces*, 2015, **7**, 10132-10145.
122. P. Schexnailder and G. Schmidt, *Colloid and Polymer Science*, 2009, **287**, 1-11.
123. K. Hayashi, K. Ono, H. Suzuki, M. Sawada, M. Moriya, W. Sakamoto and T. Yogo, *ACS applied materials & interfaces*, 2010, **2**, 1903-1911.
124. G. Giani, S. Fedi and R. Barbucci, *Polymers*, 2012, **4**, 1157-1169.
125. A. Jordan, P. Wust, H. Fähling, W. John, A. Hinz and R. Felix, *International Journal of Hyperthermia*, 2009, **25**, 499-511.
126. A. Ito, K. Tanaka, H. Honda, S. Abe, H. Yamaguchi and T. Kobayashi, *Journal of bioscience and bioengineering*, 2003, **96**, 364-369.
127. S. Brulé, M. Levy, C. Wilhelm, D. Letourneur, F. Gazeau, C. Ménager and C. Le Visage, *Advanced Materials*, 2011, **23**, 787-790.
128. M. Marguet, C. Bonduelle and S. Lecommandoux, *Chemical Society Reviews*, 2013, **42**, 512-529.
129. C. Sanson, O. Diou, J. Thevenot, E. Ibarboure, A. Soum, A. Brûlet, S. Miraux, E. Thiaudière, S. Tan and A. Brisson, *Acs Nano*, 2011, **5**, 1122-1140.
130. S. H. Hu, B. J. Liao, C. S. Chiang, P. J. Chen, I. W. Chen and S. Y. Chen, *Advanced Materials*, 2012, **24**, 3627-3632.
131. S. Deok Kong, M. Sartor, C.-M. Jack Hu, W. Zhang, L. Zhang and S. Jin, *Acta biomaterialia*, 2013, **9**, 5447-5452.
132. R. K. Singh, K. D. Patel, J.-J. Kim, T.-H. Kim, J.-H. Kim, U. S. Shin, E.-J. Lee, J. C. Knowles and H.-W. Kim, *ACS applied materials & interfaces*, 2014, **6**, 2201-2208.
133. C. Mah, T. J. Fraites, I. Zolotukhin, S. Song, T. R. Flotte, J. Dobson, C. Batich and B. J. Byrne, *Molecular Therapy*, 2002, **6**, 106-112.
134. H. H. Yiu, S. C. McBain, Z. A. Lethbridge, M. R. Lees, I. Palona, C. I. Olariu and J. Dobson, *Journal of nanoscience and nanotechnology*, 2011, **11**, 3586-3591.
135. J. Lu, M. Liong, Z. Li, J. I. Zink and F. Tamanoi, *Small*, 2010, **6**, 1794-1805.
136. E. Ruiz-Hernandez, A. Baeza and M. a. Vallet-Regí, *ACS nano*, 2011, **5**, 1259-1266.
137. H. J. Lee and Y. Bae, *Biomacromolecules*, 2011, **12**, 2686-2696.
138. V. Torchilin, *Advanced drug delivery reviews*, 2011, **63**, 131-135.
139. J. Fang, H. Nakamura and H. Maeda, *Advanced drug delivery reviews*, 2011, **63**, 136-151.
140. D. Scott, Y. Beabout, R. J. Wydra, M. Dan, R. Yokel, J. Z. Hilt and Y. Bae, *Journal of Applied Pharmaceutical Science*, 2013, **3**.
141. F. K. van Landeghem, K. Maier-Hauff, A. Jordan, K.-T. Hoffmann, U. Gneveckow, R. Scholz, B. Thiesen, W. Brück and A. Von Deimling, *Biomaterials*, 2009, **30**, 52-57.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

142. H. S. Huang and J. F. Hainfield, *International journal of nanomedicine*, 2013, **8**, 2521.
143. E. P. da Silva, D. L. Sitta, V. H. Fragal, T. S. Cellet, M. R. Mauricio, F. P. Garcia, C. V. Nakamura, M. R. Guilherme, A. F. Rubira and M. H. Kunita, *International journal of biological macromolecules*, 2014, **67**, 43-52.
- 5 144. A. K. Anal, *Recent Patents on Endocrine, Metabolic & Immune Drug Discovery*, 2007, **1**, 83-90.
145. Y. Qiu and K. Park, *Advanced drug delivery reviews*, 2012, **64**, 49-60.
146. X. Ying, Y. Wang, J. Liang, J. Yue, C. Xu, L. Lu, Z. Xu, J. Gao, Y. Du and Z. Chen, *Angewandte Chemie International Edition*, 2014, **53**, 12436-12440.
- 10 147. C. L. Weaver, J. M. LaRosa, X. Luo and X. T. Cui, *ACS nano*, 2014, **8**, 1834-1843.
148. A. Servant, V. Leon, D. Jasim, L. Methven, P. Limousin, E. V. Fernandez-Pacheco, M. Prato and K. Kostarelos, *Advanced healthcare materials*, 2014, **3**, 1334-1343.
149. A. Servant, L. Methven, R. P. Williams and K. Kostarelos, *Advanced healthcare materials*, 2013, **2**, 806-811.
- 15 150. M. Nair, R. Guduru, P. Liang, J. Hong, V. Sagar and S. Khizroev, *Nature communications*, 2013, **4**, 1707.
151. J. S. Im, B. C. Bai and Y.-S. Lee, *Biomaterials*, 2010, **31**, 1414-1419.
152. J. Ge, E. Neofytou, T. J. Cahill III, R. E. Beygui and R. N. Zare, *ACS nano*, 2011, **6**, 227-233.
153. M. ALATORRE-MEDA, *Smart Materials for Drug Delivery*, 2013, **1**, 304.
- 20 154. N. Ž. Knežević, B. G. Trewyn and V. S.-Y. Lin, *Chem. Commun.*, 2011, **47**, 2817-2819.
155. Q. Yi and G. B. Sukhorukov, *Advances in colloid and interface science*, 2013.
156. J. Babin, M. Pelletier, M. Lepage, J. F. Allard, D. Morris and Y. Zhao, *Angewandte Chemie International Edition*, 2009, **48**, 3329-3332.
157. S. Karthik, B. Saha, S. K. Ghosh and N. P. Singh, *Chemical Communications*, 2013, **49**, 10471-10473.
- 25 158. C.-W. Lo, D. Zhu and H. Jiang, *Soft Matter*, 2011, **7**, 5604-5609.
159. Y.-L. Luo, Y.-S. Shiao and Y.-F. Huang, *Acs Nano*, 2011, **5**, 7796-7804.
160. P. Wu, Y. Gao, Y. Lu, H. Zhang and C. Cai, *Analyst*, 2013, **138**, 6501-6510.
161. X. Huang, X. Teng, D. Chen, F. Tang and J. He, *Biomaterials*, 2010, **31**, 438-448.
- 30 162. S. M. Moghimi, A. C. Hunter and J. C. Murray, *The FASEB Journal*, 2005, **19**, 311-330.
163. C. Alvarez-Lorenzo, S. Deshmukh, L. Bromberg, T. A. Hatton, I. Sández-Macho and A. Concheiro, *Langmuir*, 2007, **23**, 11475-11481.
164. J. Jiang, B. Qi, M. Lepage and Y. Zhao, *Macromolecules*, 2007, **40**, 790-792.
165. H. Zhao, E. S. Sterner, E. B. Coughlin and P. Theato, *Macromolecules*, 2012, **45**, 1723-1736.
- 35 166. B. Yan, J.-C. Boyer, N. R. Branda and Y. Zhao, *Journal of the American Chemical Society*, 2011, **133**, 19714-19717.
167. J. W. Chung, K. Lee, C. Neikirk, C. M. Nelson and R. D. Priestley, *small*, 2012, **8**, 1693-1700.
168. M. A. Azagarsamy and K. S. Anseth, *Angewandte Chemie International Edition*, 2013, **52**, 13803-13807.
- 40 169. G. Liu and C.-M. Dong, *Biomacromolecules*, 2012, **13**, 1573-1583.
170. G.-Y. Liu, C.-J. Chen, D.-D. Li, S.-S. Wang and J. Ji, *Journal of Materials Chemistry*, 2012, **22**, 16865-16871.
171. C. Chen, G. Liu, X. Liu, S. Pang, C. Zhu, L. Lv and J. Ji, *Polymer Chemistry*, 2011, **2**, 1389-1397.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

172. F. Tian, Y. Yu, C. Wang and S. Yang, *Macromolecules*, 2008, **41**, 3385-3388.
173. K. J. Tangso, W.-K. Fong, T. Darwish, N. Kirby, B. J. Boyd and T. L. Hanley, *The Journal of Physical Chemistry B*, 2013, **117**, 10203-10210.
174. S. Son, E. Shin and B.-S. Kim, *Biomacromolecules*, 2014.
- 5 175. H. Meng, M. Xue, T. Xia, Z. Ji, D. Y. Tarn, J. I. Zink and A. E. Nel, *Acs Nano*, 2011, **5**, 4131-4144.
176. N. Z. Knezevic, B. G. Trewyn and V. S. Lin, *Chem Commun (Camb)*, 2011, **47**, 2817-2819.
177. Q. Liu, Y. Sun, T. Yang, W. Feng, C. Li and F. Li, *Journal of the American Chemical Society*, 2011, **133**, 17122-17125.
- 10 178. S. He, K. Krippes, S. Ritz, Z. Chen, A. Best, H.-J. Butt, V. Mailänder and S. Wu, *Chemical Communications*, 2015, **51**, 431-434.
179. M. L. Viger, M. Grossman, N. Fomina and A. Almutairi, *Advanced Materials*, 2013, **25**, 3733-3738.
180. S. Li, B. A. Moosa, J. G. Croissant and N. M. Khashab, *Angewandte Chemie*, 2015, **127**, 6908-6912.
- 15 181. M. Álvarez, A. Best, S. Pradhan-Kadam, K. Koynov, U. Jonas and M. Kreiter, *Advanced Materials*, 2008, **20**, 4563-4567.
182. M. Gary-Bobo, Y. Mir, C. Rouxel, D. Brevet, I. Basile, M. Maynadier, O. Vaillant, O. Mongin, M. Blanchard-Desce and A. Morère, *Angewandte Chemie*, 2011, **123**, 11627-11631.
- 20 183. S. Kim, T. Y. Ohulchanskyy, H. E. Pudavar, R. K. Pandey and P. N. Prasad, *Journal of the American Chemical Society*, 2007, **129**, 2669-2675.
184. F. Vatansever, W. C. de Melo, P. Avci, D. Vecchio, M. Sadasivam, A. Gupta, R. Chandran, M. Karimi, N. A. Parizotto and R. Yin, *FEMS microbiology reviews*, 2013, **37**, 955-989.
185. J. Croissant, A. Chaix, O. Mongin, M. Wang, S. Clément, L. Raehm, J. O. Durand, V. Hugues, M. Blanchard-Desce and M. Maynadier, *Small*, 2014, **10**, 1752-1755.
- 25 186. N. Graf and S. J. Lippard, *Advanced drug delivery reviews*, 2012, **64**, 993-1004.
187. E. Ruggiero, J. Hernández-Gil, J. C. Mareque-Rivas and L. Salassa, *Chemical Communications*, 2015, **51**, 2091-2094.
188. H. Xiao, G. T. Noble, J. F. Stefanick, R. Qi, T. Kiziltepe, X. Jing and B. Bilgicer, *Journal of Controlled Release*, 2014, **173**, 11-17.
- 30 189. I. Infante, J. M. Azpiroz, N. G. Blanco, E. Ruggiero, J. M. Ugalde, J. C. Mareque-Rivas and L. Salassa, *The Journal of Physical Chemistry C*, 2014, **118**, 8712-8721.
190. N. C. Fan, F. Y. Cheng, J. a. A. Ho and C. S. Yeh, *Angewandte Chemie International Edition*, 2012, **51**, 8806-8810.
- 35 191. A. Schroeder, M. S. Goldberg, C. Kastrup, Y. Wang, S. Jiang, B. J. Joseph, C. G. Levins, S. T. Kannan, R. Langer and D. G. Anderson, *Nano letters*, 2012, **12**, 2685-2689.
192. S. Mizukami, M. Hosoda, T. Satake, S. Okada, Y. Hori, T. Furuta and K. Kikuchi, *Journal of the American Chemical Society*, 2010, **132**, 9524-9525.
193. G. Baffou and R. Quidant, *Laser & Photonics Reviews*, 2013, **7**, 171-187.
- 40 194. J. Fang and Y.-C. Chen, *Current pharmaceutical design*, 2013, **19**, 6622-6634.
195. E. B. Dickerson, E. C. Dreaden, X. Huang, I. H. El-Sayed, H. Chu, S. Pushpanketh, J. F. McDonald and M. A. El-Sayed, *Cancer letters*, 2008, **269**, 57-66.
196. X. Huang, P. K. Jain, I. H. El-Sayed and M. A. El-Sayed, *Lasers in medical science*, 2008, **23**, 217-228.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

197. D. Jaque, L. M. Maestro, B. Del Rosal, P. Haro-Gonzalez, A. Benayas, J. Plaza, E. M. Rodríguez and J. G. Solé, *Nanoscale*, 2014, **6**, 9494-9530.
198. J. T. Robinson, S. M. Tabakman, Y. Liang, H. Wang, H. Sanchez Casalongue, D. Vinh and H. Dai, *Journal of the American Chemical Society*, 2011, **133**, 6825-6831.
- 5 199. S. A. Khan, R. Kanchanapally, Z. Fan, L. Beqa, A. K. Singh, D. Senapati and P. C. Ray, *Chemical Communications*, 2012, **48**, 6711-6713.
200. S. H. Hu, R. H. Fang, Y. W. Chen, B. J. Liao, I. W. Chen and S. Y. Chen, *Advanced Functional Materials*, 2014, **24**, 4144-4155.
201. W. Xiong, R. Mazid, L. W. Yap, X. Li and W. Cheng, *Nanoscale*, 2014.
- 10 202. J. Lin, S. Wang, P. Huang, Z. Wang, S. Chen, G. Niu, W. Li, J. He, D. Cui and G. Lu, *ACS nano*, 2013, **7**, 5320-5329.
203. R. Chen, X. Wang, X. Yao, X. Zheng, J. Wang and X. Jiang, *Biomaterials*, 2013, **34**, 8314-8322.
204. R. Kurapati and A. M. Raichur, *Chemical Communications*, 2013, **49**, 734-736.
- 15 205. Y. T. Chang, P. Y. Liao, H. S. Sheu, Y. J. Tseng, F. Y. Cheng and C. S. Yeh, *Advanced Materials*, 2012, **24**, 3309-3314.
206. O. J. Norum, P. K. Selbo, A. Weyergang, K. E. Giercksky and K. Berg, *Journal of photochemistry and photobiology. B, Biology*, 2009, **96**, 83-92.
207. K. Berg, P. K. Selbo, L. Prasmickaite, T. E. Tjelle, K. Sandvig, J. Moan, G. Gaudernack, Ø. Fodstad, S. Kjølrsrud and H. Anholt, *Cancer Research*, 1999, **59**, 1180-1183.
- 20 208. K. Berg, M. Berstad, L. Prasmickaite, A. Weyergang, P. K. Selbo, I. Hedfors and A. Hogset, *Topics in current chemistry*, 2010, **296**, 251-281.
209. S. Oliveira, M. M. Fretz, A. Høgset, G. Storm and R. M. Schiffelers, *Biochimica et Biophysica Acta (BBA)-Biomembranes*, 2007, **1768**, 1211-1217.
- 25 210. K. Y. Lee, M. Peters and D. Mooney, *Advanced Materials*, 2001, **13**, 837-839.
211. H. Izawa, K. Kawakami, M. Sumita, Y. Tateyama, J. P. Hill and K. Ariga, *Journal of Materials Chemistry B*, 2013, **1**, 2155-2161.
212. T. Saxer, A. Zumbuehl and B. Müller, *Cardiovascular research*, 2013, cvt102.
213. M. N. Holme, I. A. Fedotenko, D. Abegg, J. Althaus, L. Babel, F. Favarger, R. Reiter, R. Tanasescu, P.-L. Zaffalon and A. Ziegler, *Nature nanotechnology*, 2012, **7**, 536-543.
- 30 214. N. Korin, M. Kanapathipillai, B. D. Matthews, M. Crescente, A. Brill, T. Mammoto, K. Ghosh, S. Jurek, S. A. Bencherif and D. Bhatta, *Science*, 2012, **337**, 738-742.
215. S. R. Sirsi and M. A. Borden, *Advanced drug delivery reviews*, 2014, **72**, 3-14.
216. E. C. UNGER, T. P. McCREERY and R. H. SWEITZER, *Investigative radiology*, 1997, **32**, 723-727.
- 35 217. A. Azagury, L. Khoury, G. Enden and J. Kost, *Advanced drug delivery reviews*, 2014, **72**, 127-143.
218. M. Aryal, C. D. Arvanitis, P. M. Alexander and N. McDannold, *Advanced drug delivery reviews*, 2014, **72**, 94-109.
- 40 219. J. R. Lindner, *Nature Reviews Drug Discovery*, 2004, **3**, 527-533.
220. H. Chen, J. Li, J. Wan, D. A. Weitz and H. A. Stone, *Soft Matter*, 2013, **9**, 38-42.
221. S.-i. Miura, K. Tachibana, T. Okamoto and K. Saku, *Biochemical and biophysical research communications*, 2002, **298**, 587-590.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

222. A. Lawrie, A. Brisken, S. Francis, D. Cumberland, D. Crossman and C. Newman, *Gene therapy*, 2000, **7**.
223. R. V. Shohet, S. Chen, Y.-T. Zhou, Z. Wang, R. S. Meidell, R. H. Unger and P. A. Grayburn, *Circulation*, 2000, **101**, 2554-2556.
- 5 224. D. L. Miller, S. V. Pislaru and J. F. Greenleaf, *Somatic cell and molecular genetics*, 2002, **27**, 115-134.
225. R. J. Price and S. Kaul, *Journal of cardiovascular pharmacology and therapeutics*, 2002, **7**, 171-180.
226. Y. He, Y. Bi, Y. Hua, D. Liu, S. Wen, Q. Wang, M. Li, J. Zhu, T. Lin and D. He, *J Exp Clin*
10 *Cancer Res*, 2011, **30**, 104.
227. E. C. Unger, T. Porter, W. Culp, R. Labell, T. Matsunaga and R. Zutshi, *Advanced drug delivery reviews*, 2004, **56**, 1291-1314.
228. A. Lawrie, A. F. Brisken, S. E. Francis, D. I. Tayler, J. Chamberlain, D. C. Crossman, D. C. Cumberland and C. M. Newman, *Circulation*, 1999, **99**, 2617-2620.
- 15 229. J.-h. S. Kuo, M.-s. Jan and K. Sung, *International journal of pharmaceuticals*, 2003, **257**, 75-84.
230. C.-C. Hou, W. Wang, X. R. Huang, P. Fu, T.-H. Chen, D. Sheikh-Hamad and H. Y. Lan, *The American journal of pathology*, 2005, **166**, 761-771.
231. X. Zhang, Y. Zheng, Z. Wang, S. Huang, Y. Chen, W. Jiang, H. Zhang, M. Ding, Q. Li and X. Xiao, *Biomaterials*, 2014, **35**, 5148-5161.
- 20 232. R. Chen, M. Chiba, S. Mori, M. Fukumoto and T. Kodama, *Journal of dental research*, 2009, **88**, 1008-1013.
233. I. Lentacker, I. De Cock, R. Deckers, S. De Smedt and C. Moonen, *Advanced drug delivery reviews*, 2014, **72**, 49-64.
234. N. Y. Rapoport, A. M. Kennedy, J. E. Shea, C. L. Scaife and K.-H. Nam, *Journal of Controlled*
25 *Release*, 2009, **138**, 268-276.
235. G. A. Hussein and W. G. Pitt, *Advanced drug delivery reviews*, 2008, **60**, 1137-1152.
236. B. Geers, I. Lentacker, N. N. Sanders, J. Demeester, S. Meairs and S. C. De Smedt, *Journal of Controlled Release*, 2011, **152**, 249-256.
237. N. Rapoport, A. Payne, C. Dillon, J. Shea, C. Scaife and R. Gupta, *Journal of Therapeutic*
30 *Ultrasound*, 2013, **1**, 11.
238. M. Y. Spivak, R. V. Bubnov, I. M. Yemets, L. M. Lazarenko, N. O. Tymoshok and Z. R. Ulberg, *EPMA J*, 2013, **4**, 20.
239. M. de Smet, E. Heijman, S. Langereis, N. M. Hijnen and H. Grüll, *Journal of Controlled Release*, 2011, **150**, 102-110.
- 35 240. H. Grüll and S. Langereis, *Journal of Controlled Release*, 2012, **161**, 317-327.
241. A. L. Kilbanov, T. I. Shevchenko, B. I. Raju, R. Seip and C. T. Chin, *Journal of Controlled Release*, 2010, **148**, 13-17.
242. A. Yudina, M. De Smet, M. Lepetit-Coiffe, S. Langereis, L. Van Ruijssevelt, P. Smirnov, V. Bouchaud, P. Voisin, H. Grüll and C. Moonen, *Journal of Controlled Release*, 2011, **155**, 442-448.
- 40 243. F. Xie, J. Lof, T. Matsunaga, R. Zutshi and T. R. Porter, *Circulation*, 2009, **119**, 1378-1385.
244. J. Di, J. Price, X. Gu, X. Jiang, Y. Jing and Z. Gu, *Advanced healthcare materials*, 2013.
245. C. W. Burke, E. Alexander, K. Timbie, A. L. Kilbanov and R. J. Price, *Molecular Therapy*, 2013.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

246. S. Eggen, S.-M. Fagerland, Ý. Mørch, R. Hansen, K. Søvik, S. Berg, H. Furu, A. D. Bøhn, M. B. Lilledahl and A. Angelsen, *Journal of Controlled Release*, 2014, **187**, 39-49.
247. C. Alvarez-Lorenzo and A. Concheiro, *Chemical Communications*, 2014, **50**, 7743-7765.
248. C. Alvarez-Lorenzo and A. Concheiro, *Smart materials for drug delivery*, 2013, **1**, 1.
249. J. Wike-Hooley, J. Haveman and H. Reinhold, *Radiotherapy and Oncology*, 1984, **2**, 343-366.
250. G. K. Joshi, M. A. Johnson and R. Sardar, *RSC Advances*, 2014, **4**, 15807-15815.
251. B. Yu, X. Li, W. Zheng, Y. Feng, Y.-S. Wong and T. Chen, *Journal of Materials Chemistry B*, 2014, **2**, 5409-5418.
252. L. He, T. Wang, J. An, X. Li, L. Zhang, L. Li, G. Li, X. Wu, Z. Su and C. Wang, *CrystEngComm*, 2014, **16**, 3259-3263.
253. S. Rasouli, S. Davaran, F. Rasouli, M. Mahkam and R. Salehi, *Drug delivery*, 2014, **21**, 155-163.
254. F. Tu and D. Lee, *Journal of the American Chemical Society*, 2014, **136**, 9999-10006.
255. S. Ganta, M. Talekar, A. Singh, T. P. Coleman and M. M. Amiji, *AAPS PharmSciTech*, 2014, **15**, 694-708.
256. S. J. Grainger and M. E. El-Sayed, *Biologically-Responsive Hybrid Biomaterials*, 2010, 171-190.
257. Y. Wang, L. Chen, L. Tan, Q. Zhao, F. Luo, Y. Wei and Z. Qian, *Biomaterials*, 2014, **35**, 6972-6985.
258. S. Song, F. Chen, H. Qi, F. Li, T. Xin, J. Xu, T. Ye, N. Sheng, X. Yang and W. Pan, *Pharmaceutical research*, 2014, **31**, 1032-1045.
259. J. Liu, Y. Huang, A. Kumar, A. Tan, S. Jin, A. Mozhi and X.-J. Liang, *Biotechnology advances*, 2013.
260. S. Dai, P. Ravi and K. C. Tam, *Soft Matter*, 2008, **4**, 435-449.
261. H. Kamada, Y. Tsutsumi, Y. Yoshioka, Y. Yamamoto, H. Kodaira, S.-i. Tsunoda, T. Okamoto, Y. Mukai, H. Shibata and S. Nakagawa, *Clinical cancer research*, 2004, **10**, 2545-2550.
262. Y. Ge, S. Li, S. Wang and R. Moore, *Nanomedicine: Principles and Perspectives*, Springer, 2014.
263. E. R. Gillies, T. B. Jonsson and J. M. Fréchet, *Journal of the American Chemical Society*, 2004, **126**, 11936-11943.
264. S. Foster, C. L. Duvall, E. F. Crownover, A. S. Hoffman and P. S. Stayton, *Bioconjugate chemistry*, 2010, **21**, 2205-2212.
265. J. Liu, Y. Huang, A. Kumar, A. Tan, S. Jin, A. Mozhi and X.-J. Liang, *Biotechnology advances*, 2014, **32**, 693-710.
266. G. Poon and J. Garipey, *Biochemical Society Transactions*, 2007, **35**, 788-793.
267. G. A. Pietersz, C.-K. Tang and V. Apostolopoulos, *Mini reviews in medicinal chemistry*, 2006, **6**, 1285-1298.
268. M. Kitazoe, J. Futami, M. Nishikawa, H. Yamada and Y. Maeda, *Biotechnology journal*, 2010, **5**, 385-392.
269. S.-C. Park, J.-P. Nam, Y.-M. Kim, J.-H. Kim, J.-W. Nah and M.-K. Jang, *International journal of nanomedicine*, 2013, **8**, 3663.
270. Y. Oh, D. Suh, J. Kim, H. Choi, K. Shin and J. Ko, *Gene therapy*, 2002, **9**.
271. F. Meng, Y. Zhong, R. Cheng, C. Deng and Z. Zhong, *Nanomedicine*, 2014, **9**, 487-499.
272. J. Yang, J. Chen, D. Pan, Y. Wan and Z. Wang, *Carbohydrate polymers*, 2013, **92**, 719-725.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

273. S. Jana, N. Maji, A. K. Nayak, K. K. Sen and S. K. Basu, *Carbohydrate polymers*, 2013, **98**, 870-876.
274. H. Wu, L. Zhu and V. P. Torchilin, *Biomaterials*, 2013, **34**, 1213-1222.
275. B. Čalija, N. Cekić, S. Savić, R. Daniels, B. Marković and J. Milić, *Colloids and Surfaces B: Biointerfaces*, 2013, **110**, 395-402.
276. M.-C. Chen, F.-L. Mi, Z.-X. Liao, C.-W. Hsiao, K. Sonaje, M.-F. Chung, L.-W. Hsu and H.-W. Sung, *Advanced drug delivery reviews*, 2013, **65**, 865-879.
277. Y. Yang, S. Wang, Y. Wang, X. Wang, Q. Wang and M. Chen, *Biotechnology advances*, 2014, **32**, 1301-1316.
278. M. Wang, H. Hu, Y. Sun, L. Qiu, J. Zhang, G. Guan, X. Zhao, M. Qiao, L. Cheng and L. Cheng, *Biomaterials*, 2013, **34**, 10120-10132.
279. D. R. Nogueira, L. Tavano, M. Mitjans, L. Pérez, M. R. Infante and M. P. Vinardell, *Biomaterials*, 2013, **34**, 2758-2772.
280. H. O. McCarthy, J. McCaffrey, C. M. McCrudden, A. Zholobenko, A. A. Ali, J. W. McBride, A. S. Massey, S. Pentlavalli, K.-H. Chen and G. Cole, *Journal of Controlled Release*, 2014, **189**, 141-149.
281. S. P. Loughran, C. M. McCrudden and H. O. McCarthy, *European Journal of Nanomedicine*, 2015, **7**, 85-96.
282. H. Akita, K. Kogure, R. Moriguchi, Y. Nakamura, T. Higashi, T. Nakamura, S. Serada, M. Fujimoto, T. Naka and S. Futaki, *Journal of controlled release*, 2010, **143**, 311-317.
283. M. Cavazzana-Calvo, S. Hacein-Bey, G. de Saint Basile, F. Gross, E. Yvon, P. Nusbaum, F. Selz, C. Hue, S. Certain and J.-L. Casanova, *Science*, 2000, **288**, 669-672.
284. S. Hacein-Bey-Abina, F. Le Deist, F. Carlier, C. Bouneaud, C. Hue, J.-P. De Villartay, A. J. Thrasher, N. Wulffraat, R. Sorensen and S. Dupuis-Girod, *New England Journal of Medicine*, 2002, **346**, 1185-1193.
285. S. Hacein-Bey-Abina, J. Hauer, A. Lim, C. Picard, G. P. Wang, C. C. Berry, C. Martinache, F. Rieux-Laucat, S. Latour and B. H. Belohradsky, *New England Journal of Medicine*, 2010, **363**, 355-364.
286. A. Kim and F. C. Szoka Jr, *Pharmaceutical research*, 1992, **9**, 504-514.
287. Y. Sakurai, H. Hatakeyama, Y. Sato, H. Akita, K. Takayama, S. Kobayashi, S. Futaki and H. Harashima, *Biomaterials*, 2011, **32**, 5733-5742.
288. X. D. Guo, N. Wiradharma, S. Q. Liu, L. J. Zhang, M. Khan, Y. Qian and Y.-Y. Yang, *Biomaterials*, 2012, **33**, 6284-6291.
289. K. A. Watkins and R. Chen, *International journal of pharmaceutics*, 2015, **478**, 496-503.
290. Y. Liu, W. Wang, J. Yang, C. Zhou and J. Sun, *asian journal of pharmaceutical sciences*, 2013, **8**, 159-167.
291. J. Siepmann, R. A. Siegel and M. J. Rathbone, *Fundamentals and applications of controlled release drug delivery*, Springer, 2012.
292. R. A. Shenoi, B. F. Lai, M. Imran ul-haq, D. E. Brooks and J. N. Kizhakkedathu, *Biomaterials*, 2013, **34**, 6068-6081.
293. K. Guk, H. Lim, B. Kim, M. Hong, G. Khang and D. Lee, *International journal of pharmaceutics*, 2013, **453**, 541-550.
294. M. S. Shim and Y. J. Kwon, *Polymer Chemistry*, 2012, **3**, 2570-2577.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

295. I. Lee, M. Park, Y. Kim, O. Hwang, G. Khang and D. Lee, *International journal of pharmaceutics*, 2013, **448**, 259-266.
296. C. Ding, J. Gu, X. Qu and Z. Yang, *Bioconjugate chemistry*, 2009, **20**, 1163-1170.
297. Z. Zhou, L. Li, Y. Yang, X. Xu and Y. Huang, *Biomaterials*, 2014, **35**, 6622-6635.
298. C. Liu, F. Liu, L. Feng, M. Li, J. Zhang and N. Zhang, *Biomaterials*, 2013, **34**, 2547-2564.
299. H. Nakamura, T. Etrych, P. Chytil, M. Ohkubo, J. Fang, K. Ulbrich and H. Maeda, *Journal of Controlled Release*, 2014, **174**, 81-87.
300. T. Etrych, V. Šubr, R. Laga, B. Říhová and K. Ulbrich, *European Journal of Pharmaceutical Sciences*, 2014, **58**, 1-12.
301. T.-M. Sun, Y.-C. Wang, F. Wang, J.-Z. Du, C.-Q. Mao, C.-Y. Sun, R.-Z. Tang, Y. Liu, J. Zhu and Y.-H. Zhu, *Biomaterials*, 2014, **35**, 836-845.
302. D.-W. Dong, B. Xiang, W. Gao, Z.-Z. Yang, J.-Q. Li and X.-R. Qi, *Biomaterials*, 2013, **34**, 4849-4859.
303. M. Ding, N. Song, X. He, J. Li, L. Zhou, H. Tan, Q. Fu and Q. Gu, *Acs Nano*, 2013, **7**, 1918-1928.
304. L. Zhou, D. Liang, X. He, J. Li, H. Tan, J. Li, Q. Fu and Q. Gu, *Biomaterials*, 2012, **33**, 2734-2745.
305. J. Heller, J. Barr, S. Y. Ng, K. S. Abdellauoi and R. Gurny, *Advanced drug delivery reviews*, 2002, **54**, 1015-1039.
306. X. Wang, G. Wu, C. Lu, W. Zhao, Y. Wang, Y. Fan, H. Gao and J. Ma, *European Journal of Pharmaceutical Sciences*, 2012, **47**, 256-264.
307. K. P. Koutroumanis, R. G. Holdich and S. Georgiadou, *International journal of pharmaceutics*, 2013, **455**, 5-13.
308. W. She, N. Li, K. Luo, C. Guo, G. Wang, Y. Geng and Z. Gu, *Biomaterials*, 2013, **34**, 2252-2264.
309. K. Raghupathi, L. Li, J. Ventura, M. Jennings and S. Thayumanavan, *Polym. Chem.*, 2014, **5**, 1737-1742.
310. Y. Kang, X.-M. Zhang, S. Zhang, L. Ding and B.-J. Li, *Polymer Chemistry*, 2015.
311. Y. Liu, F.-P. Gao, D. Zhang, Y.-S. Fan, X.-G. Chen and H. Wang, *Journal of Controlled Release*, 2014, **173**, 140-147.
312. S. V. Lale, A. Kumar, F. Naz, A. C. Bharti and V. Koul, *Polymer Chemistry*, 2015, **6**, 2115-2132.
313. D. Sun, J. Ding, C. Xiao, J. Chen, X. Zhuang and X. Chen, *Advanced healthcare materials*, 2015, **4**, 844-855.
314. J.-Z. Du, X.-J. Du, C.-Q. Mao and J. Wang, *Journal of the American Chemical Society*, 2011, **133**, 17560-17563.
315. T. Kavitha, S. I. H. Abdi and S.-Y. Park, *Physical Chemistry Chemical Physics*, 2013, **15**, 5176-5185.
316. L. Ren, T. Liu, J. Guo, S. Guo, X. Wang and W. Wang, *Nanotechnology*, 2010, **21**, 335701.
317. L. Feng, K. Li, X. Shi, M. Gao, J. Liu and Z. Liu, *Advanced healthcare materials*, 2014, **3**, 1261-1271.
318. J. Shi, Y. Liu, L. Wang, J. Gao, J. Zhang, X. Yu, R. Ma, R. Liu and Z. Zhang, *Acta biomaterialia*, 2014, **10**, 1280-1291.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

319. Y. Wang, Q. Zhao, N. Han, L. Bai, J. Li, J. Liu, E. Che, L. Hu, Q. Zhang and T. Jiang, *Nanomedicine: Nanotechnology, Biology and Medicine*, 2014.
320. I. I. Slowing, J. L. Vivero-Escoto, C.-W. Wu and V. S.-Y. Lin, *Advanced drug delivery reviews*, 2008, **60**, 1278-1288.
- 5 321. F. Muhammad, M. Guo, W. Qi, F. Sun, A. Wang, Y. Guo and G. Zhu, *Journal of the American Chemical Society*, 2011, **133**, 8778-8781.
322. Z. Jia, P. Lin, Y. Xiang, X. Wang, J. Wang, X. Zhang and Q. Zhang, *European Journal of Pharmaceutics and Biopharmaceutics*, 2011, **79**, 126-134.
323. H. Meng, M. Xue, T. Xia, Y.-L. Zhao, F. Tamanoi, J. F. Stoddart, J. I. Zink and A. E. Nel,
10 *Journal of the American Chemical Society*, 2010, **132**, 12690-12697.
324. Q. Gan, X. Lu, W. Dong, Y. Yuan, J. Qian, Y. Li, J. Shi and C. Liu, *Journal of Materials Chemistry*, 2012, **22**, 15960-15968.
325. L. Chen, Z. Zhang, X. Yao, X. Chen and X. Chen, *Microporous and Mesoporous Materials*,
2015, **201**, 169-175.
- 15 326. S. R. Choi, D.-J. Jang, S. Kim, S. An, J. Lee, E. Oh and J. Kim, *Journal of Materials Chemistry B*, 2014, **2**, 616-619.
327. S. Nowag and R. Haag, *Angewandte Chemie International Edition*, 2014, **53**, 49-51.
328. L. Mei, F. He, R.-Q. Zhou, C.-D. Wu, R. Liang, R. Xie, X.-J. Ju, W. Wang and L.-Y. Chu, *ACS applied materials & interfaces*, 2014, **6**, 5962-5970.
- 20 329. I. Singh, A. P. Sagare, M. Coma, D. Perlmutter, R. Gelein, R. D. Bell, R. J. Deane, E. Zhong, M. Parisi and J. Ciszewski, *Proceedings of the National Academy of Sciences*, 2013, **110**, 14771-14776.
330. J. Lindgren, P. Segerfeldt, S. B. Sholts, A. Gräslund, A. E. Karlström and S. K. Wärmländer, *Journal of inorganic biochemistry*, 2013, **120**, 18-23.
- 25 331. C. Treiber, M. A. Quadir, P. Voigt, M. Radowski, S. Xu, L.-M. Munter, T. A. Bayer, M. Schaefer, R. Haag and G. Multhaupt, *Biochemistry*, 2009, **48**, 4273-4284.
332. H. Ejima, J. J. Richardson, K. Liang, J. P. Best, M. P. van Koeverden, G. K. Such, J. Cui and F. Caruso, *Science*, 2013, **341**, 154-157.
333. N. Gogoi and D. Chowdhury, *Journal of Materials Chemistry B*, 2014, **2**, 4089-4099.
- 30 334. S. Thamphiwatana, V. Fu, J. Zhu, D. Lu, W. Gao and L. Zhang, *Langmuir*, 2013, **29**, 12228-12233.
335. M. C. Koetting and N. A. Peppas, *International journal of pharmaceutics*, 2014, **471**, 83-91.
336. W. Gui, W. Wang, X. Jiao, L. Chen, Y. Wen and X. Zhang, *ChemPhysChem*, 2014.
337. H. Yu, Z. Xu, X. Chen, L. Xu, Q. Yin, Z. Zhang and Y. Li, *Macromolecular bioscience*, 2014,
35 **14**, 100-109.
338. C.-S. Chiang, S.-H. Hu, B.-J. Liao, Y.-C. Chang and S.-Y. Chen, *Nanomedicine: Nanotechnology, Biology and Medicine*, 2014, **10**, 99-107.
339. Q. Zhang, R. Ran, L. Zhang, Y. Liu, L. Mei, Z. Zhang, H. Gao and Q. He, *Journal of Controlled Release*, 2015, **197**, 208-218.
- 40 340. P. Rajpoot, V. Bali and K. Pathak, *International journal of pharmaceutics*, 2012, **426**, 219-230.
341. F. Meng, R. Cheng, C. Deng and Z. Zhong, *Materials Today*, 2012, **15**, 436-442.
342. M. Aon, S. Cortassa and B. O'Rourke, *Biochimica et Biophysica Acta (BBA)-Bioenergetics*, 2010, **1797**, 865-877.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

343. R. Cheng, F. Feng, F. Meng, C. Deng, J. Feijen and Z. Zhong, *Journal of controlled release*, 2011, **152**, 2-12.
344. A. Kumar, A. Farhana, L. Guidry, V. Saini, M. Hondalus and A. J. Steyn, *Expert reviews in molecular medicine*, 2011, **13**, e39.
- 5 345. Y.-M. Go and D. P. Jones, *Biochimica et Biophysica Acta (BBA)-General Subjects*, 2008, **1780**, 1273-1290.
346. Y. Sun, X. Yan, T. Yuan, J. Liang, Y. Fan, Z. Gu and X. Zhang, *Biomaterials*, 2010, **31**, 7124-7131.
347. Y.-C. Wang, F. Wang, T.-M. Sun and J. Wang, *Bioconjugate chemistry*, 2011, **22**, 1939-1945.
- 10 348. J. Li, M. Huo, J. Wang, J. Zhou, J. M. Mohammad, Y. Zhang, Q. Zhu, A. Y. Waddad and Q. Zhang, *Biomaterials*, 2012, **33**, 2310-2320.
349. Y. Li, K. Xiao, J. Luo, W. Xiao, J. S. Lee, A. M. Gonik, J. Kato, T. A. Dong and K. S. Lam, *Biomaterials*, 2011, **32**, 6633-6645.
350. A. N. Koo, H. J. Lee, S. E. Kim, J. H. Chang, C. Park, C. Kim, J. H. Park and S. C. Lee, *Chemical Communications*, 2008, 6570-6572.
- 15 351. H. Kim, S. Kim, C. Park, H. Lee, H. J. Park and C. Kim, *Advanced Materials*, 2010, **22**, 4280-4283.
352. J.-H. Ryu, R. T. Chacko, S. Jiwanich, S. Bickerton, R. P. Babu and S. Thayumanavan, *Journal of the American Chemical Society*, 2010, **132**, 17227-17235.
- 20 353. W. Ong, Y. Yang, A. C. Cruciano and R. L. McCarley, *Journal of the American Chemical Society*, 2008, **130**, 14739-14744.
354. Y. E. Kurtoglu, R. S. Navath, B. Wang, S. Kannan, R. Romero and R. M. Kannan, *Biomaterials*, 2009, **30**, 2112-2121.
355. Y. Li, B. S. Lokitz, S. P. Armes and C. L. McCormick, *Macromolecules*, 2006, **39**, 2726-2728.
- 25 356. Y. Kakizawa, A. Harada and K. Kataoka, *Biomacromolecules*, 2001, **2**, 491-497.
357. Y. Takeoka, T. Aoki, K. Sanui, N. Ogata, M. Yokoyama, T. Okano, Y. Sakurai and M. Watanabe, *Journal of controlled release*, 1995, **33**, 79-87.
358. B. J. Crielgaard, C. J. Rijcken, L. Quan, S. van der Wal, I. Altintas, M. van der Pot, J. A. Kruijtzter, R. M. Liskamp, R. M. Schiffelers and C. F. van Nostrum, *Angewandte Chemie International Edition*, 2012, **51**, 7254-7258.
- 30 359. R. Wei, L. Cheng, M. Zheng, R. Cheng, F. Meng, C. Deng and Z. Zhong, *Biomacromolecules*, 2012, **13**, 2429-2438.
360. A. N. Koo, K. H. Min, H. J. Lee, S.-U. Lee, K. Kim, I. C. Kwon, S. H. Cho, S. Y. Jeong and S. C. Lee, *Biomaterials*, 2012, **33**, 1489-1499.
- 35 361. L.-Y. Tang, Y.-C. Wang, Y. Li, J.-Z. Du and J. Wang, *Bioconjugate chemistry*, 2009, **20**, 1095-1099.
362. Z.-Y. Li, J.-J. Hu, Q. Xu, S. Chen, H.-Z. Jia, Y.-X. Sun, R.-X. Zhuo and X.-Z. Zhang, *Journal of Materials Chemistry B*, 2015, **3**, 39-44.
363. H. Kuang, S. Wu, F. Meng, Z. Xie, X. Jing and Y. Huang, *Journal of Materials Chemistry*, 2012, **22**, 24832-24840.
- 40 364. H. Wang, L. Tang, C. Tu, Z. Song, Q. Yin, L. Yin, Z. Zhang and J. Cheng, *Biomacromolecules*, 2013, **14**, 3706-3712.
365. Y. Lu, W. Sun and Z. Gu, *Journal of Controlled Release*, 2014, **194**, 1-19.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

366. Z. Gu, T. T. Dang, M. Ma, B. C. Tang, H. Cheng, S. Jiang, Y. Dong, Y. Zhang and D. G. Anderson, *ACS nano*, 2013, **7**, 6758-6766.
367. S. Wu, X. Huang and X. Du, *Angewandte Chemie*, 2013, **125**, 5690-5694.
368. M. K. Chu, J. Chen, C. R. Gordijo, S. Chiang, A. Iovic, K. Koulajian, A. Giacca, X. Y. Wu and Y. Sun, *Lab on a Chip*, 2012, **12**, 2533-2539.
369. M. Chen, C. Huang, C. He, W. Zhu, Y. Xu and Y. Lu, *Chemical Communications*, 2012, **48**, 9522-9524.
370. S. H. Lee, M. K. Gupta, J. B. Bang, H. Bae and H. J. Sung, *Advanced healthcare materials*, 2013, **2**, 908-915.
371. D. Zhang, Y. Wei, K. Chen, X. Zhang, X. Xu, Q. Shi, S. Han, X. Chen, H. Gong and X. Li, *Advanced healthcare materials*, 2015, **4**, 69-76.
372. M. K. Gupta, T. A. Meyer, C. E. Nelson and C. L. Duvall, *Journal of Controlled Release*, 2012, **162**, 591-598.
373. Z. Su, M. Chen, Y. Xiao, M. Sun, L. Zong, S. Asghar, M. Dong, H. Li, Q. Ping and C. Zhang, *Journal of Controlled Release*, 2014, **196**, 370-383.
374. S. Biswas, K. Kinbara, T. Niwa, H. Taguchi, N. Ishii, S. Watanabe, K. Miyata, K. Kataoka and T. Aida, *Nature chemistry*, 2013, **5**, 613-620.
375. Q. Yan and Y. Zhao, *Chemical Science*, 2015.
376. R. Mo, T. Jiang, W. Sun and Z. Gu, *Biomaterials*, 2015, **50**, 67-74.
377. P. Zhang, F. Cheng, R. Zhou, J. Cao, J. Li, C. Burda, Q. Min and J. J. Zhu, *Angewandte Chemie International Edition*, 2014, **53**, 2371-2375.
378. M. R. Molla, P. Prasad and S. Thayumanavan, *Journal of the American Chemical Society*, 2015.
379. J. Hu, G. Zhang and S. Liu, *Chemical Society Reviews*, 2012, **41**, 5933-5949.
380. J. E. Ghadiali and M. M. Stevens, *Advanced Materials*, 2008, **20**, 4359-4363.
381. R. De La Rica, D. Aili and M. M. Stevens, *Advanced drug delivery reviews*, 2012, **64**, 967-978.
382. R. Weissleder, K. Kelly, E. Y. Sun, T. Shtatland and L. Josephson, *Nature biotechnology*, 2005, **23**, 1418-1423.
383. A. S. Aricò, P. Bruce, B. Scrosati, J.-M. Tarascon and W. Van Schalkwijk, *Nature materials*, 2005, **4**, 366-377.
384. S. Kawata, Y. Inouye and P. Verma, *Nature Photonics*, 2009, **3**, 388-394.
385. S. Cooper, C. Bamford and T. Tsuruta, *Allan S. Hoffman, Utrecht, The Netherlands: VSP*, 1995.
386. T. Matsuda, M. Takahashi-Tezuka, T. Fukada, Y. Okuyama, Y. Fujitani, S. Tsukada, H. Mano, H. Hirai, O. Witte and T. Hirano, *Blood*, 1995, **85**, 627-633.
387. K. Hoshino, M. Taniguchi, H. Ueoka, M. Ohkuwa, C. Chida, S. Morohashi and T. Sasakura, *Journal of fermentation and bioengineering*, 1996, **82**, 253-258.
388. C. López-Otín and J. S. Bond, *Journal of Biological Chemistry*, 2008, **283**, 30433-30437.
389. M. T. Basel, T. B. Shrestha, D. L. Troyer and S. H. Bossmann, *ACS nano*, 2011, **5**, 2162-2175.
390. M. J. Vicent, F. Greco, R. I. Nicholson, A. Paul, P. C. Griffiths and R. Duncan, *Angewandte Chemie*, 2005, **117**, 4129-4134.
391. J. C. Imperiale, P. Nejamkin, M. J. del Sole, C. E. Lanusse and A. Sosnik, *Biomaterials*, 2015, **37**, 383-394.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

392. H. K. S. Leiros, B. O. Brandsdal, O. A. Andersen, V. Os, I. Leiros, R. Helland, J. Otlewski, N. P. Willassen and A. O. Smalås, *Protein science*, 2004, **13**, 1056-1070.
393. W. Xue, G. Zhang and D. Zhang, *Analyst*, 2011, **136**, 3136-3141.
394. K. Radhakrishnan, J. Tripathy and A. M. Raichur, *Chemical Communications*, 2013, **49**, 5390-5392.
395. K. Radhakrishnan, J. Tripathy, D. P. Gnanadhas, D. Chakravorty and A. M. Raichur, *RSC Advances*, 2014, **4**, 45961-45968.
396. X.-F. Hou, Y. Chen and Y. Liu, *Soft matter*, 2015, **11**, 2488-2493.
397. A. Wells and J. R. Grandis, *Clinical & experimental metastasis*, 2003, **20**, 285-290.
398. K. F. Scott, M. Sajinovic, J. Hein, S. Nixdorf, P. Galettis, W. Liauw, P. de Souza, Q. Dong, G. G. Graham and P. J. Russell, *Biochimie*, 2010, **92**, 601-610.
399. W. Wu, Y. Yang and G. Sun, *Gastroenterology research and practice*, 2012, **2012**.
400. F. Iwańczak and B. Iwańczak, *Adv Clin Exp Med*, 2012, **21**, 671-680.
401. T. L. Andresen, J. Davidsen, M. Begtrup, O. G. Mouritsen and K. Jørgensen, *Journal of medicinal chemistry*, 2004, **47**, 1694-1703.
402. S. Thamphiwatana, W. Gao, D. Pornpattananangkul, Q. Zhang, V. Fu, J. Li, J. Li, M. Obonyo and L. Zhang, *Journal of Materials Chemistry B*, 2014, **2**, 8201-8207.
403. A. Bernardos, L. Mondragon, E. Aznar, M. D. Marcos, R. n. Martínez-Mañez, F. I. Sancenón, J. Soto, J. M. Barat, E. Pérez-Payá and C. Guillem, *Acs Nano*, 2010, **4**, 6353-6368.
404. B. D. Semple, A. Trivedi, K. Gimlin and L. J. Noble-Haesslein, *Neurobiology of disease*, 2015, **74**, 263-280.
405. A. V. F. Ferreira, 2013.
406. J. Rao, C. Hottinger and A. Khan, *Journal of the American Chemical Society*, 2014.
407. A. J. Harnoy, I. Rosenbaum, E. Tirosh, Y. Ebenstein, R. Shaharabani, R. Beck and R. J. Amir, *Journal of the American Chemical Society*, 2014.
408. K. Patel, S. Angelos, W. R. Dichtel, A. Coskun, Y.-W. Yang, J. I. Zink and J. F. Stoddart, *Journal of the American Chemical Society*, 2008, **130**, 2382-2383.
409. J. K. Kundu and Y.-J. Surh, *Pharmaceutical research*, 2010, **27**, 999-1013.
410. D. A. Butterfield, S. S. Hardas and M. L. B. Lange, *Journal of Alzheimer's Disease*, 2010, **20**, 369-393.
411. Y. Imanishi and Y. Ito, *Pure and applied chemistry*, 1995, **67**, 2015-2022.
412. G. Kai and Y. Min, *Journal of controlled release*, 2001, **71**, 221-225.
413. M. Tang, R. Zhang, A. Bowyer, R. Eienthal and J. Hubble, *Biotechnology and bioengineering*, 2003, **82**, 47-53.
414. K. Podual, F. J. Doyle III and N. A. Peppas, *Journal of Controlled Release*, 2000, **67**, 9-17.
415. T. Miyata, T. Urugami and K. Nakamae, *Advanced drug delivery reviews*, 2002, **54**, 79-98.
416. F. Q. Schafer and G. R. Buettner, *Free Radical Biology and Medicine*, 2001, **30**, 1191-1212.
417. A. Napoli, M. J. Boerakker, N. Tirelli, R. J. Nolte, N. A. Sommerdijk and J. A. Hubbell, *Langmuir*, 2004, **20**, 3487-3491.
418. M. H. Xiong, Y. J. Li, Y. Bao, X. Z. Yang, B. Hu and J. Wang, *Advanced Materials*, 2012, **24**, 6175-6180.
419. D. Gogoi, T. Barman, B. Choudhury, M. Khan, Y. Chaudhari, M. Dehingia, A. R. Pal, H. Bailung and J. Chutia, *Materials Science and Engineering: C*, 2014, **43**, 237-242.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

420. M. Stoytcheva, R. Zlatev, S. Cosnier, M. Arredondo and B. Valdez, *Biosensors and Bioelectronics*, 2013, **41**, 862-866.
421. Y.-C. Chuang, J.-C. Li, S.-H. Chen, T.-Y. Liu, C.-H. Kuo, W.-T. Huang and C.-S. Lin, *Biomaterials*, 2010, **31**, 6087-6095.
- 5 422. R. de la Rica, R. M. Fratila, A. Szarpak, J. Huskens and A. H. Velders, *Angewandte Chemie*, 2011, **123**, 5822-5825.
423. C. Alvarez-Lorenzo, L. Bromberg and A. Concheiro, *Photochemistry and photobiology*, 2009, **85**, 848-860.
424. A. Chan, R. P. Orme, R. A. Fricker and P. Roach, *Advanced drug delivery reviews*, 2013, **65**, 497-514.
- 10 425. L. Wu, Y. Zou, C. Deng, R. Cheng, F. Meng and Z. Zhong, *Biomaterials*, 2013, **34**, 5262-5272.
426. R. Cheng, F. Meng, S. Ma, H. Xu, H. Liu, X. Jing and Z. Zhong, *Journal of Materials Chemistry*, 2011, **21**, 19013-19020.
427. W. S. Shim, J. S. Yoo, Y. H. Bae and D. S. Lee, *Biomacromolecules*, 2005, **6**, 2930-2934.
- 15 428. N. K. Singh and D. S. Lee, *Journal of Controlled Release*, 2014, **193**, 214-227.
429. M. Adeli, A. K. Fard, F. Abedi, B. K. Chegeni and F. Bani, *Nanomedicine: Nanotechnology, Biology and Medicine*, 2013, **9**, 1203-1213.
430. C. T. Huynh, M. K. Nguyen and D. S. Lee, *Chemical Communications*, 2012, **48**, 10951-10953.
- 20 431. Y.-C. Chen, L.-C. Liao, P.-L. Lu, C.-L. Lo, H.-C. Tsai, C.-Y. Huang, K.-C. Wei, T.-C. Yen and G.-H. Hsiue, *Biomaterials*, 2012, **33**, 4576-4588.
432. Y. Liu, X. Cao, M. Luo, Z. Le and W. Xu, *Journal of colloid and interface science*, 2009, **329**, 244-252.
433. P. Du, T. Wang and P. Liu, *Colloids and Surfaces B: Biointerfaces*, 2013, **102**, 1-8.
- 25 434. L. Zhu, D. Wang, X. Wei, X. Zhu, J. Li, C. Tu, Y. Su, J. Wu, B. Zhu and D. Yan, *Journal of Controlled Release*, 2013, **169**, 228-238.
435. L. Jing, X. Liang, X. Li, Y. Yang and Z. Dai, *Acta biomaterialia*, 2013, **9**, 9434-9441.
436. V. Sundaresan, J. U. Menon, M. Rahimi, K. T. Nguyen and A. S. Wadajkar, *International journal of pharmaceuticals*, 2014, **466**, 1-7.
- 30 437. H.-Y. Huang, S.-H. Hu, S.-Y. Hung, C.-S. Chiang, H.-L. Liu, T.-L. Chiu, H.-Y. Lai, Y.-Y. Chen and S.-Y. Chen, *Journal of Controlled Release*, 2013, **172**, 118-127.
438. X. Cheng, H. Li, Y. Chen, B. Luo, X. Liu, W. Liu, H. Xu and X. Yang, *PloS one*, 2013, **8**, e85003.
439. J. Zhang, L. Wu, F. Meng, Z. Wang, C. Deng, H. Liu and Z. Zhong, *Langmuir*, 2011, **28**, 2056-2065.
- 35 440. Y. Lu, R. Mo, W. Tai, W. Sun, D. B. Pacardo, C. Qian, Q. Shen, F. S. Ligler and Z. Gu, *Chemical Communications*, 2014.
441. S. Park, B. Kwon, W. Yang, E. Han, W. Yoo and D. Lee, *Journal of Controlled Release*, 2014.
442. J. Peng, T. Qi, J. Liao, B. Chu, Q. Yang, W. Li, Y. Qu, F. Luo and Z. Qian, *Biomaterials*, 2013, **34**, 8726-8740.
- 40 443. C. Gao, T. Liu, Y. Dang, Z. Yu, X. Zhang, G. He, H. Zheng, Y. Yin and X. Kong, *Carbohydrate Polymers*, 2014.
444. R. Yin, Z. Tong, D. Yang and J. Nie, *International journal of biological macromolecules*, 2011, **49**, 1137-1142.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

445. C. Yang, W. Guo, L. Cui, N. An, T. Zhang, H. Lin and F. Qu, *Langmuir*, 2014, **30**, 9819-9827.
446. S. W. Kim, K. T. Oh, Y. S. Youn and E. S. Lee, *Colloids and Surfaces B: Biointerfaces*, 2014, **116**, 359-364.
447. N. Feng, G. Han, J. Dong, H. Wu, Y. Zheng and G. Wang, *Journal of colloid and interface science*, 2014, **421**, 15-21.
448. T. Yadavalli, S. Ramasamy, G. Chandrasekaran, I. Michael, H. A. Therese and R. Chennakesavulu, *Journal of Magnetism and Magnetic Materials*, 2014.
449. S. Y. Lee, H. Lee, I. In and S. Y. Park, *European Polymer Journal*, 2014, **57**, 1-10.
450. B. Chang, X. Sha, J. Guo, Y. Jiao, C. Wang and W. Yang, *Journal of Materials Chemistry*, 2011, **21**, 9239-9247.
451. X. Liu, H.-J. Liu, F. Cheng and Y. Chen, *Nanoscale*, 2014.
452. Y. Chen, P. Xu, Z. Shu, M. Wu, L. Wang, S. Zhang, Y. Zheng, H. Chen, J. Wang and Y. Li, *Advanced Functional Materials*, 2014.
453. X. Yang, Y. Wang, X. Huang, Y. Ma, Y. Huang, R. Yang, H. Duan and Y. Chen, *Journal of materials chemistry*, 2011, **21**, 3448-3454.
454. H. Z. M. A. M. R. M. Ghazaghi, H. Shir Khanloo, R. Rahighi, *Analytica Chimica Acta*, 2015.
455. S. Sun and P. Wu, *Journal of Materials Chemistry*, 2011, **21**, 4095-4097.
456. Z.-Y. Qiao, R. Zhang, F.-S. Du, D.-H. Liang and Z.-C. Li, *Journal of Controlled Release*, 2011, **152**, 57-66.
457. J. Liu, C. Detrembleur, A. Debuigne, M.-C. De Pauw-Gillet, S. Mornet, L. Vander Elst, S. Laurent, C. Labrugère, E. Duguet and C. Jérôme, *Nanoscale*, 2013, **5**, 11464-11477.
458. P. Bilalis, A. Chatzipavlidis, L.-A. Tziveleka, N. Boukos and G. Kordas, *Journal of Materials Chemistry*, 2012, **22**, 13451-13454.
459. A. Sahu, W. I. Choi and G. Tae, *Chemical Communications*, 2012, **48**, 5820-5822.
460. H. Kim, D. Lee, J. Kim, T.-i. Kim and W. J. Kim, *ACS nano*, 2013, **7**, 6735-6746.
461. Z. Yang, D. Gao, Z. Cao, C. Zhang, D. Cheng, J. Liu and X. Shuai, *Biomaterials Science*, 2015.
462. F. D. Jochum and P. Theato, *Chemical Society Reviews*, 2013, **42**, 7468-7483.
463. Q. Mu, G. Jiang, L. Chen, H. Zhou, D. Fourches, A. Tropsha and B. Yan, *Chemical reviews*, 2014, **114**, 7740-7781.
464. S. Tenzer, D. Docter, J. Kuharev, A. Musyanovych, V. Fetz, R. Hecht, F. Schlenk, D. Fischer, K. Kiouptsi and C. Reinhardt, *Nature nanotechnology*, 2013, **8**, 772-781.
465. M. Chanana, P. Rivera_Gil, M. A. Correa-Duarte, L. M. Liz-Marzán and W. J. Parak, *Angewandte Chemie International Edition*, 2013, **52**, 4179-4183.
466. S. Wan, P. M. Kelly, E. Mahon, H. Stöckmann, F. Caruso, K. A. Dawson, Y. Yan and M. P. Monopoli, *ACS nano*, 2015.
467. C. Ge, J. Tian, Y. Zhao, C. Chen, R. Zhou and Z. Chai, *Archives of toxicology*, 2015, **89**, 519-539.
468. M. Lundqvist, J. Stigler, T. Cedervall, T. Berggård, M. B. Flanagan, I. Lynch, G. Elia and K. Dawson, *ACS nano*, 2011, **5**, 7503-7509.
469. C. D. Walkey, J. B. Olsen, F. Song, R. Liu, H. Guo, D. W. H. Olsen, Y. Cohen, A. Emili and W. C. Chan, *ACS nano*, 2014, **8**, 2439-2455.
470. C. Wang and L. Dong, *Trends in biotechnology*, 2015, **33**, 10-14.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

471. R. Ahmad Khanbeigi, T. F. Abelha, A. Woods, O. Rastoin, R. D. Harvey, M.-C. Jones, B. Forbes, M. A. Green, H. L. Collins and L. A. Dailey, *Biomacromolecules*, 2015.
472. E. Casals and V. F. Puentes, *Nanomedicine*, 2012, **7**, 1917-1930.
473. M. P. Monopoli, D. Walczyk, A. Campbell, G. Elia, I. Lynch, F. Baldelli Bombelli and K. A. Dawson, *Journal of the American Chemical Society*, 2011, **133**, 2525-2534.
474. X. Hu and Q. Zhou, *Chemical reviews*, 2013, **113**, 3815-3835.
475. S. Milani, F. Baldelli Bombelli, A. S. Pitek, K. A. Dawson and J. Rädler, *ACS nano*, 2012, **6**, 2532-2541.
476. Y. Yan, K. T. Gause, M. M. Kamphuis, C.-S. Ang, N. M. O'Brien-Simpson, J. C. Lenzo, E. C. Reynolds, E. C. Nice and F. Caruso, *ACS nano*, 2013, **7**, 10960-10970.
477. A. Albanese, P. S. Tang and W. C. Chan, *Annual review of biomedical engineering*, 2012, **14**, 1-16.
478. M. Mahmoudi, S. E. Lohse, C. J. Murphy, A. Fathizadeh, A. Montazeri and K. S. Suslick, *Nano letters*, 2013, **14**, 6-12.
479. L. Wang, J. Li, J. Pan, X. Jiang, Y. Ji, Y. Li, Y. Qu, Y. Zhao, X. Wu and C. Chen, *Journal of the American Chemical Society*, 2013, **135**, 17359-17368.
480. T. Miclaus, V. E. Bochenkov, R. Ogaki, K. A. Howard and D. S. Sutherland, *Nano letters*, 2014, **14**, 2086-2093.
481. M. Mahmoudi, S. N. Saeedi-Eslami, M. A. Shokrgozar, K. Azadmanesh, M. Hassanlou, H. R. Kalhor, C. Burtea, B. Rothen-Rutishauser, S. Laurent and S. Sheibani, *Nanoscale*, 2012, **4**, 5461-5468.
482. M. P. Monopoli, C. Åberg, A. Salvati and K. A. Dawson, *Nature nanotechnology*, 2012, **7**, 779-786.
483. J. H. Shannahan, J. M. Brown, R. Chen, P. C. Ke, X. Lai, S. Mitra and F. A. Witzmann, *Small*, 2013, **9**, 2171-2181.
484. S. Behzadi, V. Serpooshan, R. Sakhtianchi, B. Müller, K. Landfester, D. Crespy and M. Mahmoudi, *Colloids and Surfaces B: Biointerfaces*, 2014, **123**, 143-149.
485. A. Salvati, A. S. Pitek, M. P. Monopoli, K. Prapainop, F. B. Bombelli, D. R. Hristov, P. M. Kelly, C. Åberg, E. Mahon and K. A. Dawson, *Nature nanotechnology*, 2013, **8**, 137-143.
486. L. Treuel, S. Brandholt, P. Maffre, S. Wiegele, L. Shang and G. U. Nienhaus, *ACS nano*, 2014, **8**, 503-513.
487. A. Lesniak, A. Salvati, M. J. Santos-Martinez, M. W. Radomski, K. A. Dawson and C. Åberg, *Journal of the American Chemical Society*, 2013, **135**, 1438-1444.
488. A. Kraus, L. Wortmann, L. Hermanns, N. Feliu, M. Vahter, S. Stucky, S. Mathur and B. Fadeel, *Nanomedicine: Nanotechnology, Biology and Medicine*, 2014, **10**, 1421-1431.
489. O. Lunov, T. Syrovets, C. Loos, J. Beil, M. Delacher, K. Tron, G. U. Nienhaus, A. Musyanovych, V. Mailander and K. Landfester, *Acs Nano*, 2011, **5**, 1657-1669.
490. Z. J. Deng, M. Liang, M. Monteiro, I. Toth and R. F. Minchin, *Nature nanotechnology*, 2011, **6**, 39-44.
491. A. J. Paula, R. T. Araujo Júnior, D. S. f. T. Martinez, E. J. Paredes-Gamero, H. B. Nader, N. Durán, G. Z. Justo and O. L. Alves, *ACS applied materials & interfaces*, 2013, **5**, 8387-8393.
492. M. Yu, C. Zhou, J. Liu, J. D. Hankins and J. Zheng, *Journal of the American Chemical Society*, 2011, **133**, 11014-11017.
493. H.-m. Ding and Y.-q. Ma, *Biomaterials*, 2014, **35**, 8703-8710.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

494. W. Jiang, B. Y. Kim, J. T. Rutka and W. C. Chan, *Nature nanotechnology*, 2008, **3**, 145-150.
495. C. C. Zimmer, Y. X. Liu, J. T. Morgan, G. Yang, K.-H. Wang, I. M. Kennedy, A. I. Barakat and G.-y. Liu, *The Journal of Physical Chemistry B*, 2014, **118**, 1246-1255.
496. F. Zhao, Y. Zhao, Y. Liu, X. Chang, C. Chen and Y. Zhao, *Small*, 2011, **7**, 1322-1337.
- 5 497. N. Chen, Y. He, Y. Su, X. Li, Q. Huang, H. Wang, X. Zhang, R. Tai and C. Fan, *Biomaterials*, 2012, **33**, 1238-1244.
498. M. Tejamaya, I. Römer, R. C. Merrifield and J. R. Lead, *Environmental science & technology*, 2012, **46**, 7011-7017.
499. A. Menard, D. Drobne and A. Jemec, *Environmental Pollution*, 2011, **159**, 677-684.
- 10 500. Z. Magdolenova, A. Collins, A. Kumar, A. Dhawan, V. Stone and M. Dusinska, *Nanotoxicology*, 2014, **8**, 233-278.
501. N. Golbamaki, B. Rasulev, A. Cassano, R. L. M. Robinson, E. Benfenati, J. Leszczynski and M. T. Cronin, *Nanoscale*, 2015.
502. A. I. Astashkina, C. F. Jones, G. Thiagarajan, K. Kurtzeborn, H. Ghandehari, B. D. Brooks and D. W. Grainger, *Biomaterials*, 2014, **35**, 6323-6331.
- 15 503. Y. K. Lee, E.-J. Choi, T. J. Webster, S.-H. Kim and D. Khang, *International journal of nanomedicine*, 2015, **10**, 97.
504. M. Mahmoudi, K. Azadmanesh, M. A. Shokrgozar, W. S. Journey and S. Laurent, *Chemical reviews*, 2011, **111**, 3407-3432.
- 20 505. S. Sharifi, S. Behzadi, S. Laurent, M. L. Forrest, P. Stroeve and M. Mahmoudi, *Chemical Society Reviews*, 2012, **41**, 2323-2343.
506. S. Arora, J. M. Rajwade and K. M. Paknikar, *Toxicology and applied pharmacology*, 2012, **258**, 151-165.
507. A. Kumar and A. Dhawan, *Archives of toxicology*, 2013, **87**, 1883-1900.
- 25 508. S. J. Soenen, W. J. Parak, J. Rejman and B. Manshian, *Chemical reviews*, 2015, **115**, 2109-2135.
509. K. Peynshaert, B. B. Manshian, F. Joris, K. Braeckmans, S. C. De Smedt, J. Demeester and S. J. Soenen, *Chemical reviews*, 2014, **114**, 7581-7609.
510. A. Elsaesser and C. V. Howard, *Advanced drug delivery reviews*, 2012, **64**, 129-137.
- 30 511. D. Guarnieri, S. Sabella, O. Muscetti, V. Belli, M. A. Malvindi, S. Fusco, E. De Luca, P. P. Pompa and P. A. Netti, *Nanoscale*, 2014, **6**, 10264-10273.
512. F. M. Winnik and D. Maysinger, *Accounts of chemical research*, 2012, **46**, 672-680.
513. M. Luo, C. Shen, B. N. Feltis, L. L. Martin, A. E. Hughes, P. F. Wright and T. W. Turney, *Nanoscale*, 2014, **6**, 5791-5798.
- 35 514. I.-L. Hsiao and Y.-J. Huang, *Science of the Total Environment*, 2011, **409**, 1219-1228.
515. V. K. Sharma, K. M. Siskova, R. Zboril and J. L. Gardea-Torresdey, *Advances in colloid and interface science*, 2014, **204**, 15-34.
516. M. V. Park, A. M. Neigh, J. P. Vermeulen, L. J. de la Fonteyne, H. W. Verharen, J. J. Briedé, H. van Loveren and W. H. de Jong, *Biomaterials*, 2011, **32**, 9810-9817.
- 40 517. C. A. Jimenez-Cruz, S. g. Kang and R. Zhou, *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*, 2014, **6**, 329-343.
518. E. Fröhlich, *International journal of nanomedicine*, 2012, **7**, 5577.
519. K. J. Smock, R. L. Schmidt, G. Hadlock, G. Stoddard, D. W. Grainger and M. A. Munger, *Nanotoxicology*, 2014, **8**, 328-333.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

520. D. Kim, S. Finkenstaedt-Quinn, K. R. Hurley, J. T. Buchman and C. L. Haynes, *Analyst*, 2014, **139**, 906-913.
521. S. H. De Paoli, L. L. Diduch, T. Z. Tegegn, M. Orecna, M. B. Strader, E. Karnaukhova, J. E. Bonevich, K. Holada and J. Simak, *Biomaterials*, 2014, **35**, 6182-6194.
522. W. Hu, C. Peng, M. Lv, X. Li, Y. Zhang, N. Chen, C. Fan and Q. Huang, *Acs Nano*, 2011, **5**, 3693-3700.
523. C. Ge, J. Du, L. Zhao, L. Wang, Y. Liu, D. Li, Y. Yang, R. Zhou, Y. Zhao and Z. Chai, *Proceedings of the National Academy of Sciences*, 2011, **108**, 16968-16973.
524. M. Elsabahy and K. L. Wooley, *Chemical Society Reviews*, 2012, **41**, 2545-2561.
525. M. Mahmoudi, M. A. Shokrgozar and S. Behzadi, *Nanoscale*, 2013, **5**, 3240-3244.
526. X. Wang, S. P. Reece and J. M. Brown, *Toxicology mechanisms and methods*, 2013, **23**, 168-177.
527. D. Hühn, K. Kantner, C. Geidel, S. Brandholt, I. De Cock, S. J. Soenen, P. Rivera_Gil, J.-M. Montenegro, K. Braeckmans and K. Mullen, *ACS nano*, 2013, **7**, 3253-3263.
528. T. H. Kim, M. Kim, H. S. Park, U. S. Shin, M. S. Gong and H. W. Kim, *Journal of Biomedical Materials Research Part A*, 2012, **100**, 1033-1043.
529. K. Gerloff, I. Fenoglio, E. Carella, J. Kolling, C. Albrecht, A. W. Boots, I. Förster and R. P. Schins, *Chemical research in toxicology*, 2012, **25**, 646-655.
530. A. R. Gliga, S. Skoglund, I. O. Wallinder, B. Fadeel and H. L. Karlsson, *Part Fibre Toxicol*, 2014, **11**.
531. Z. Ji, X. Wang, H. Zhang, S. Lin, H. Meng, B. Sun, S. George, T. Xia, A. E. Nel and J. I. Zink, *ACS nano*, 2012, **6**, 5366-5380.
532. X. Zhao, S. Ng, B. C. Heng, J. Guo, L. Ma, T. T. Y. Tan, K. W. Ng and S. C. J. Loo, *Archives of toxicology*, 2013, **87**, 1037-1052.
533. M. Palombo, M. Deshmukh, D. Myers, J. Gao, Z. Szekely and P. J. Sinko, *Annual review of pharmacology and toxicology*, 2014, **54**, 581.
534. S. Rodrigues, C. Cordeiro, B. Seijo, C. Remuñán-López and A. Grenha, *Carbohydrate polymers*, 2015, **123**, 369-380.
535. J. Wang, H. Liu, F. Leng, L. Zheng, J. Yang, W. Wang and C. Z. Huang, *Microporous and Mesoporous Materials*, 2014, **186**, 187-193.
536. X. Hu, Y. Wang and B. Peng, *Chem Asian J*, 2014, **9**, 319-327.
537. M. L. Etheridge, S. A. Campbell, A. G. Erdman, C. L. Haynes, S. M. Wolf and J. McCullough, *Nanomedicine: nanotechnology, biology and medicine*, 2013, **9**, 1-14.
538. R. J. Ho and J. Y. Chien, *Journal of pharmaceutical sciences*, 2009, **98**, 1928-1934.
539. S. Mura, J. Nicolas and P. Couvreur, *Nature materials*, 2013, **12**, 991-1003.
540. A. Garcia, R. Kempf, M. Rogers and F. Muggia, *Annals of oncology*, 1998, **9**, 1131-1133.
541. V. P. Israel, A. A. Garcia, L. Roman, L. Muderspach, A. Burnett, S. Jeffers and F. M. Muggia, *Gynecologic oncology*, 2000, **78**, 143-147.
542. S. Iqbal, D. D. Tsao-Wei, D. I. Quinn, B. J. Gitlitz, S. Groshen, A. Aparicio, H. J. Lenz, A. El-Khoueiry, J. Pinski and A. A. Garcia, *American journal of clinical oncology*, 2011, **34**, 27-31.
543. A. A. Garcia, L. Roman, L. Muderspach, A. O'Meara, G. Facio, S. Edwards and A. Burnett, *Cancer investigation*, 2005, **23**, 665-670.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

544. A. M. Keller, R. G. Mennel, V. A. Georgoulas, J.-M. Nabholz, A. Erazo, A. Lluch, C. L. Vogel, M. Kaufmann, G. von Minckwitz and I. C. Henderson, *Journal of Clinical Oncology*, 2004, **22**, 3893-3901.
545. M. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. Kieback, P. Tomczak and S. Ackland, *Annals of oncology*, 2004, **15**, 440-449.
546. A. T. Stopeck, E. M. Hersh, E. T. Akporiaye, D. T. Harris, T. Grogan, E. Unger, J. Warneke, S. F. Schluter and S. Stahl, *Journal of Clinical Oncology*, 1997, **15**, 341-349.
547. A. T. Stopeck, A. Jones, E. M. Hersh, J. A. Thompson, D. M. Finucane, J. C. Gutheil and R. Gonzalez, *Clinical cancer research*, 2001, **7**, 2285-2291.

10